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Introduction  Metastatic medulloblastoma (MB) manifests in one third of 
paediatric patients at diagnosis, conferring a poor prognosis. Our limited 
capacity to detect dissemination at diagnosis and disease recurrence 
however, results in the erroneous risk stratification of paediatric patients 
with MB, with serious subsequent prognostic implications.  
Hypothesis Significantly correlated with metastasis and poor prognosis 
in other solid cancers, tumour-derived enzymes that facilitate their 
dissemination known as matrix metalloproteinases (MMPs) and 
specifically MMP-2 and MMP-9, were postulated to be potential 
biomarkers of metastasis in MB. We hypothesised that differential levels 
of functionally active MMP-2 and MMP-9, as expressed and secreted by 
a panel of primary and metastatic sub-grouped MB cell lines and patient 
tumours, would correlate with their propensity to metastasise. Once 
biologically characterised, these findings would be translatable, using our 
locally synthesised 19Fluorine-MMP-MRI biosensor, which would 
demonstrate an increase in the fluorine signal proportional to the 
concentration of the MMP-2/MMP-9 within the sample, as its substrate 
linker is cleaved from a paramagnetic gadolinium III-DOTA complex over 
time.   
Methods Protein microarrays, western blotting and qRT-PCR were 
performed to determine the levels of MMP-2 and MMP-9 protein and 
gene expression in nine sub-grouped primary and metastatic MB cell 




conditioned supernatants from the same MB cell lines and cerebrospinal 
fluid (CSF) from six paediatric patients with MB were assayed using 
gelatin zymography. Functional migration and invasion assays of 3-D 
cultured MB were performed to determine whether the detected levels of 
functionally active MMP-2 and MMP-9, would correlate to their migratory 
capacity and expected metastatic potential. The same samples were 
further examined using fluorescence resonance energy transfer (FRET) 
assays, to simulate and optimise the conditions for the biosensor 
experiments, prior to their imaging.  
Results Our data strongly suggests that MMP-2 gene and protein is 
upregulated in metastatic MB cell lines. This was most evident in a 
matched pair of Group 4 MB where the recurrent cell line CHLA-01R-
MED consistently expressed higher MMP-2 at all regulatory levels in 
comparison to its primary counterpart, CHLA-01-MED. This finding was 
also reflected in their increased migratory capacity in invasion assays. 
Zymography of MB patient CSF demonstrated significantly increased 
levels of functionally active MMP-2 in the recurrent samples; a finding 
resonated in our FRET assay experiments. 19Fluorine-MRI-MMP 
biosensor imaging demonstrated increased signal from the Fluorine 
moiety, following enzymatic degradation of the sensor by recombinant 
MMP-2 protein, demonstrating its capacity to detect the levels of 
functionally active MMP-2 and MMP-9  in MB patient cerebrospinal fluid 





Conclusions Levels of functionally active MMP-2 could prove to be a 
sensitive marker of metastasis in paediatric patients with 
medulloblastoma, at their initial diagnosis and ongoing disease 
surveillance. With further optimisation, we believe that our MMP-2 
biosensor could become a useful adjunct as an intra-operative marker of 
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PDGFRα  Platelet derived growth factor receptor alpha 
PLGF   Placental growth factor 
PMS2   Postmeiotic segregation increased 2 
POLH   DNA polymerase eta 
PTCH1   Patched 1 
SHH   Sonic Hedgehog 
SMARCA4  SWI/SNF related, matrix associated, actin   
   dependent regulator of chromatin, subfamily a,  
   member 4 




SNCAIP  Synuclein alpha interacting protein 
SPARC   Secreted protein Acidic and Cysteine rich 
STAT3   Signal transducer and activator of transcription 3 
SUFU   Suppressor of fused homolog 
P53/TP53  Tumour suppressor gene p53 
TERT   Telomerase reverse transcriptase 
TGF-β   Transforming growth factor-β 
TIMPs   Tissue inhibitors of metalloproteinases 
TNF   Tumour necrosis factor 
TWIST1  Twist related protein 1 
VEGF   Vascular endothelial factor 
WNT   Wingless 
XPA   Xeroderma pigmentosum complementation group A 
XPC   Xeroderma pigmentosum complementation group C 


























Since its debut as the small round blue cell tumour of the cerebellum 
described by Cushing and Bailey a century ago, medulloblastoma (MB) 
has remained the most common malignant brain tumour in children, 
accounting for one-fifth of all paediatric brain tumours (Ramaswamy and 
Taylor 2017). Owing to its embryonal origins, MB predominantly affects 
children within their first decade of life, with a bimodal peak of incidence 
between the ages of 1-4 years and 5-9 years old (Millard and De 
Braganca 2016, Juraschka and Taylor 2019).  
Given its reported annual incidence of five cases per million children, MB 
is considered a rare condition, with a slight preponderance for males 
[male to female ratio of 1.7:1]. While it can occur in adulthood, it is 
incredibly infrequent with an incidence of 0.05 cases per 100,000 adults, 
and will usually present before the age of 40 years (Millard and De 
Braganca 2016, Juraschka and Taylor 2019).   
While 75% of MB patients are reported to survive up to 5 years following 
their initial diagnosis (Orr 2020), progress in genetic and molecular 
pathology have highlighted prognostic implications of the molecular 
subgroup of the patient’s tumour. This is due to their distinct 
epidemiological and clinical characteristics, including the age groups 
most commonly affected as well as the frequency of metastasis and 









Figure 1.1 Clinical, genetic, molecular and histopathological characteristics of 
paediatric medulloblastoma (Ivanov, Coyle et al.). MB was recently determined to exist 
as four distinct molecular subgroups, each with varying 5-year overall survival- Wingless 
(WNT>95%), Sonic hedgehog (SHH-75%), Group 3 (50-60%) and Group 4 (75%) as shown 





1.2 Pre-disposing risk factors to MB 
1.2.1 Genetic mutations  
Genomic advances in the biological heterogeneity of MB led to the 
consensus that it exists as four molecularly defined subgroups: Wingless 
(WNT), Sonic hedgehog (SHH), Group 3 and Group 4 MB. While 
hereditary syndromes associated with aberrant signalling in the 
developmental WNT and SHH pathways are responsible for less than 
5% of MB (Millard and De Braganca 2016), the increased prevalence of 
MB in patients with hereditary cancer predisposing syndromes, led to the 
discovery of shared germline genetic mutations, that are involved in MB 
aetiology or drive MB metastatic behaviour (Table 1. 1). Genetic 
mutations in MB seem to occur most frequently in the WNT (β-
CATENIN1) and SHH (PTCH1, SUFU and TP53) subgroups (Roussel 
and Stripay 2018, Northcott, Robinson et al. 2019).  
Table 1. 1 Hereditary syndromes and germline mutations that predispose to MB.  
TP53, PTCH1, SUFU, APC, PALB2 and BRCA2 genes were the most cited to significantly 
increase the risk of developing MB. Adapted from (Northcott, Robinson et al. 2019) 
Predisposing hereditary conditions Germline genetic mutations involved 
Gorlin syndrome PTCH1, SUFU 
Li-Fraumeni syndrome TP53 
Familial adenomatous polyposis syndrome APC 
Fanconi anaemia FANCA-W, PALB2, BRCA2 
Curry-Jones syndrome SMO 
Greig cephalopolysyndactyly syndrome GLI3 
Bloom syndrome BLM 
Constitutional mismatch repair deficiency MSH2, MSH6, MLH1, PMS2 
Ataxia telangiectasia ATM 
Nijmegen breakage syndrome NBN 
Rubinstein-Taybi syndrome CREBBP, EP300 
Xeroderma pigmentosum DDB2, ERCC1, ERCC2, ERCC3, ERCC4, 





1.2.2 Epigenetic regulation  
Epigenetics relates to the regulation of gene expression without changes 
to the DNA sequences or genome (Roussel and Stripay 2018). The 
significance of epigenetic regulation in the pathogenesis of MB has 
become indisputable, given the detection of the several subgroup-
specific epigenetic alterations, some of which have been correlated to 
more aggressive MB phenotypes (Northcott, Robinson et al. 2019).  As 
succinctly described by Zou et al, ‘epigenetic regulators serve as 
oncogenes or tumour suppressors in a context-dependent manner 
across the distinct subtypes of MB’ (Zou, Poore et al. 2020), effecting 
activation of the former or suppression of the latter (Roussel and Stripay 
2018). 
While these epigenetic alterations encompass changes in DNA 
methylation, histone modifications, non-coding micro- and long RNAs, 
the most commonly implicated in MB development, are concerned with 
chromatin remodelling, with almost 50% of MBs demonstrating altered 
chromatin-regulating genes (Northcott, Robinson et al. 2019).  In 
addition, anomalous methylation patterns in the histones H3K4 and 
H3K27 exist in all MB subgroups (Roussel and Stripay 2018). Of the 4 
MB subgroups, Group 3 and Group 4 are most frequently associated with 
metastasis at diagnosis and early recurrence in comparison to SHH and 
WNT (Northcott, Robinson et al. 2019). The relative infrequency of 





conundrum, and led to the emerging notion that their increased 
metastatic potential is due to underlying epigenetic dysregulation 
(Roussel and Stripay 2018).  
Table 1.2 Recurrently mutated chromatin-regulating genes implicated in MB. Table 
from (Northcott, Jones et al. 2012) 
1.2.3 Other factors  
While no geographical or ethnicity related factors have been identified to 
increase the risk of developing MB, high birth weight was purported by 
Harder et al. in 2008, to be a pre-disposing factor to developing MB 





ratio of 1.27 [confidence interval 1.02-1.60] (Massimino, Biassoni et al. 
2016).  
1.3 Clinical presentation  
As MB commonly presents within the first decade of life with non-specific 
symptoms that could be attributable to a vast array of differential 
diagnoses, it results in diagnostic delays and consequently, treatment 
provision. While this delay to diagnosis has improved from a median of 
12-13 weeks in 2007 to 6.5 weeks more recently following the 
introduction of clinical guidelines aiding diagnosis of brain tumours in 
children, more work is needed to improve MB patient outcomes 
(HeadSmart:-Be-Brain-Tumour-Aware 2015).  
The clinical presentation of a paediatric patient with MB varies according 
to the patient’s age and the anatomical location of the tumour. The rapidly 
growing nature of medulloblastoma results in presentation with either 
cerebellar symptoms due to its anatomical location, and/or obstruction of 
the cerebrospinal fluid (CSF) pathways due to invasion into or 
compression of the fourth ventricle, resulting in obstructive 
hydrocephalus. While the former could present with cranial nerve palsies, 
reduced coordination, muscle tone, stability and disturbances in motor 
function and gait; the latter frequently presents with headaches, nausea 
and vomiting, cognitive impairment in school-going children, 





As the patient’s age at diagnosis determines how they clinical present, it 
can result in a delay to diagnosis. Considering the non-specific manner 
in which infants may present, as well as the fact that their open cranial 
sutures (from infancy up to 18 months of age) can accommodate the 
increasing intracranial pressure, their MB may manifest as insidious 
gradual increments in their head circumference, which may not be 
detected as quickly as other symptoms. Paediatric patients with MB may 
also present with symptoms suggestive of metastatic dissemination 
including back pain, urinary or bowel disturbance, or focal 
radiculopathies (Northcott, Robinson et al. 2019, Kumar, Liu et al. 2020).  
Following referral to a tertiary neurosurgery centre for thorough clinical 
assessment, the child with suspected medulloblastoma will have 
diagnostic and staging magnetic resonance imaging (MRI) of their entire 
neuroaxis for anatomical localisation of their tumour and exclusion of 
macroscopic metastases. A multidisciplinary team then considers the 
patient’s demographics, clinical assessment and imaging before 
recommending a treatment plan. This would include a combination of 
neurosurgery for the excisional biopsy of the tumour and decompression 
of the posterior fossa, adjuvant chemotherapy for systemic control of 
metastases and craniospinal irradiation for the treatment and prevention 
of leptomeningeal macrometastases. This multimodal therapeutic 
approach to medulloblastoma has culminated in a substantial reduction 





borne by the survivors of this devastating disease (Dufour, Beaugrand et 
al. 2012, Ramaswamy and Taylor 2017). 
1.4 Pathological classification of MB 
1.4.1 Histopathological classification of MB  
Historically, the sole method used for grading medulloblastoma was the 
histopathological examination of resected MB tumour specimens. The 
World health organisation (WHO) designates tumours to Grade I, II III or 
IV, reflecting the scale of histological divergence of the tumour from its 
cells of origin. All MB histological variants are designated to be grade IV 
tumours due to their ‘cytologically malignant, mitotically active and 
necrosis-prone’ appearances coupled with their associated poor 
outcomes (Louis, Ohgaki et al. 2007).  
Previous editions of the WHO classification of central nervous system 
(CNS) tumours included ‘medulloblastoma with myogenic differentiation/ 
medullomyoblastomas’, an MB phenotype described in any histological 
MB exhibiting rhabdomyoblast-like appearances (small round cells with 
desmin, myoglobin and myosin immunopositivity) (Louis, Ohgaki et al. 
2007).  This descriptor along with another, ‘medulloblastoma with 
melanocytic differentiation/ melanocytic medulloblastoma’, were omitted 
from the most recently published WHO classification in 2016 (Louis, 
Ohgaki et al. 2007, Louis, Perry et al. 2016). Of the 5 remaining 





(Ramaswamy, Remke et al. 2016) and large cell/ anaplastic (LCA) 
variants were combined, due to their similar metastatic behaviour.  
1.4.1.1 Classic MB 
Up to 80% of MB exhibit classic histology denoted by densely packed 
tissue consisting of small round blue cells with large hyperchromatic 
nuclei and scanty cytoplasm as shown in Figure 1.2 (Kumar, Kumar et 
al. 2017).  While majority of WNT MB demonstrate classic histology, this 
morphology is also observed in 40-45% of SHH and in a smaller 
proportion of Group 3 and 4 MB (Northcott, Robinson et al. 2019).  
1.4.1.2 Desmoplastic/Nodular MB 
While most MB demonstrating the desmoplastic nodular (DN) histological 
subtype are SHH MB, it is observed in 30-35% of tumours in this 
subgroup (Northcott, Robinson et al. 2019) and is characterised by round 
nodules enveloped by reticulin fibres (Figure 1.2) resulting in a firm tissue 
architecture (Kumar, Kumar et al. 2017).  
1.4.1.3 Medulloblastoma with extensive nodularity (MBEN) 
Phenotypically similar to its DN histological counterpart, this variant is 
observed in 1-2% of all MB. These tumours with highly neuronally 
differentiated phenotypes consist of round cells with low mitotic indices 






1.4.1.4 Large cell/ Anaplastic  
Heralding a poor prognosis, this histological subtype is defined by large 
cells with significant nuclear pleomorphism and prominent nucleoli with 
scanty cytoplasm (Figure 1.2). High proliferative rates signified by their 
high mitotic indices and frequent associations with necrosis are 
characteristic (Kumar, Kumar et al. 2017). 
Figure 1.2 Histological subtypes of MB  
The four main histological variants in MB are demonstrated following haematoxylin and 
eosin staining of MB tumour samples. A. Classical MB is denoted by the small round blue 
cells. B. Desmoplastic/Nodular MB is characterised by densely packed nodular tissue, 
enveloped by reticulin fibres. C. MB with extensive nodularity is characterised by pale 
islands of uniformly round cells surrounded by fibrillary tissue.  D. Anaplastic MB 
demonstrating irregular large hyperchromatic nuclei with scanty cytoplasm. (Images from 









1.4.2 Molecular classification of MB 
1.4.2.1 Wingless Medulloblastoma (WNT) 
Emerging from the dorsal brainstem, WNT tumours are postulated to 
originate from progenitor cells of the lower rhombic lip (Northcott, Jones 
et al. 2012). With more than 95% of patients with WNT tumours having 
an overall survival of 10 years, WNT has been identified as the subgroup 
conferring the best outcome in children with medulloblastoma, following 
the standard management of surgical resection, chemotherapy and 
craniospinal irradiation (Ramaswamy, Remke et al. 2016). It is the least 
frequently occurring subgroup of all the medulloblastoma subtypes (10%) 
and is incident in males and females in equal proportions, with a 
propensity for affecting children over 3 years of age (Northcott, Jones et 
al. 2012).  
Up to 90% of WNT tumours harbour missense mutations in the β-
catenin1 gene located on chromosome 3, which manifests as the 
upregulation of the β-catenin WNT signalling pathway, a key regulator of 
stem cell pluripotency (Holgado, Guerreiro Stucklin et al. 2017). 
Diagnostic techniques used to identify β-catenin 1 mutation and establish 
WNT tumour subgrouping include DNA methylation profiling, gene 
expression profiling and sequencing as well as by 
immunohistochemistry. In addition, up to 80% of WNT tumours exhibit 
monosomy 6, a pathognomonic finding in this subgroup. The excellent 





typically stable genomes. This could also explain the low likelihood of 
metastasis and recurrence observed in patients with WNT tumours 
(Holgado, Guerreiro Stucklin et al. 2017, Ramaswamy and Taylor 2017). 
Other mutations implicated in the tumorigenesis of WNT tumours include 
DDX3X observed in 50%, SMARCA4 in a 25% and TP53 mutations in 
13% of WNT tumours (Holgado, Guerreiro Stucklin et al. 2017). WNT 
tumours also tend toward classic histological appearance, with majority 
of medulloblastoma previously categorised as classical 
medulloblastoma, being identified as WNT in molecular nature 









Figure 1.3 The WNT signalling pathway showing consequences of its activation.  
Following nuclear translocation of β-catenin1, its phosphorylation in the absence of the WNT 
ligand results in breakdown of proteasomes (left), while in the presence the bound WNT 
ligand, activation of the pathway occurs, resulting in perpetual transcription of genes 
implicated in MB metastasis such as C-MYC, SOX9 and CD44. Image from (McCord, 






1.4.2.2 Sonic Hedgehog (SHH) MB 
Derived from multiple progenitors including cerebellar granule neuron 
precursors, sub-ventricular zone neural stem cells and cochlear nuclei 
(Northcott, Jones et al. 2012), SHH tumours are so named due to their 
possession of somatic nucleotide variants and mutations in drivers of the 
sonic hedgehog pathway (a pathway involved in cerebellar 
development). These drivers culminate in upregulation of the SHH 
pathway, as observed in approximately 90% of SHH medulloblastoma 
(Ramaswamy, Remke et al. 2016). Demographically, SHH tumours 
constitute 30% of medulloblastoma and preferentially occur in infants and 
in adulthood with a slight male preponderance (Northcott, Jones et al. 
2012). 
The most commonly identified mutations are inactivating mutations in 
PTCH1 in 23.3% and SUFU in 13.5% (Holgado, Guerreiro Stucklin et al. 
2017). These mutations inactivate these genes, both being negative 
regulators of the SHH pathway. Mutations in the PI3K pathway in SHH 
tumours have also been identified to negate SUFU function and thereby 
result in increased SHH signalling. In addition, mutations resulting in the 
activation of SMO in 14.3% are also postulated to result in increased 
SHH pathway activity. A small proportion of SHH medulloblastoma are 
reported to harbour MYCN and GLI2 amplicons, while 40% of SHH 





dysfunctional cellular proliferation (Ramaswamy, Remke et al. 2016, 
Holgado, Guerreiro Stucklin et al. 2017, Ramaswamy and Taylor 2017). 
Figure 1.4 SHH signalling and interactions with the PI3K/AKT/MTOR and PKA 
pathways 
Mutations in the genes above have been implicated in the pathophysiology of SHH-MB, due 
to their amplification or alterations in their activation (green-activated, red-inactivated). 
These changes culminate in primed oncogenes such as GLI proteins, which exert canonical 
effects downstream, driving SHH-MB tumours. Image from (Kool, Jones et al. 2014) 
 
The most widely accepted prognostic indicator of SHH tumours are 
mutations in the tumour suppressor gene, TP53. Recognised to occur 
sporadically as well as in association with germline syndromes such as 
Li Fraumeni, SHH tumours harbouring this mutation have been 





classical or large cell/anaplastic histology. SHH-TP53 mutant tumours 
are most common in patients over 3 years of age and are associated with 
significantly poorer outcomes compared to their counterparts without 
TP53 mutations (Louis, Perry et al. 2016, Ramaswamy, Remke et al. 
2016).  
SHH medulloblastoma present with metastases in 15-20% (Northcott, 
Jones et al. 2012) and tend to recur within the resection margins of the 
primary tumour, a finding that appears to be distinct to this subgroup 
(Ramaswamy, Remke et al. 2016). With 5 year survival depicted at 75% 
(Northcott, Jones et al. 2012), SHH tumours are often considered to 
confer intermediate prognosis (Louis, Perry et al. 2016). Though all 
histological variants may be seen in SHH, they commonly exhibit 
desmoplastic/nodular histology (Northcott, Jones et al. 2012).  
1.4.2.3 Group 3 
Group 3 medulloblastoma tumours confer the worst prognosis with an 
overall 5-year survival of approximately 50% (Louis, Perry et al. 2016, 
Ramaswamy, Remke et al. 2016). Worse still, approximately half of these 
patients will have metastasis at diagnosis, culminating in an even poorer 
clinical outcome (Northcott, Jones et al. 2012, Holgado, Guerreiro 
Stucklin et al. 2017). This is especially evident in the approximate 20% 
of patients with Group 3 tumours that exhibit recurrent MYC 
amplifications (Ramaswamy, Remke et al. 2016, Holgado, Guerreiro 





dissemination throughout the neuroaxis, without radiological evidence of 
disease in the original resection cavity (Ramaswamy, Remke et al. 
2016). 
Identified in 25% of WNT tumours, mutations in the SMARCA4 gene are 
the most frequently implicated genetic mutation in Group 3 
medulloblastoma (Holgado, Guerreiro Stucklin et al. 2017). Similar to 
group 4, group 3 tumours demonstrate significant genomic instability with 
multiple structural variations including isochromosome 17q, as well as 
recurrent deletions in the long arms of chromosomes 10, 11 and 16 and 
the short arm on chromosome 17, and genetic amplicons that play key 
roles in the TGF-β and NF-κB signalling pathways. These aberrations 
culminate in a highly unstable genome. In addition, 40% of group 3 
tumours exhibit activation and overexpression of the oncogenes GFI1A 
or GFI1B and OTX2 amplicons. Demographically, group 3 occurs more 
frequently in males with a predilection for presenting in infants and young 
children (Northcott, Jones et al. 2012, Holgado, Guerreiro Stucklin et al. 
2017). 
1.4.2.4 Group 4 
Group 4 medulloblastoma is the most frequently occurring subgroup, with 
a strong predilection for males (M: F=3:1) and occurs most frequently in 
children and adolescents (Northcott, Jones et al. 2012, Ramaswamy, 
Remke et al. 2016). Commonly identified chromosomal abnormalities in 





including isochromosome 17q and amplifications in MYCN and cyclin-
dependent kinase 6 (CDK6). Though occurring at a lower frequency than 
is observed in WNT and SHH tumours, 10% of group 4 tumours exhibit 
recurrent single nucleotide variants in the histone demethylase gene, 
KDM6A. Group 4 tumours may also possess SNCA1P duplications and 
loss of the long arms on chromosome 10 (Northcott, Jones et al. 2012, 
Ramaswamy, Remke et al. 2016). 
Similar to group 3 tumours, group 4 medulloblastoma present with 
dissemination throughout the neuroaxis, with no radiological evidence of 
recurrent tumour at the previous site of the primary as is observed with 
SHH medulloblastoma (Holgado, Guerreiro Stucklin et al. 2017, 
Ramaswamy and Taylor 2017).  As group 3 and 4 tumours harbour 
similar chromosomal anomalies, tend to occur in the midline and behave 
in a similar fashion at recurrence, it is possible that these subgroups 
exploit similar metastatic mechanisms. Group 4 medulloblastoma are the 
second most likely subgroup to present with metastasis which is 
observed in 35-40% of these patients (Northcott, Jones et al. 2012). 
1.5 Risk stratification of paediatric patients with MB  
From Cushing’s discovery of better survival outcomes in children with MB 
following tumour resection compared to biopsy, the volume of <1.5cm3 
of residual tumour burden has remained an important prognostic 
predictor. In addition, the patient’s age at diagnosis as well as the 





clinically significant risk factors when paediatric patients with MB are 
stratified to either average or high risk (Juraschka and Taylor 2019).  
Following the pioneering work in adjuvant craniospinal irradiation for 
management of paediatric medulloblastoma by Paterson et al. in 1953, 
the previously assigned ‘hopeless’ prognosis of surgically resected 
medulloblastoma was transformed into a 3-year 60% survival (Paterson 
and Farr 1953). The subsequent introduction of adjuvant chemotherapy, 
culminated in the current 5 year survival rates of 70-80% in patients 
stratified to the average risk category, while in the less fortunate high risk 
patients, 5 year survival is given as 60-65% (Juraschka and Taylor 2019).  
Infantile MB carries a particularly poor prognosis as below the age of 
three, paediatric patients suffer unacceptable complications from 
irradiation of the neuro-axis. For this reason, radiation-sparing treatment 
regimens are utilised in this age group and produce good outcomes in 
those without metastases at diagnosis and with either WNT or SHH-MBs 
(Yeo, Margol et al. 2019).  
Since the discovery of the molecular heterogeneity in MB, better risk 
stratification models have been proposed (Table 1.3) , that take this as 
well as other genetic characteristics observed in more aggressive 
disease into account (Juraschka and Taylor 2019). Furthermore, the 
recent discovery of 8 molecular subtypes of Group 3 and 4 MB with 





further refined our ability to prognosticate medulloblastoma patients 
(Sharma, Schwalbe et al. 2019).  
Table 1.3 Improved risk stratification of medulloblastoma in paediatric patients over 
3 years of age. Taken from (Ramaswamy, Remke et al. 2016, Juraschka and Taylor 2019) 
 
1.6 Clinical management of paediatric MB 
1.6.1 Surgical resection  
The goals of neurosurgical intervention in MB are to obtain tissue for 
histomolecular diagnosis, reduce the tumour burden as much as is safely 
possible (maximal safe resection) and relieve hydrocephalus- the 
obstruction of the CSF flow through the ventricular system due to 
invasion or compression of the fourth ventricle by the cerebellar tumour 
(Menyhárt and Győrffy 2020). As they tend to grow in the midline 
cerebellar vermian region, Group 3 and 4 MB are most likely to be 
associated with obstructive hydrocephalus. While the volume of residual 
tumour burden >1.5cm3 (also considered subtotal resection-STR) is 
considered a high risk stratifier, complications associated with standard 
and radical surgical resection such as cerebellar mutism, neurocognitive, 





Furthermore, studies investigating the prognosis of MB patients following 
near-total resection versus gross-total resection of their tumours, found 
no progression-free nor overall survival benefit, thus the neurosurgical 
consensus is of maximal safe resection (Juraschka and Taylor 2019).  
If emergency management of obstructive hydrocephalus is required prior 
to resection of the tumour, an external ventricular drain is placed under 
image guidance through a burr hole (surgical window created in the skull) 
and into the ventricles for CSF diversion. If still required following 
surgery, this can be internalised by insertion of a ventriculo-atrial, 
ventriculo-pleural or ventriculoperitoneal shunt, the cranial portion of 
which is inserted through a frontal or parietal burr hole into the lateral 
ventricle. The distal portion is tunnelled through subcutaneous tissues 
and inserted into the atria, pleural or peritoneal cavities. Risks of these 
procedures include infection, bleeding, injury to surrounding structures, 
pneumothoraces,  seizures and shunt/drain displacement and 
malfunction (COG 2018).  
While resection of primary MB is the mainstay of treatment, surgical 
intervention at recurrence or relapse is only performed on candidates 
selected by a multi-disciplinary team. This is due to the high risk  nature 
of these operations as well as the poor prognosis associated with 
disease recurrence (Juraschka and Taylor 2019). Improved overall 
survival has been reported in the patient cohort in whom re-resection of 





1.6.2 Radiotherapy  
Traditionally, radiation therapy provided as external beam photon 
irradiation, is offered to two risk-stratified groups, ideally 4 weeks 
following resection of their tumour, provided the patient has recovered 
with a well-healed operative wound. These are average and high-risk 
paediatric patients aged ≥3-5 years. Infants and children younger than 3 
years are typically offered radiation-sparing treatment regimens due to 
their increased susceptibility to treatment related complications 
(Menyhárt and Győrffy 2020).  
Average and high-risk stratified patients older than 3 years of age are 
usually designated to receive a total of 54-55.8 grays (Gy) including a 
boost to the operative site. A further dose of 23.4 Gy of photon therapy 
is administered to the entire neuroaxis of average-risk patients and 
escalated to 36-39.6 Gy in the high-risk group (Menyhárt and Győrffy 
2020).  
While radiotherapy dose-reducing strategies are being explored for 
paediatric patients with WNT sub-grouped MB, de-escalation of 
craniospinal irradiation regimes for other patients has been shown to 
result in poorer outcomes in comparison to the standard (Menyhárt and 
Győrffy 2020). Furthermore, delays of more than 4 weeks post-
operatively to the initiation of adjuvant radiotherapy correlate with poor 





Technological advances resulting in improved radiotherapy planning, 
modulating of intensity and hyperfractionation (2 doses/day) of regimes, 
as well as newer techniques of proton-based radiotherapy have led to 
better side-effect profiles with reduced irradiation of healthy tissue. These 
measures culminated in better quality of life in these patients with 
decreased rates of hearing loss (Juraschka and Taylor 2019, Menyhárt 
and Győrffy 2020).  
1.6.3 Chemotherapy  
At present, there are multiple ongoing clinical trials into various 
combinations of multi-agent chemotherapy and subgroup specific 
immunotherapy regimes in MB. However, the current consensus for 
radiation-sparing regimens in infants and children younger than 3 years 
of age, prescribes either a high-dose chemotherapy regimen 
incorporating vincristine, cyclophosphamide, etoposide and cisplatin with 
subsequent stem cell rescue known as the CCG-99703 protocol; or a 
regimen incorporating intrathecal (delivered via Ommaya reservoir) 
Methotrexate alongside parenteral methotrexate, vincristine, 
cyclophosphamide and cisplatin (Menyhárt and Győrffy 2020).  
In the average and high-risk patients, 6-8 weeks of adjuvant intensive 
chemotherapy regimens consisting of cyclophosphamide, cisplatin and 
vincristine are instigated following weekly intravenous vincristine during 





and 70% 5-year OS in the latter group. While the regimens used in high-
risk patients with disseminated disease are often variable, they can 
receive additional boosts of craniospinal irradiation to metastatic sites 
(Juraschka and Taylor 2019, Menyhárt and Győrffy 2020).  
1.6.4 Complications of MB treatment 
While the multimodal therapy of MB has improved patient OS and 
progression-free survival in all risk groups, each therapeutic approach is 
associated with unavoidable adverse effects. In addition, these effects 
may be compounded further by subsequent therapies. Hence the need 
for robust risk-stratification methods to enable tailored regimens that 
maximise treatment efficacy and minimise concomitant neuro-cognitive 
and psychosocial complications. 
Notwithstanding the common complications associated with 
neurosurgery under general anaesthetic in the paediatric population, up 
to 25% MB patients develop posterior fossa syndrome (PFS) also known 
as cerebellar mutism (CMS). This presents in a delayed fashion post-
operatively, with mutism, emotional lability and hypotonia, alongside 
bulbar symptoms and brainstem dysfunction (Jabarkheel, Amayiri et al. 
2020). Published risk factors for development of this syndrome include 
younger patients at diagnosis and large tumours in the midline 





While radiotherapy has been correlated with increased rates of cataracts, 
stroke and radiation-induced tumours in MB survivors, cytotoxic 
chemotherapy can cause reno-, oto- hepato- and neuro-toxicity as well 
as blood and urinary tract malignancies (COG 2018).  For surviving MB 
patients, the ensuing neurocognitive, hormonal, developmental and 
psycho-social effects of these life-saving therapies heavily impact their 
quality of life, highlighting the need for personalised therapy (Millard and 
De Braganca 2016, Juraschka and Taylor 2019).  
1.7 Metastasis and Recurrence in Medulloblastoma  
Metastasis and recurrence account for more than 95% of paediatric 
patients with MB who succumb to their disease (Menyhárt and Győrffy 
2020). Metastasis is defined by the dissemination or spread of cancer 
cells from their original location to other sites. Most theories regarding 
the mechanisms of metastasis converge upon the idea that metastasis 
begins with mutations in a select population of cells- cancer stem cells 
(CSCs), wherein they develop mutations in their oncogenes and tumour 
suppressor genes, enabling their differentiation into several clones 
resulting in tumour heterogeneity (Pavelic, Sedic et al. 2011). Genomic 
studies have proven that while the molecular subgroup of the MB is 
preserved at metastasis, recurrence and relapse, alterations in the 
genetic mutations of surviving clones occur. This is observed at high 
frequencies in gene pathways such as TP53, especially within SHH-MBs 





chemotherapy regimens fail or why recurrence may occur despite 
previously established effectual cytotoxic chemotherapy and 
radiotherapy regimes (Pavelic, Sedic et al. 2011, Steeg, Camphausen et 
al. 2011). 
Cancer stem cells have similar characteristics to normal stem cells 
including their autonomous growth, pluripotency and capacity to maintain 
clonal expansion (Pavelic, Sedic et al. 2011). In addition, their activation 
and functioning depends on the very pathways that facilitate self-renewal 
in normal stem cells, namely the WNT/Beta-catenin and Hedgehog 
signalling pathways as well as the Notch and PTEN pathways (Pavelic, 
Sedic et al. 2011). In both WNT and Sonic Hedgehog medulloblastoma, 
upregulation of these pathways are thought to play a major role in the 
initiation and propagation of tumours belonging to these 
medulloblastoma subgroups (Holgado, Guerreiro Stucklin et al. 2017). 
Metastasis of brain tumours can be categorised into either parenchymal 
or leptomeningeal metastasis (Steeg, Camphausen et al. 2011), wherein 
the circulating tumour cells inhabit these anatomically and metabolically 
diverse microenvironments (Boire, Brastianos et al. 2020). The former 
occurs when tumour cells disseminate from the location of the primary 
tumour and invade the adjacent substance of the brain tissue, while the 
latter occurs when tumour cells invade and colonize the cerebrospinal 
fluid pathways and the meninges covering the brain and spinal cord 





common and occurs with highest frequency in Group 3 and 4 tumours 
which tend to arise in the midline cerebellar area, circumscribing the 
fourth ventricle (Ramaswamy, Remke et al. 2016, Holgado, Guerreiro 
Stucklin et al. 2017, Kralik, O'Neill et al. 2017). In contrast to Group 3 MB 
patients in whom recurrence of their disease occurs early in the disease 
progression, recurrence in Group 4 MB presents later and incurs better 
survival outcomes following relapsed disease (Menyhárt and Győrffy 
2020).  
For metastases to occur, it is believed that the acquisition of 
mesenchymal gene expression promotes loss of epithelial contacts 
between cells of the primary tumour. Subsequent interactions with the 
tumour microenvironment facilitate and precede tumour cell migration, 
enabling the extravasation (or intravasation) of tumour cells into the 
vasculature, a possible  route of spread of metastatic medulloblastoma 
cells to the rest of the neuroaxis (Steeg, Camphausen et al. 2011, Kralik, 
O'Neill et al. 2017). Studies of brain metastases from aggressive breast 
cancers have demonstrated that interactions between the tumour cells 
and brain milieu enable their metastatic cells to adapt morphologically 
and via their β1 integrins, adhere and invade the vascular basement 
membranes (Steeg, Camphausen et al. 2011).  
While the brain is well recognised to be immune privileged due to the 
robust blood-brain barrier and specialised ‘glymphatic’ network of 





waste to the cervical lymphatics; both these routes provide possible 
means by which circulating tumour cells (CTCs) may reach their 
preferred metastatic niche (Boire, Brastianos et al. 2020). These CTCs 
are postulated to mimic leucocyte mechanisms of migrating across these 
tight barriers, in addition to manipulating their surrounding cellular and 
acellular brain tumour microenvironments, causing these previously tight 
blood-brain and blood-CSF barriers to become leaky and conducive to 
their permeation (Boire, Brastianos et al. 2020).  
Additionally, histological examination of metastatic brain parenchyma 
have revealed features of inflammation, with activation of astrocytes and 
microglia. Thus disruption of the blood-brain barrier by inflammatory 
mediators such as interleukin-6 secreted by activated microglia and the 
more recently implicated cytokine C3, reduce its integrity and in theory 
could facilitate intravascular access of tumour cells (Steeg, Camphausen 
et al. 2011, Boire, Zou et al. 2017).  
For migrating cancer cells to metastasize to the brain, they must be 
capable of adapting to the unfamiliar surroundings. Most brain 
metastases originate from primary tumours outside of the neuroaxis and 
are thought to gain entry by breaking down the blood-brain barrier. 
However in the case of medulloblastoma, haematogenous, perivascular 
and leptomeningeal routes result in nodular and laminar leptomeningeal 
metastases in Group 3 and 4 MB, whereas SHH MB tend to recur within 





preferred metastatic niches within the MB subgroups suggest subgroups 
specific differences in their interactions with the tumour 
microenvironment.  
The increasing prominence of the role of the tumour microenvironment 
plays in the progression on metastasis and recurrence in cancer warrants 
a closer look at the unique milieu that is the brain tumour 
microenvironment (Boire, Brastianos et al. 2020)  
1.7.1 The brain tumour microenvironment 
1.7.1.1 The cellular microenvironment 
This unique microenvironment constitutes cells found only in the 
neuroaxis as well as a tightly regulated extracellular environment. These 
include astrocytes and oligodendrocytes as well as neurons and 
microglia, the latter being the resident immune cells. While neuronal 
secretion of glutamate and factors such as the brain neurotrophic factor 
have been shown to support growth of gliomas, reactive astrocytes and 
activated microglia have been reported to interact with primary and 
metastatic tumour cells through paracrine signalling; culminating in the 
production of a microenvironment that is conducive to cell migration 
(Schulz, Salamero-Boix et al. 2019).  
Endothelial cells, components of all brain vasculature have also been 
shown to interact and respond to tumour-derived factors that drive neo-





Furthermore, their central role in the integrity, function and permeability 
of the blood-brain and blood-CSF barriers necessitates their 
consideration in the brain tumour microenvironment (Morad and Moses 
2019).  
1.7.1.2 The Blood-brain barrier and regional differences in its 
cellular architecture 
The blood-brain barrier (BBB) can be regarded as a highly selective 
multi-level structure that acts as an anatomical and physiological 
protective barricade between the periphery and the brain (Abbott, 
Rönnbäck et al. 2006). Anatomically, it has been characterised to consist 
of endothelial tight junctions between the capillary endothelial cells which 
are enveloped by the astrocytic foot processes and reinforced by the 
capillary basement membrane as well as pericytes (contractile 
connective tissue cells), glia limitans (comprised by astrocytic end-feet) 
and microglia. Various laminin isoforms, type IV collagen, proteoglycans 
and fibronectin are some of the constituents of the basal lamina of the 
BBB.  Physiologically, the blood-brain barrier restricts molecular and 
cellular transport into the brain by specific active and facilitated diffusion 
of substances necessary for neuronal function. This is beneficial as it is 
thought to reduce the pathological spread of infective organisms, 
immune cells and circulating cancer cells (Abbott, Rönnbäck et al. 2006, 





The brain and spinal cord are housed within coverings called meninges, 
the first of which are a dual layer of dura mater, between which venous 
sinuses and lakes are situated. Dural-based vasculature tend to be 
capacious, fenestrated vessels that lack tight junctions. The second layer 
the avascular arachnoid mater measures approximately 200 microns 
thick, and is comprised of a dual squamous epithelium layer with a 
laminin α5 rich basal lamina. The pia mater is adherent to the brain 
parenchyma and constitutes of laminin α1 basement membrane as well 
as fibroblast-like cells. Unlike the subarachnoid mater, the pia mater 
lacks tight junctions (Mastorakos and McGavern 2019).  
The vast majority of arteries supplying the brain are enclosed within the 
cerebrospinal fluid filled subarachnoid space, the space between the 
arachnoid and pia maters. From here, they enter into the brain 
parenchyma enveloped within the glia limitans and pia mater, creating 
perivascular spaces between their walls and the pia. The aforementioned 
pial fenestrations enable fluid and molecule movement through the 
subpial (perivascular), pial and subarachnoid space (Mastorakos and 
McGavern 2019).  
In physiological circumstances, the glia limitans that envelope the 
parenchymal surfaces of the brain and spinal cord are permeable to  
substances of 0.8-70kDa, while larger molecules up to 2000kDa are 
housed within the perivascular space. The 20nM gaps within the glia 





decisive determinants of fluid and molecule exchange between the 
interstitial and cerebrospinal fluid (Mastorakos and McGavern 2019). 
 The function of the BBB has been shown to be impaired by inflammatory 
and coagulation cascade mediators, neurotransmitters such as 
glutamate, free radicals, endothelin-1 and nitric oxide to name a few. A 
growing body of evidence suggests that these mediators may provide the 
mechanistic routes by which metastatic cells circumvent this protective 
barricade to invade the neuroaxis and lead to leptomeningeal 
metastases (Abbott, Rönnbäck et al. 2006, Boire, Zou et al. 2017, 
Mastorakos and McGavern 2019).  
Regional variations in its composition have been observed to correlate 
with the functions of the specific anatomical region of the brain. At sites 
such as the choroid plexus and circumventricular organs (Figure 1.5), the 
BBB is specialised to suit their physiological functions. The main 
difference is the paucity of tight junctions in the endothelia lining their 
vasculature, enabling easier access of molecules and inflammatory 
mediators from the systemic circulation into the brain. Circumventricular 
organs such as the subfornical organ, area postrema and vascular organ 
of the lamina terminalis play important homeostatic roles that require a 
direct communication to the systemic vasculature as well as others that 
secrete hormones into the systemic circulation for example the posterior 






Figure 1.5 Overview of the structural differences in the composition of the blood-brain 
barrier at anatomically distinct regions of the brain. 
A. Meningeal vasculature. As shown, blood vessels within the dura are fenestrated allowing 
direct communication with the systemic circulation, in contrast to blood vessels within the 
arachnoid space whose tight junctions prevent diffusion of large molecules or free fluid 
exchange between the dura and systemic vasculature. B. As the subarachnoid blood 
vessels enter the parenchyma and become parenchymal capillaries, they are enveloped by 
pia and glia limitans from the end-feet of astrocytic foot processes. C. Specialised choroid 
plexus vasculature lacking tight junctions enable the secretion of CSF into the ependymal 
lining D. Vascular architecture of periventricular organs showing fenestrated capillaries 
within but tight junctions between the tancytes that line their exterior CSF facing surface. 





1.7.1.3 The leptomeninges, cerebrospinal fluid and the blood-CSF 
barrier  
The leptomeninges are comprised of the two innermost membranous 
layers covering the surfaces of the brain and spinal cord; the pia mater 
that adheres to the surfaces of the brain and spinal cord and the 
subarachnoid mater above it (Steeg, Camphausen et al. 2011).  Between 
the pia and subarachnoid layers is the subarachnoid space which is filled 
with cerebrospinal fluid (CSF), an acellular, low solute fluid secreted by 
specialised choroid plexus epithelium, into the lateral, third and fourth 
ventricles (Boire, Zou et al. 2017).  While the fenestrated endothelia of 
the choroidal vessels lack tight junctions and glia limitans, they are lined 
by ependymal cells, which have tight junctions and form the ventricular 
walls. This allows diffusion of proteins from the systemic circulation into 
the choroid capillaries, further passage into the ventricles is limited by 
the ependyma (Mastorakos and McGavern 2019).  
The ventricles are a low pressure, ependymal-lined cavities within which 
the cerebrospinal fluid circulates. From its genesis in the choroid plexus, 
it flows through the lateral ventricles through the foramen of Munro into 
the third ventricle, passing into the cerebral aqueduct into the fourth 
ventricle, which sits just anterior to the cerebellum as shown in Figure 1. 
6. Traversing through the medial Magendie and lateral Lushka foramina, 







Figure 1. 6 CSF flow through the ventricles and around the brain 
Once secreted by the choroid plexus in the lateral ventricle, it flows into the third ventricle 
through the interventricular foramen, down the cerebral aqueduct and into the fourth 
ventricle. This is the point at which a medulloblastoma within the cerebellum could invade 
or compress the fourth ventricle causing obstructive hydrocephalus. Image taken from 
http://cnx.org/content/m46719/1.3/, 2013 (OpenStaxCollege 2013) 
 
While it was historically thought that all CSF was reabsorbed at the 
arachnoid granulations on the superior cortical surface of the 
subarachnoid mater, recent MRI tracer studies have demonstrated 
paravascular flow of ISF/CSF along brain vasculature as it penetrates 
the subarachnoid space into the pia mater (Vinje, Eklund et al. 2020).  
The perivascular CSF enables transport of solutes to the interstitium and 
metabolic waste away from the extracellular space, which it accesses via 
aquaporin-4 (AQP-4) channels between glial cell foot-processes. This 





leptomeningeal arteries. CSF drainage is postulated to occur at the 
arachnoid granulations and into the venous superior sagittal sinus from 
where it proceeds to enter the peripheral circulation, as well as via the 
paravenous outflow into cervical lymphatics (Vinje, Eklund et al. 2020). 
This may be the course by which primary brain tumours disseminate to 
extra-neural sites (Boire, Zou et al. 2017).  
Furthermore, the co-localisation of antigen presenting cells within the 
perivascular spaces and in close proximity to leptomeningeal 
vasculature, the choroid plexus and subarachnoid space; highlights their 
role in maintaining the brain’s immune privilege but may also implicate 
them in the tumour-immune system interactions observed in primary and 
metastatic microenvironments that propagate metastasis (Mastorakos 
and McGavern 2019) .  
1.8 Leptomeningeal metastasis 
Several mechanisms by which leptomeningeal metastases may occur 
have been proposed. Direct invasion of the glia limitans by cancer cells 
within the brain parenchyma, venous access through the Bateson’s 
venous plexus and entry via the choroid epithelium are some of the 
plausible routes of dissemination of cancer cells into the leptomeningeal 
space (Boire, Zou et al. 2017). Enzymatic degradation of the glia limitans 





astrocytes and microglia at the perivascular spaces (Mastorakos and 
McGavern 2019). 
Furthermore, the continuity of the subarachnoid space allows free 
movement of cancer cells within the CSF which can then invade the pia 
mater and establish focal metastases, visible as focal nodular 
enhancement on spinal MRI contrast-enhanced images or drop/nodular 
metastases on the surface of the spinal cord (Kralik, O'Neill et al. 2017). 
While the continuity of the subarachnoid space may present 
advantageous routes for chemotherapeutic drug delivery as has been 
used in the intrathecal administration of antibiotics, it also raises 
questions regarding how the metastatic cells are able to survive within 
the dynamic, deficient environment that is the constantly replenished 
cerebrospinal fluid environment (Boire, Zou et al. 2017).  
In a recently published paper it was postulated that complement C3 
secreted into the cerebrospinal fluid by circulating metastatic cells within 
the subarachnoid space, binds to its receptor at the epithelial surface of 
the choroid plexus, triggering disruption of the choroid epithelium (Boire, 
Zou et al. 2017).  As this epithelium is responsible for the bulk of secretion 
of cerebrospinal fluid into the lateral and third ventricles, the blood-brain 
barrier here is physiologically deficient compared to other regions of the 
brain, making it a possible route by which breast and lung cancer 
metastatic cells gain access to the neuroaxis. Once in the CSF pathways, 





cerebrospinal fluid long enough to invade the leptomeninges, the brain 
and spinal cord. This might explain the significant mortality associated 
with leptomeningeal metastases, with the natural history of this 
complication of disseminated cancer culminating in death within 6-8 
weeks in untreated individuals (Boire, Zou et al. 2017).  
Boire et al. identified two distinct populations of metastatic tumour cells 
following intra-arterial injection of metastatic lung and breast cancer cells 
in immunocompromised mice. Those that established leptomeningeal 
metastases were biologically determined to be specifically aggressive 
towards invading the leptomeninges with distinct phenotypic and 
transcriptomic profiles to the cells that invaded the brain parenchyma 
(Boire, Zou et al. 2017). 
1.8.1 Current methods employed in the diagnosis of metastasis 
recurrence and prognostication in MB  
 
Patients with metastatic medulloblastoma are classified into four 
categories using Chang’s operative classification ranging from: no 
cytological/radiological evidence of metastases (M0), cytological 
evidence of tumour cells in cerebrospinal fluid (M1), nodular metastases 
within the intracranial subarachnoid spaces or ventricles (M2), 
metastases within the spinal subarachnoid space (M3) and extraneural 





Given the propensity for leptomeningeal metastasis in MB, the current 
clinical methods of detection at diagnosis and recurrence are less than 
accurate in their determination of metastatic disease. Considering the 
impact that this has on the prognostication of children with 
medulloblastoma, safe and minimally-invasive detection methods with 
better accuracy are needed to correctly identify patients for whom 
escalated doses of craniospinal irradiation or chemotherapy would be 
most appropriate (Bennett, Ashmawy et al. 2017). The WHO staging of 
medulloblastoma shows the current staging of MB according to 
molecular and histological diagnosis (Louis, Perry et al. 2016). 
Table 1.4  Summary of the re-classification of MB in the 2016 World Health 
Organisation Classification of CNS tumours (Louis, Perry et al. 2016).  
Genetic profile Histology Prognosis 
WNT-activated 
Classic Low risk, common in most WNT-MB 
Large cell/ Anaplastic Uncertain clinicopathological significance 
SHH-activated 
TP53-mutant 
Classic Uncommon, high risk tumour 
Large cell/ Anaplastic 
High risk, prevalent in patients 7-17 years 
old 
Desmoplastic/Nodular  Uncertain clinicopathological significance 
SHH-activated 
TP53-wild type 
Classic Standard/ Average risk 
Large cell/ Anaplastic Uncertain clinicopathological significance 
Desmoplastic/Nodular  
Low risk in infants, prevalent in adults and 
infants 
Extensive nodularity Low risk in infants 
Group 3  
Classic Standard/ Average risk 
Large cell/ Anaplastic High risk 
Group 4 
Classic 
Standard/ Average risk, common in Group 
4-MB 






To streamline prognostication in patients with tumours that metastasise 
to the leptomeninges, a response assessment in neuro-oncology 
(RANO) working group defined standardised methods and criteria by 
which leptomeningeal disease can be diagnosed. They proposed three 
main domains which when combined, would give the best chance of 
accurate prognostication of disease for appropriate treatment 
assignment. These domains included a full neurological examination to 
exclude symptoms secondary to leptomeningeal MB deposits; contrast 
enhanced magnetic resonance imaging of the entire neuroaxis at 1.5 or 
3-tesla scanners; and cerebrospinal fluid cytology usually performed 10-
14 days post-operatively (Bennett, Ashmawy et al. 2017, Chamberlain, 
Junck et al. 2017). These assessments should be performed in a timely 
fashion; the brain and spinal MRI pre-operatively to avoid artefacts 
associated with surgical manipulation and cerebrospinal fluid cytology 
within 10-14 days post-operatively to avoid detection of iatrogenic 
dissemination of medulloblastoma cells at surgery (Bennett, Ashmawy et 
al. 2017).  
Dufour et al. found that patients with nodular metastases had better 
survival rates compared to those who had either cytological evidence of 
medulloblastoma cells in CSF or laminar metastases. Both CSF 
cytological analysis and spinal MRI used in the detection of disseminated 
medulloblastoma have limited sensitivity and specificity in this regard 





leptomeningeal metastatic disease confirmed by histology, revealed a 
positive CSF result in only 59% (Kralik, O'Neill et al. 2017). Additionally, 
spinal MRI at the clinical strength of up to three Tesla (1.5-3T) has limited 
spatial resolution especially when compounded with artefact from patient 
movement, CSF flow and lack of specialist neuro-radiological expertise. 
Thus, the determination of patients with metastases in the absence of 
macroscopic radiologically detectable disease remains a challenge. 
Hence, more sensitive MRI techniques that can detect disseminated 
disease at diagnosis and surveillance are required to improve the 
prognostication of patients with medulloblastoma. This in turn, would 
enable the identification of patients at highest risk, in whom it would be 
justified to administer high dose craniospinal irradiation for treatment and 
control of their metastatic disease (Holgado, Guerreiro Stucklin et al. 
2017, Kralik, O'Neill et al. 2017).  
Another factor that has greatly improved prognostication of 
medulloblastoma patients is its re-classification from the histological 
variants to the molecularly defined subgroups WNT, Sonic Hedgehog 
(SHH), Group 3 and Group 4 medulloblastoma. Genomic studies have 
revealed prognostic correlations for each subgroup and identified 
disparate clinical phenotypes in the age groups they frequently affect, 
their metastatic profiles and even where they arise anatomically, within 
the posterior fossa. Though further work into their characterisation is 





consistently shown it to be the subgroup with the most favourable 
prognosis, while Group 3 tumours tend to be more aggressive and most 
likely to recur (Holgado, Guerreiro Stucklin et al. 2017, Ramaswamy and 
Taylor 2017). Even so, clinical practice presently advocates the 
indiscriminate provision of craniospinal irradiation where the patient is 
older than 3 years of age. As such, adverse effects from the high doses 
of radiotherapy remain high in the surviving patients who suffer from long 
term neurocognitive deficits, neuroendocrine dysfunction and secondary 
radiation-induced malignancies (Ramaswamy, Remke et al. 2016, 
Holgado, Guerreiro Stucklin et al. 2017). 
The Royal College of radiologists advocate MRI as the gold standard for 
diagnosis and surveillance of paediatric brain tumours, due to its 
excellent safety profile and good spatial resolution. Its non-invasive 
nature allows for its use in the diagnosis and monitoring of treatment 
response, in patients who would otherwise come to harm from the effects 
of accumulated ionising radiation, especially in paediatric patients who 
would be particularly susceptible (Manias, Gill et al. 2017).  
However, due to the limited availability, long duration of acquisition and 
high cost of MRI, contrast-enhanced computed tomography (CT) is 
sometimes used to diagnose paediatric brain tumours and metastases 
within the neuroaxis. Unlike MRI, CT scanning exploits the differential 
absorption and consequently transmission of ionising radiation through 





of carcinogenesis associated with the forms of ionising radiation 
employed in imaging modalities such as computed tomography (CT) and 
positron emission tomography (PET), MRI is advantageous as it permits 
the detection of micrometastases (<5mm in diameter) with less bone 
derived artefact, superior soft tissue contrast and minimal propensity to 
instigate carcinogenesis (due to lack of ionising radiation as is the case 
in CT imaging). All three modalities require administration of exogenous 
contrast for vascular enhancement of the tumour, a characteristic thought 
to occur due to disruption of the BBB that is believed to occur more so in 
aggressive tumours (Goo and Ra 2017).  
Unfortunately, both contrast agents used in the respective modalities- 
Gadolinium in MRI and Niopam in CT imaging, are associated with 
adverse effects including allergic reactions, anaphylaxis, nephrotoxicity 
and accumulation within soft tissues. For these reasons, development of 
safer, equally effective contrast agents are required or the development 
of molecular magnetic resonance imaging techniques that can negate or 
minimise the amount of exogenous contrast agents. Newer contrast 
agents using chelated paramagnetic oxide nanoparticles or activatable 
‘smart’ probes may fulfil this purpose, albeit with different potential 
adverse effects (Carril 2017). 
1.9 Candidate biomarkers of metastasis  
Biomarkers of metastasis, by definition, must be quantifiable biological, 





reliably indicate the presence, advancement or resurgence of 
disseminated cancer (O'Connor, Aboagye et al. 2017). For use in clinical 
practice, imaging biomarkers of metastases must be reproducible, 
readily accessible, cost-beneficial and adequately specific and sensitive 
for the detection of the desired target, in this case, brain metastases 
(O'Connor, Aboagye et al. 2017).  
The development of an imaging biomarker that is compatible with clinical 
3-Tesla MRI scanners would be ideal, for the detection of neuroaxial 
metastases and the exclusion of recurrence during disease monitoring. 
Furthermore, such a biomarker could be used intra-operatively, to 
determine the invasive margins of MB tumours, to guide targeted 
resection of these tumour populations. Considering the increasing 
evidence that safe maximal resection of medulloblastoma in paediatric 
patients is superior to radical resection, due to the ensuing adverse 
effects of the aforementioned strategy, chief being cerebellar mutism 
syndrome (Thompson, Hielscher et al. 2016). 
Though characteristic subgroup specific metastatic signatures are yet to 
be discovered, a number of proteomic and genomic markers have been 
proposed to correlate with increased metastatic potential (Steeg, 
Camphausen et al. 2011, Gu, Chen et al. 2017). Based on the well 
accepted premise of metastasis requiring interactions between the 
tumour cells and their immediate microenvironment to establish a 





mesenchymal transformation theory have been accorded significance 
and demonstrated to change during the process (Termini, Neman et al. 
2014). Notable suspects include the chemokine ligands CCL5, CCL4 and 
its receptor CCL12 as well as WIP1, the latter being implicated in the 
SHH pathway (Northcott, Jones et al. 2012). Other proteomic studies 
have implicated α9β1 integrin (a transmembrane receptor that facilitates 
cell migration), SPARC (a cysteine-enriched matrix protein) and PDGFR 
α (Platelet derived growth factor α that functions as a mitogen for 
mesenchymal cells) as facilitators of metastasis in medulloblastoma (Gu, 
Chen et al. 2017).  
Astrocytes that normally play a supportive role to glial cells in the brain 
have been implicated in the facilitation of a pro-metastatic niche by 
secreting factors such as TWIST1, BCL21 and GSTA5 when activated 
(Termini, Neman et al. 2014). These factors have been shown to 
increase survival of metastatic cells (Termini, Neman et al. 2014). Given 
that metastasis is a pro-inflammatory state, a number of inflammatory 
mediators have been correlated with metastasis including cytokine-C3 
that has the propensity to disrupt the blood brain barrier. Other mediators 
that have the propensity to disrupt the blood-brain barrier (BBB) include 
interleukins (1, 6, 8), tumour necrosis factor (TNF) and transforming 
growth factor-β (TGF-β), the latter demonstrated to be upregulated in 
leptomeningeal metastases (Steeg, Camphausen et al. 2011, Boire, Zou 





For established metastases, cultivation of the site of metastasis requires 
neo-angiogenesis to satisfy the increased oxygen demand associated 
with the more metabolically active metastatic cells (Termini, Neman et al. 
2014). Vascular endothelial factor (VEGF-A) has been demonstrated to 
correlate with the radiological detection of melanoma metastases to the 
brain (Steeg, Camphausen et al. 2011). Monoclonal antibodies to VEGF 
such as Bevacizumab are already in clinical use and VEGF receptor 
antagonists are undergoing clinical validation to assess their efficacy in 
impeding metastatic progression. Through inhibitory pre-clinical 
experiments, other mediators proposed to alter the progression of brain 
metastases include Epidermal growth factor receptor (EGFR) and Signal 
transducer and activator of transcription 3 (STAT3) (Steeg, Camphausen 
et al. 2011).  
Specific to the MB molecular subgroups, nuclear expression of β-
catenin1 in WNT tumours, SUFU (a key negative regulator in the 
hedgehog pathway) and mutant TP53 expression in SHH, and MYC 
amplification in both Group 3 and 4 tumours, have all been postulated to 
correlate with their subgroup-specific metastatic potential, as reflected in 
the new WHO prognostic criteria (Louis, Perry et al. 2016). Further 
mediators postulated to play key roles in the invasion of medulloblastoma 
include ERBB2, IGF-1R, c-MET and placental growth factor (PLGF), 
which all appear to be upregulated in metastatic medulloblastoma 





primary and metastatic Group 4 medulloblastoma cell lines revealed 
increased expression of YAP1 and MMP-2 in the metastatic cell line 
compared to its counterpart (Gu, Chen et al. 2017). 
Though seemingly exhausted in cancer research, matrix 
metalloproteinases and their regulators have resurfaced as interesting 
modulators of the metastatic neural niche (Termini, Neman et al. 2014, 
Isaacson, Jensen et al. 2017). Extracellular Matrix metalloproteinase 
inducer (EMMPRIN) is an MMP associated glycoprotein that has been 
shown to be upregulated in medulloblastoma compared to normal 
cerebellar tissue and has been correlated to higher metastatic type, more 
aggressive histological variants and poor tumour differentiation in 
medulloblastoma; factors that commonly signify poorer prognoses (Chu, 
Chen et al. 2011). 
With the exception of the aforementioned very recent publication by Gu 
et al. 2017, the majority of the research investigating the differential 
expression of MMPs in medulloblastoma was performed prior to its 
molecular subgrouping and therefore according to the histological 
variants (Vince, Herbold et al. 2001, Ö., B. et al. 2004, Bhoopathi, Chetty 
et al. 2011). This mandates a fresh look at the functional activity as well 
as the gene and protein expression of MMPs in the different molecular 






1.10 Matrix Metalloproteinases as biomarkers of 
Metastasis 
1.10.1 Introduction 
The significance of the role played by interactions between cancer cells 
and their microenvironment in the progression and dissemination of 
metastatic disease have borne fluctuating scientific interest in matrix 
metalloproteinases over the years. With over 23 different matrix 
metalloproteinases identified in the human genome (Shimoda and 
Khokha 2017), the gelatinases MMP-2 and MMP-9 are the most 
commonly correlated MMPs with metastasis of solid cancers including 
medulloblastoma (Ö., B. et al. 2004, Bhoopathi, Chetty et al. 2011). 
Overexpression of matrix metalloproteinases has been closely related to 
the staging and consequently predicted clinical outcomes of patients with 
disseminated cancer (Isaacson, Jensen et al. 2017). Moreover, where 
MMP upregulation is detected, multiple studies have demonstrated 
augmented neo-angiogenesis, cellular growth and migration, lymphatic 
spread of tumour cells and increased risks of recurrence (Isaacson, 
Jensen et al. 2017). Thus, if differentially expressed between the 
molecular subgroups of medulloblastoma, MMPs could provide a 
potential biomarker that may correlate with their differential metastatic 
potentials.  
MMPs are zinc and calcium endopeptidases with domains which consist 





their preferred substrates (Kessenbrock, Plaks et al. 2010). They can 
either be bound to the cell membranes of inflammatory cells as in the 
case of membrane-type MMPs or be secreted from the cytosol into the 
extracellular matrix where their activation enables their functions as 
modulators of the extracellular matrix (Kessenbrock, Plaks et al. 2010, 
Isaacson, Jensen et al. 2017).  
MMPs are synthesised as zymogens i.e. as inactive proenzymes that 
require activation by a number of mediators through interaction with the 
zinc-cysteine catalytic domains (Ö., B. et al. 2004). Though most MMPs 
are believed to be activated in the extracellular space, there is evidence 
that cytosolic activation also occurs especially concerning MMP-2 
(Isaacson, Jensen et al. 2017). 
MMPs can be categorised by the specific substrates that they hydrolyse. 
The characterised MMPs include the aforementioned Gelatinases 
(MMP-2 and MMP-9), the Collagenases (MMP-1, MMP-8, MMP-13), the 
Stromelysins (MMP-3, -10, -11), the Matrilysins (MMP-7, MMP-26) and 
those bound to the surface of the cell membrane (MTMMP-14, -15, -16, 
-17, -24 and -25) (Isaacson, Jensen et al. 2017).  
1.10.2 Regulation of Matrix Metalloproteinases 
The multilevel regulation of matrix metalloproteinases ensures a tightly 
controlled homeostasic tumour microenvironment. For instance, pro-





surface, where upon fusing with it, is activated by chelating with another 
activated membrane-bound metalloproteinase MMP-14. In addition to 
activating each other, the regulated function of matrix metalloproteinases 
is also dependent upon the presence of tissue inhibitors of 
metalloproteinases (TIMPs 1-4). These can impose both positive and 
negative regulation of various MMPs through complex formation, 
rendering the affected MMP active or inactive according to the desired 
effect (Ö., B. et al. 2004, Isaacson, Jensen et al. 2017, Shimoda and 
Khokha 2017).  
In addition to the mechanisms of regulation previously alluded to such as 
zymogen activation, MMP regulation has been characterised at the 
genomic and proteomic levels, at their transcellular exocytosis via 
membrane bound vesicles (Shimoda and Khokha 2017), their inhibition 
by TIMPS and complex formation with other MMPs (Isaacson, Jensen et 
al. 2017). Even more enthralling, is their recognised overexpression at 
each stage of carcinogenesis in many solid cancers (Isaacson, Jensen 
et al. 2017). Their widespread regulation and mechanisms of action have 
stimulated their consideration as targets for modulation of metastatic 
progression in cancers and culminated in the experimental investigations 
using exogenous MMP inhibitors. This was demonstrated in a study 
where Bhoopathi et al. who showed that inhibition of MMP-9 expressed 
by a SHH medulloblastoma cell line- DAOY cells, resulted in their integrin 





the development of specific targets of MMP inhibitors, for disruption of 
metastasis is warranted. 
1.10.3 Functions of Matrix Metalloproteinases 
MMPs have been widely documented to perform functions distinct to their 
modulation of extracellular matrix components. In fact, only a fifth of 
MMPs have been characterised to undertake matrix remodelling, while 
the majority are implicated in regulating cellular growth, proliferation and 
inflammation by the hydrolysis of growth factors, their receptors and 
modulating immune mediators such as cytokines. Thus MMPs appear to 
play key roles in homeostasis, tissue healing, embryogenesis and organ 
development, further highlighting their prominence in most bodily 
processes (Isaacson, Jensen et al. 2017).  
MMPs have been implicated in the facilitation of every stage of 
carcinogenesis from enabling loss of cell-to-cell connections allowing 
tumour cells to migrate through ‘pathways of least resistance’ within the 
extracellular matrix. Some theories put forward the role of MMPs in 
maintaining the stiffness of the ECM according to physiological or 
pathological need can impede or promote invasion or migration of tumour 
cells. In addition, MMPs have been shown to promote the production and 
maintenance of pro-inflammatory mediators that facilitate essential 





expression of angiogenic, proliferative and migratory factors (Isaacson, 
Jensen et al. 2017).  
 
Figure 1. 7 Stages of carcinogenesis in which matrix metalloproteinases are involved.  
As important modulators of the extracellular matrix in physiology and cancer, MMPs 
originating from tumour cells and their surrounding cellular microenvironment, digest 
matricellular substrates, releasing factors that prime the metastatic niche as well as create 
a more conducive milieu promoting migration, metastasis and intravascular invasion 
(Kessenbrock, Plaks et al. 2010).  
 
1.10.4 MMPs as biomarkers of metastasis and prognosis in 
Medulloblastoma 
To evaluate their potential as prognostic markers of metastasis and 
staging in various cancers, several studies have investigated their 





immunohistochemistry, genomic analysis using real time PCR (qPCR), 
protein expression quantification by Immunoblotting, ELISA and Gelatine 
Zymography (Isaacson, Jensen et al. 2017). 
As alluded to previously, several MMPs have been characterised to be 
upregulated in metastatic liquid biopsies from patients with cancer, by a 
10-fold incremental MMP expression compared to healthy controls. 
These levels have also been shown to relate significantly with the staging 
of the patient’s disease, and more importantly have been associated with 
increased risk of brain metastases as seen with aggressive breast 
cancer. This pathological overexpression of MMPs has been postulated 
to accord medulloblastoma cells with chemo- and radio-resistance, 
thereby promoting their dissemination and recurrence (Ganji, Nalla et al. 
2011). Consequent features of worsened survival, increased propensity 
to metastasize and invade locally as well as poorer tumour differentiation 
are seen, all of which correlate with increasing metastatic potential of the 
tumour cells (Ö., B. et al. 2004, Isaacson, Jensen et al. 2017). 
The most commonly implicated MMPs in medulloblastoma metastasis 
are MMP-1, -2, 9 and -13. MMP-1 in particular has been implicated in 
increasing endothelial permeability, making intravasation of metastatic 
cells and their haematogenous spread thereafter, much easier. In 
preparation of sites for metastases, MMPs are postulated to enable 





new niche for establishment of new metastases (Isaacson, Jensen et al. 
2017).  
Remarkably, MMP-9 is often preferentially associated with the cell 
membranes of cancer cells and is postulated to exert its effects in cellular 
proliferation, growth and angiogenesis (Isaacson, Jensen et al. 2017). In 
addition, MMP-2 and MMP-9 proteins have been detected within 
extracellular vesicles of malignant liquid biopsies from patients with 
aggressive ovarian and breast cancer (Shimoda and Khokha 2017).  
Furthermore, tumour cell derived membrane type 1-MMP activates 
MMP-2 and has also been shown to exert functions in the hydrolysis of 
gelatin and collagen type 1. This suggests that MT1-MMPs work in 
synergy with MMP-2 to create paths for migration of cells along these 
routes. There is little evidence regarding the overexpression of these 
gelatinases in CSF from patients with brain metastases, which presents 
an exciting opportunity for further research. It is plausible that 
metalloproteinase-containing endovascular vesicles cultivate new niches 
within the leptomeningeal space, thereby enhancing survival of the 
metastatic cells. Surface transport of highly concentrated 
metalloproteinases on extracellular vesicles such as exosomes and 
microvesicles promote shedding of anchoring proteins in the receptive 
cells following their incorporation, promoting free movement and invasion 
of these cells, as well as cultivating sites for neo-angiogenesis (Shay, 







Figure 1.8 The anatomically and physiologically distinct primary and metastatic 
niches in medulloblastoma.  
Emanating from the cerebellum (the top purple area) the primary MB tumour 
microenvironment consists of the cellular (astrocytes, oligodendrocytes, neurons, microglia 
and macrophages) and the extracellular matrix, rich in hyaluronan and proteoglycans. This 
nutrient-rich and supportive milieu create a conducive pro-migratory niche, that enables 
cancer stem cells to eventually leave the primary tumour and permeate brain vasculature, 
through defective BBB. Upon reaching the leptomeninges, circulating tumour cells are 
thought to acclimatise to their new sparse surroundings, by secreting immune mediators 
e.g. MMP-2 and MMP-9 themselves or through paracrine signalling to endothelial, immune 
and ependymal cells, rendering the BBB and blood-CSF barriers to become permeable to 
enriching factors. The now replenished metastatic cells then settle into their primed niche as 
nodular or laminar metastatic leptomeningeal coatings. [D] dura mater, [A] Arachnoid mater, 
[P] Pia mater, [SS] subarachnoid space, [E] endothelial cells, [G] glia limitans, [N] neurons, 
[BM] basement membrane. Image adapted from (Van Ommeren, Garzia et al. 2020).  
 
 














1.11 Molecular Magnetic Resonance Imaging  
1.11.1 Introduction 
Advances made in understanding the molecular mechanisms of 
medulloblastoma through genomic and proteomic analyses have been 
paralleled by achievements in the field of translational imaging, with the 
emergence of molecular magnetic resonance imaging. Even so, 
analogous to the delayed assimilation of molecular subgrouping of 
medulloblastoma into clinical practice, few pre-clinical techniques have 
been integrated into the mainstream.  Most attribute this to the existence 
of imaging modalities of equal standard, the increased need for specialist 
radiological expertise, scarcity of resources within the national health 
system and limited availability of equipment required (Haris, Yadav et al. 
2015).  
Magnetic resonance imaging exploits the natural magnetism derived 
from the precession of charged unpaired protons that can be excited by 
absorbing energy from a radiofrequency pulse, targeted to their specific 
resonance frequency.  Following excitation within an external magnetic 
field, these protons achieve higher energy states and return to their 
stable state, emitting the absorbed energy, which is then detected and 
transduced into an image by a number of processes.  
The strength of the signal from the emitted electromagnetic energy is 





thus signal strength is achieved by the characteristic molecular and 
proton density of the specific tissue (Panigrahy and Blüml 2009). This 
can be further augmented by ‘weighting’ the image to improve spatial 
resolution, applying further radiofrequency pulses or altering their 
duration, or by administering intravenous contrast agents composed of 
paramagnetic metals such as gadolinium, which amplify vascular 
enhancement.  In clinical practice, intolerance to the contrast agents 
used, limit their use and necessitate their replacement with sensitive 
nuclear magnetic resonance (NMR) modalities that negate the need for 
exogenous contrast. Two such techniques include 1H Magnetic 
Resonance Spectroscopy (1H-MRS) and diffusion-weighted imaging 
(DWI) (Blüml, Margol et al. 2015, Goo and Ra 2017). 
1.11.2 Magnetic Resonance Spectroscopy 
Magnetic Resonance Spectroscopy (MRS) is a well-established NMR 
technique that allows for direct evaluation of the metabolite profiles of 
tissues and cells, thus depicting the metabolic microenvironment. It is 
preferred to mass spectrometry, as MRS is allows for in vivo detection of 
the metabolite profiles of tumours in situ (Haris, Yadav et al. 2015, 
Manias, Gill et al. 2017).  
MRS has been demonstrated to be useful in predicting clinical outcomes 
based upon metabolite profiles that have been correlated with aggressive 





medulloblastoma subgroups in patient samples, by using a 5-metabolite 
discriminator (Blüml, Margol et al. 2015). Bluml et al 2015 demonstrated 
accurate sub-group differentiation of 30 medulloblastoma tumours by 
correlating their differential spectra of creatine, myo-inositol, taurine, 
aspartate and lipid 13 (Blüml, Margol et al. 2015). The ease with which 
MRS can be performed in the clinical setting enabled its translation. 
Though important, the determination of medulloblastoma subgroup of a 
patient’s tumour is not sufficient for the determination of its metastatic 
potential and is consequently inadequate for the complete 
prognostication of their disease (Holgado, Guerreiro Stucklin et al. 2017, 
Ramaswamy and Taylor 2017). Thus, other non-invasive, translational 
imaging modalities are required to address this problem.  
MRS is also limited in its portrayal of the tumour environment at a 
molecular level due to its poor resolution for detection of low 
concentration metabolites. In addition, a phenomenon referred to as 
‘resonance frequency overcrowding’ prevents the identification of 
individual spectra of metabolites that have similar resonance 
frequencies. Moreover, the detection of many metabolites will be affected 
by uncontrollable factors such as basal metabolic activity, presence of 
oxidative stress, age and any simultaneous physiological or pathological 
processes that may alter the metabolite concentrations. Thus, it is difficult 
to distinguish whether alterations in metabolite concentrations are solely 





Even so, proton magnetic resonance spectroscopy (1H MRS) has been 
shown to successfully predict the aggressiveness of tumours by 
evaluating the ratios of endogenous metabolites detected, to produce 
spectra of increased amplitude compared to those expressed by normal 
tissue. For example, the Choline (Cho): N-acetylaspartate (NAA) ratio 
has been used in the staging of astrocytomas and gliomas, while the 
Cho: Creatine ratio has been used to differentiate low-grade gliomas 
from normal brain tissue. Choline compounds such as phosphocholine 
have also been correlated with malignant transformation of several solid 
cancers including breast and ovarian carcinoma (Haris, Yadav et al. 
2015).  
1.11.3 Diffusion-weighted imaging MRI 
Diffusion weighted magnetic resonance imaging (DWI-MRI) is an 
advanced technique that quantitatively portrays characteristics of 
tumours and metastases that correlate with increased metastatic 
potential. These include parameters such as cellularity and associated 
vasogenic oedema, vascularity and proliferation. It does so by measuring 
the diffusion of water within a tissue at a molecular level, producing a 
value known as the ‘apparent diffusion co-efficient’ (ADC) which 
inversely correlates with the cellularity of a given tumour. Consequently, 
the ADC value of MB tumours is typically low in comparison to normal 





 In addition to use in cancer, DWI-MRI also helps the clinician to 
distinguish between infective cavities and high-grade tumours, which on 
conventional MRI would not be easily established. As such, it forms a 
part of the newer multiparametric MRI protocols for the diagnosis and 
surveillance of patients with brain tumours and prognostication of 
metastatic disease (Sawlani, Patel et al. 2020).  
1.11.4 MMP-2 and MMP-9 as Imaging Biomarkers using 19F MRI 
Enzymatic Probes  
In the quest for developing MR Imaging biomarkers, biomarker studies 
in cancer have used activatable enzymatic probes as contrast agents to 
enhance MRI sensitivity and specificity (Carril 2017). 1H enzymatic 
probes have been the most frequently published agents to demonstrate 
increased activity of enzymes thought to play significant roles in 
carcinogenesis and metastasis. Examples of previously investigated 
enzymes including tyrosine kinases, caspase-3, caspase-7 and -
Galactosidase, the latter of which has also been used with fluorine 
probes (Carril 2017).  
As previously mentioned, standard MRI techniques target the differential 
resonance frequencies of protons attached to different molecules within 
soft tissue. As 1H is highly prevalent in the human body, its high 
background signal confers high signal-to-noise ratios (SNRs) as well as 
low specificity. For this reason, 19F MR imaging with similar natural 





because most fluorine in the body exists as a stable isotope. Therefore, 
any resulting MR signal is derived from the probe given, while the low 
background signal of endogenous fluorine, affords enhanced specificity 
(Carril 2017). 
For use as enzymatic biomarkers, we wish to quantify the levels of MMP-
2 and MMP-9 in our medulloblastoma cell line supernatants and correlate 
the resulting differences in signal strengths to the patterns of functional 









Figure 1.9 Our locally synthesised 19-Fluorine MMP-MRI probe 
Our locally synthesised Fluorine-MMP MRI biosensor allows for the dynamic quantification 
of MMP-2 and MMP-9. Cleavage of the MMP specific substrate results the increased 
distance between the fluorine moiety and gadolinium DOTA complex. Due to the previously 
paramagnetically shielded fluorine moiety by the chelate, the resulting increased distance 






Similar to other 19F-MRI enzymatic probes, our MMP-biosensor consists 
of the fluorine-containing moiety, which upon excitation with its specific 
radiofrequency pulse delivers the signal, the paramagnetic Gd III-bound 
DOTA-complex and the peptide substrate which links the other two 
constituents. Therefore in the presence of MMP-2/MMP-9, cleavage of 
the gelatin peptide linker results in 19F-MRI signal (Carril 2017).  
Building upon the strides achieved in understanding the mechanisms of 
metastasis using genomic profiling, we aim to characterise differentially 
expressed proteins that correlate the behaviour of different metastatic 
medulloblastoma cell lines and enable detection of potential indicators of 
poorer prognosis and disease dissemination.   
To this end, we plan to identify biomarkers of metastasis that can predict 
the metastatic behaviour of medulloblastoma and are detectable on safe 
translational MRI techniques, to better stratify patients at highest risk of 
metastatic and recurrent disease, who would benefit most from the more 
aggressive multimodal therapeutic strategies. We are initially 
investigating Matrix Metalloproteinases (MMPs), enzymes implicated in 
tumorigenesis and at every stage of metastasis, to ascertain whether 
they are differentially expressed between different metastatic 
medulloblastoma cell lines. We hope to detect and correlate these 
biological analyses using MRI-MMP biosensors, a novel technique which 
would allow for the real-time in vivo determination of the metastatic 












Chapter 2.  












Materials and Methods 
2.1 Cell culture 
All medulloblastoma cell lines used in the subsequent 2-D and 3-D 
experiments are indicated in Table 2.1, with brief details of the clinical 
history pertaining to the patient donors from whom the cell lines were 
derived. The cells were obtained from sub-cultures previously defrosted 
by fellow colleagues, to reduce the time taken for the cell lines to recover 
and establish their respective proteome in culture. Cell culture was 
undertaken in aseptic conditions and all equipment decontaminated with 
70% IMS thoroughly prior to use to reduce the risk of infection.  
2.1.1 Procurement of cell lines 
The group 4 matched primary and recurrent medulloblastoma cell lines 
CHLA-01-MED (ATCC®CRL-3021) and CHLA-01R-MED (ATCC®CRL-
3034) were kindly donated by Professor Geoff Pilkington (University of 
Portsmouth, UK)  while the group 3 cell line HD-MB03 was kindly donated 
by Dr Till Milde (DKFZ, Heidelberg, Germany). The cell line D283 Med, 
categorised as intermediate Group 3/4 medulloblastoma was purchased 
from ATCC (ATCC®HTB-185™) as was the DAOY SHH cell line 
(ATCC®HTB-186™). The cell lines ONS-76 (a wild type p53 cell line as 
well as its counterpart with and a dominant negative TP53 ONS-76, were 
gifted by Annette Künkele (Charité Universitätsmedizin, Berlin) and Dr 





UW228-3 cell line.  The primary of the matched Group 3 cell lines pair, 
D425-Med, was kindly donated by Marcel Kool (DKFZ, Heidelberg) and 
its metastatic counterpart D458-Med, by John R. Silber (University of 
Washington, Seattle). The neural stem cells used as controls in the 
western blotting experiments were FB83 were derived from human foetal 
tissue obtained via a Joint MRC/Wellcome Trust grant (#099175/Z/12/Z), 
and H1-NSC a kind gift from a colleague from Dr Ruman Rahman’s team 
at the CBTRC.  
2. 1.2 Sub-culture of cell lines  
2.1.2.1 Adherent cell lines 
The FB83, DAOY, UW228-3 and ONS-76 cell lines were cultured in 
treated flasks (Eppendorf/Corning) as per our lab’s local standard 
operating procedures. Cell supernatants were aspirated and the 
adherent 70-80% confluent cells, washed with 10 mL of HBSS (Gibco, 
14170) prior to  dissociation from the flask bottom with 2mL of 1X Trypsin-
EDTA (Sigma, LH-SIG2044) and then allowed to incubate at 37°C in 5% 
CO2 for 5 minutes. Following confirmed dissociation into single cells by 
microscopy, 3 mL of the required medium was added to the flask to 
inactivate the trypsin. The resulting 5mL cell suspension was transferred 
to a clean labelled falcon as well as a further 5mL of media used to wash 
the flask to obtain residual cells. A dilution of 1:3 or 1:5 of cell suspension: 











2.1.2.2 Semi-adherent cell lines 
The semi-adherent medulloblastoma group 3 cell lines D425-Med, D458-
Med, D283-Med and the HD-MB03 cells and were cultured in treated T75 
or T25 flasks (Eppendorf/Corning). Firstly, cell suspensions were 
transferred into the respective labelled falcons and retained. As with the 
adherent cells, following a wash with 10mL of HBSS, the semi-adherent 
cells were incubated with 1X Trypsin-EDTA in the same incubator 
conditions as before. 7mL of the required media was added to inactivate 
the trypsin and the resultant mixture added to the previously removed 
cell suspension. As HD-MB03 cells grew faster than the D283 Med cells, 
they were split in 1:5 and 1:3 respectively with fresh media every 48-72 
hours.  
2.1.2.3 Suspension cultured cell lines 
The paired group 4 cell lines CHLA-01-MED and CHLA-01R-MED were 
cultured in non-treated T75 or T25 flasks (Eppendorf). In suspension 
culture, the primary CHLA-01-MED formed more clusters and appeared 
to proliferate more rapidly requiring a slightly harsher split compared to 
its recurrent counterpart, CHLA-01R-MED. As per ATCC 
recommendations, the cells were always sub-cultured in 25% of their 
previously conditioned medium, with 75 % of fresh media which was 





weekly, the cell suspensions were centrifuged at 100g for 7 minutes and 
re-suspended in the aforementioned ratio of conditioned: fresh media.  
2.2 Preparation of 2-D cultured medulloblastoma cell line 
samples for gelatin zymography, gene and protein 
expression from the same cell population 
The preparation of matched cell pellets and supernatant samples from a 
panel of nine medulloblastoma cell lines was performed, to reduce the 
effects of any confounding technical or environmental factors that would 
be difficult to control.  
Figure 2.1 demonstrates a schematic of how this was performed. Prior to 
their use in any experiments, mycoplasma infections were excluded on 
a regular basis and cell viability confirmed using PrestoBlue blue reagent 
(ThermoFisher, A13261). The PrestoBlue was diluted in medium (1 in 5 
dilution) and added to cells within black-walled 96 well plates. After an 
hour’s incubation at 37˚C in the dark, fluorescence was quantified using 
our FLUOstar microplate reader (BMG, labtech). 
2.2.1 Preparation of cell pellets for molecular analysis 
Following removal of the conditioned medium from the adherent cell 
lines, 1XTrypsin-EDTA was used to detach the cells and thereafter 
inactivated with the respective cell line growth medium, resulting in a cell 
suspension. For the semi-adherent cell lines, the conditioned medium 





Eppendorf and the remaining cells trypsinised with 1XTrypsin-EDTA, 
which was inactivated with the respective media and added to the cells 
already in suspension.   
All cell suspensions including the group 4 cell lines that required no prior 
preparation as they grow in suspension, were thereafter subjected to 
centrifugation at 100g for 7 minutes. The supernatants were removed 
and the resulting cell pellets re-suspended in 1 mL of PBS and re-
centrifuged in the same conditions. The excess PBS was removed with 
a 1mL pipette with care not to disperse the pellet and the cell pellets snap 
















Figure 2.1 Schematic workflow of the main methods described in this thesis.  RNA and protein were extracted from the same cell pellets to enable comparison of 
the gene and protein expression of the same cell population from each MB cell line. The supernatant aspirated prior to cell harvest was first split into two following 





2.3 Experimental set-up for Gelatin Zymography 
2.3.1 Controls 
For the initial zymogram experiments, concentrated Foetal Bovine Serum 
(FBS, HyClone) was used as a positive control to assess for technical 
validity. Once a positive zymogram was obtained, the positive controls 
used were Recombinant human MMP-2 (Peprotech, 420-02) and 
Recombinant human MMP-9 (R&D systems, 911-MP-010). Both were 
re-constituted according to the instructions received from the respective 
companies. As the signal from the latter seemed to obscure adjacent 
wells on the zymogram, a further Recombinant human MMP-9 was 
obtained from Abcam (Ab168863). As serum (FBS) had produced a 
positive signal in the first optimisation zymography experiments, the 
respective serum-containing culture media were loaded in equal volumes 
as the supernatant samples and used as further positive controls.  
2.3.2 Preparation of conditioned medium for 
zymography, ELISA and protease/protease inhibitor 
arrays  
2.3.2.1 Cell counting 
For each experiment, the same cell number of each cell line were seeded 
into their respective flasks and conditioned medium collected 48 hours 
after culture in 37°C, 5% CO2 conditions. From the resulting cell 





cells with 7mL of required media for both semi-adherent and adherent 
cells lines, 10µl of this was added to 10µl of Trypan blue and cells 
counted on either an EVE™ Automated Cell Counter (Nanotech) or  
manually using a haemocytometer and clicker.  
For the paired group 4 cell lines growing as clusters and single cells in 
suspension culture, dissociation into single cells was achieved by 
centrifuging an aliquot of the cell suspension at 100g for 7 minutes and 
extracting the supernatant. The resulting cell pellet was thereafter re-
suspended 10X in Accutase cell detachment solution (AT104-500) in a 
ratio of 1:5 of Accutase to the volume of the aliquot taken for cell 
counting.  This mixture was then re-suspended 10X, incubated for 10 
minutes and re-suspended again 10X before 10µL was added to an 
equal volume of the trypan blue and cells counted on an EVE™ 
Automated Cell Counter (Nanotech) or manually using a 
haemocytometer and clicker.  
For each cell suspension, trypan blue mixture was mixed by pipetting up 
ten times and 10µL of the mixture loaded to the EVE counting slides. 
After insertion of the slide, the default cell counting mode was selected 
and a live cell count per mL obtained. This was used to calculate the 
required volume of cell suspension of the respective cell lines, required 
for the seeding of 5X106 cells in the respective flasks. The volume of 
required media was then added to the flasks and incubated at 37°C, 5% 





487 hours later, MB cell suspensions obtained as described in the 
manner detailed in the preceding cell culture section were centrifuged 
first at 800 rpm, then at 1500rpm each for 7 minutes.  
 
2.3.3 Preparation of SDS Polyacrylamide Zymogram gel 
To prepare the gelatine constituent of the separating zymogram gel, a 
5mL solution of (3mg/mL) of Gelatine (Sigma, G1890) was completely 
dissolved in distilled water by gentle warming in a water bath at 37°C. 
Once fully dissolved, it was cooled completely by incubating at 4°C and 
filtered prior to use.  
To prepare the 3% Gelatin impregnated SDS-PAGE gel, the reagents 
were added as per Table 2 and vortexed for 10 seconds prior to pouring 
the separating gel mix into a clean 1mm spacer (Biorad). This was 
allowed to set 1 hour after which the stacking gel was made. A thin layer 
of 70% IMS was overlaid above the separating gel mix to ensure it set in 
a straight line.  
The stacking gel was made by adding the following components (Table 
3), mixing by vortex for 10 seconds and pipetting it onto the separating 






Table 2.2 Separating gel mix 
 






The stacking gel set after 90 minutes and the gel cassettes covered with 
a damp paper towel and stored within a plastic sealed bag at 4°C for at 
least 1-2 hours prior to use. For best results, gels and the supernatant 
samples were used within 7 days to prevent expiry of the gelatine and 





2.3.4 Zymography buffer components 
The solutions used in the zymography technique were made according 
to buffer constitution instructions kindly advised by our postdoctoral 
research fellow, Dr Franziska Linke. The constituents of the buffers used 
were as follows; 10X running buffer: 25mM Tris Base (X), 192 mM 
Glycine and 0.1% SDS; the 2X sample buffer: 0.5M Tris-HCl pH. 6.8, 
10% SDS, 25% Glycine and 1% Bromophenol blue (Santa Cruz, E0807); 
10XRenaturing buffer: 2.5% Triton-X-100 (Sigma, T8787) and the 
Developing buffer was procured from Biorad, 161-0766. The Coomassie 
Blue staining solution was made up as a 0.5% Coomassie R-250 
(ThermoScientific, 20278) solution in 10% Acetic acid and 40% 
methanol, while the de-staining solution was 40% Methanol and 10% 
Acetic acid in distilled water.  
2.3.5 Loading and running the gel 
Following a 48-hour incubation at 37C and 5% CO2, the supernatant 
from each MB cell line, was removed and twice centrifuged at 100g for 7 
mins to exclude any cell debris. Cell supernatant samples were collected 
within a week of the zymography being performed. 30L of each 
supernatant and control sample were mixed with an equal volume of 2X 
sample buffer (SB) and 20L of this was loaded with a Hamilton pipette 
into each well. The gel was run at a constant voltage of 125V until the 





separating gel and with the electricity off, a further 20L of the 
sample/control:2XSB solution was added and the gel allowed to run until 
the sample buffer ran off the gel.  To allow for the best separation, the 
gel was electrophoresed for a further 15-20 minutes before being 
removed from the gel cassettes and washed in renaturing buffer for 1 
hour under slight agitation at room temperature. The renaturing buffer 
was then replaced with developing buffer and the gel washed for a further 
30 minutes. After this step, the developing buffer wash was replaced and 
the gel incubated at 37C for 18 hours (2D) and 24 hrs (3D).  
 
After the appropriate incubation time, the gel was thrice washed in 
deionised water with gentle agitation at room temperature and thereafter 
submerged in the coomassie blue staining solution for 15 minutes. The 
gel was then placed in de-staining solution for up to 2 hours or until clear 
bands of digested gelatin were visible on the blue background of the gel. 
Images of the gel were then acquired either by scanning the gel within a 
sealed, transparent plastic case or with a phone camera. The images 
were then imported into Image J and semi-quantitative determination of 
MMP-2 and MMP-9 functional activity thereafter determined by 






2.4 Investigating the MMP-2 and MMP-9 gene expression 
in medulloblastoma cell lines 
Real-time polymerase chain reaction (qRT-PCR) is a technique that 
enables the sensitive quantification of a gene’s expression in multiple 
samples simultaneously. A primer sequence specific to the gene of 
interest initiates the transcription of the gene within the double stranded 
cDNA template of the sample being examined. Optimal conditions 
created by cyclical temperature variations programmed in the real-time 
PCR cycler, result in amplification of the DNA product until the reaction 
is stopped. Addition of a fluorescent dye such a SYBR Green I (Biorad) 
that binds to double stranded DNA, results in an increasing fluorescence 
signal that is proportional to the quantity of the amplified DNA product of 
interest. The continuous fluorescence signal is detected with time and 
plotted graphically. To improve validity of the experiment, the 
quantification of a gene that is expressed by all the samples being 
compared, is performed alongside that of the gene of interest and the 
latter normalised according to the former, known as the housekeeping 
gene.  For these experiments, the Glyceraldehyde-3—phosphate 







2.4.1 RNA extraction 
A panel of nine sub-grouped medulloblastoma cell lines were cultured in 
their normal media for 48 hours in 5% CO2 at 37˚C and cell pellets 
containing approximately 2.5X106 cells were obtained and frozen down 
at -80˚C. RNA extraction using the Nucleospin© RNA plus (Fisher) kit 
was performed simultaneously on all cell pellet samples designated for 
the same experiment.  RNA quality and concentrations were quantified 








Figure 2. 2 Analysis of the concentrations (ng/ µl) of RNA extracted from sub-grouped 
MB cell lines. 
Brackets indicate paired Group 3 and Group 4 cell lines. While the paired Group 3 cell lines 
D425 (primary) and D458 (metastatic) demonstrated similar quantities of RNA from the 
same number of cells, the Group 4 primary cell line CHLA-01 produced higher quantities of 






Table 2.4 RNA Nanodrop table showing quantities of RNA from MB cell lines 
Cell line samples Nucleic Acid Conc. (ng/µl) 260/280 260/230 
DAOY 3039.8 2.16 2.04 
DAOY 1480.8 2.14 2.16 
DAOY 1977.4 2.12 2.16 
ONS76 1931.3 2.12 2.14 
ONS-76 1364.6 2.19 2.12 
ONS-76 2179.8 2.12 2.07 
ONS-76 1716.4 2.14 2.1 
ONS-76 1723.4 2.12 2.21 
ONS-76 dnp53 2269.5 2.1 2.18 
ONS-76 dnp53 2002.9 2.11 2.22 
ONS-76 dnp53 1959.6 2.1 2.05 
UW228-3 1199.3 2.15 2.15 
UW228-3 2180.3 2.1 2.04 
UW228-3 1345.7 2.13 2.02 
CHLA-01 783.5 2.15 2.1 
CHLA-01 1548.4 2.16 1.98 
CHLA-01 1667.6 2.13 2.04 
CHLA-01R 1230 2.17 2.02 
CHLA-01R 877.8 2.12 2.04 
CHLA-01R 799.1 2.11 2.18 
CHLA-01R 798.5 2.15 2.07 
D283 606.5 2.07 2.07 
D283 1187.4 2.14 2.12 
D425 1141 2.1 2.2 
D425 821.7 2.08 2.16 
D425 787.8 2.07 2.19 
D458 1355.7 2.15 2.1 
D458 786.4 2.11 2.08 
D458 1095.3 2.11 2.22 
D458 993.3 2.1 2.2 
D458 940.7 2.1 2.26 
D458 1150.3 2.14 2.15 
HDMB03 1783.4 2.15 2.04 
HDMB-03 2162.8 2.15 2.1 
HD-MB03 1153 2.13 2.23 





Once the quality and concentration of the eluted RNA from each sample 
was confirmed, they were stored at -80˚C or transcribed into cDNA, the 
beginning blocks for the real-time PCR experiments.  
2.4.2 cDNA synthesis 
RNA samples for cDNA synthesis were defrosted on ice and diluted to a 
concentration of 1µg/mL of RNA before being combined with the 
reagents as indicated in Table 2.5.  
Table 2.5 Reagents and volumes required to be added to RNA and dH2O for cDNA 
synthesis 
 
The samples were then heated up in a thermocycler on an automated 
program that heated the samples to 25˚C for 5 minutes, 50˚C for 45 
minutes and lastly 70 ˚C for 15 mins. The resulting cDNA was stored at 





2.4.3 MMP-2 Primer optimisation 
The MMP-2 prime sequence used for the PCR experiments was a kind 
gift from a collaborator, Professor Anna Grabowska (University of 
Nottingham).  The primer sequence was then confirmed to have suitable 
properties on searchable free online software programs, Oligocalc © and 
Oligoanalyzer©. 
Table 2.6 MMP-2 (human) gene primer sequence 
Matrix metalloproteinase 
2 (MMP-2), Gelatinase A 
GCCTTTAACTGGAGCAAAAACAA TCCATTTTCTTCTTCACCTCATTG 
 
2.4.3.1 Determining the annealing temperature of the MMP-2 
primer 
Gradient polymerase chain reaction (PCR) experiments were performed 
to determine the optimal annealing temperature of the MMP-2 primer in 
Table 3.2. Positive and negative cDNA samples were tested alongside a 
no template control (NTC) at five different temperatures i.e. 57.1˚C, 58.1 
˚C, 59.6 ˚C, 60.2 ˚C, and 62.2 ˚C, to obtain a temperature gradient. After 
adding the same volume of a master mix containing SYBR green I 
(Biorad), forward and reverse MMP-2 primers (see table 3.2) and PCR 
grade water, the samples were centrifuged prior to incubation in a 
thermocycler and a pre-set program run as detailed in the methodology 
chapter of this thesis. Once synthesised, equal volumes of the PCR 





ladder of 100 base pairs and allowed to run for 30-45 minutes at 120V 
until good band separation was achieved.   
The MMP-2 primer product length was approximately 98 base pairs at 
the optimal annealing temperature of 60 ˚C. Once the primer efficiency 
of the MMP-2 primer was determined by a fellow student, Hannah 
Jackson, confirmation experiments were performed and the MMP-2 





Figure 2.3  Results from confirmation experiments of MMP-2 primer efficiency. A. Melt 
peak shows a single product above the threshold and smaller peaks of secondary products 
below. B. Amplification plots of the SYBR Green I fluorescence at different levels of DNA 
concentration. C. Indicates good pipetting technique, as all values were either superimposed 
or proximal to each other. 
 
A panel of nine sub-grouped medulloblastoma cell lines were cultured in 
their normal media for 48 hours in 5% CO2 at 37˚C and cell pellets 
obtained for RNA extraction and subsequent cDNA synthesis. RNA 





74098450) and cDNA synthesised as described in chapter 2 of this 
thesis. Real time PCR experiments using SYBR green I (Biorad) were 
performed and results normalised to the expression of GAPDH, to enable 
comparison of MMP-2 gene expression of each MB cell line. 
2.4.4 MMP-9 Primer optimisation 
 
To date, five MMP-9 primers were tested and failed at either the Gradient 
PCR stage or at the primer efficiency experiments. Unfortunately, during 
the time of the experiments, substantial equipment problems were 
experienced that prevented return to testing further MMP-9 primers.  
The most successful MMP-9 primer tested, was a sequence also 
donated as a kind gift from a collaborator, Professor Anna Grabowska 
(University of Nottingham).  
Table 2.7 MMP-9 (human) gene primer sequence 
Matrix metalloproteinase 
9 (MMP-9), Gelatinase B 
GCCTTTAACTGGAGCAAAAACAA TCCATTTTCTTCTTCACCTCATTG 
 
2.4.4.1 Determining the annealing temperature of the MMP-9 
primer 
Following the same procedure as that performed for the MMP-2 primer, a gradient 
PCR experiment ( 











Figure 2.4 Gradient PCR for MMP-9 primer (Table 3.3) optimisation showing a PCR 
product at approximately 100 base pairs with equally strong signals at all 5 
temperatures tested. From left to right T1= 57.1˚C, T2=58.1 ˚C, T3=59.6 ˚C, T4= 60.2 ˚C, 
and T5= 62.2 ˚C. 
 
2.4.4.2 MMP-9 Primer efficiency experiments 
Having been previously demonstrated to express MMP-9 (ref), cDNA 
from the DAOY cell line was selected to confirm primer efficiency of the 
MMP-9 sequence in table 3.3. Several challenges were encountered and 
further experiments modified to surmount them. However, due to limited 
time, MMP-9 gene expression experiments were not taken further.  
To confirm correct experimental technique, the experiments were first 
performed using primers from the housekeeping gene, GAPDH. As it is 
a routinely used primer, it was optimised by previous PhD students in our 
lab. These results were then used as a benchmark, to compare the 
results from the MMP-9 primer efficiency experiments.  A dilution series 
of cDNA was performed and the resulting GAPDH gene expression 





peak curve and clear sample amplification plots from the samples with 




F: ATGTTCGTCATGGGTGTGAA R: GTCTTCTGGGTGGCAGTGAT 
 
Figure 2.5 Results from primer efficiency experiments on GAPDH primer.  
A. Melt peak shows a single product above the green line (threshold) which shows no other 
DNA products or primer dimers were obtained. B. Amplification of the SYBR Green I 
fluorescence at different levels of DNA concentration. C. indicates good pipetting technique 
as all values were either superimposed or proximal to each other. D. GAPDH sequence  
 
Detailed efforts to further optimise this and published MMP-9 primers 








2.5 MMP-2 and MMP-9 protein expression in 
medulloblastoma cell lines 
2.5 Determination of relative protein concentration using 
Bradford assay 
For the calculation of relative protein content of the samples loaded on 
the gel, a Bradford assay was performed using the Protein Assay Dye 
Reagent concentrate (Biorad, 500-0006) This was diluted 1:4 in distilled 
water to the volume required depending on the number of samples to be 
tested (1mL/sample). A 0.2% solution of Bovine serum albumin (Sigma-
Aldrich, A7906) was used to prepare the required standards shown in 
Table 2.8 below. 
Table 2.8 Bradford assay standards with increasing BSA concentration 
 
 
These were then loaded onto a pre-planned 96-well flat bottomed plate 
along with similar volumes of supernatant samples (Eppendorf). Once 
the protein content of the samples was visually determined to be in the 
range of the Bradford assay standards, the plate was inserted into the 
plate reader (FLUOstar Omega, BMG Labtech) and the Bradford assay 
program on Omega selected. The results were then exported into a pre-





Figure 2.6 Graphical representation of the stepwise incremental protein 
concentrations of the Bradford reagent standard curve. 
 




Figure 2.6 Graphical representation of the stepwise incremental protein 
concentrations of the Bradford reagent standard curve. 
 
 











































Blank 0.276 0.274 0.257 0.269 0 0.000
1 0.29 0.289 0.291 0.29 1 0.021
5 0.328 0.326 0.335 0.329667 5 0.061
10 0.377 0.382 0.391 0.383333 10 0.114
15 0.438 0.44 0.448 0.442 15 0.173
20 0.48 0.484 0.492 0.485333 20 0.216
30 0.57 0.583 0.586 0.579667 30 0.311
40 0.661 0.658 0.658 0.659 40 0.390
D283 media 0.483 0.508 0.5 0.497 D283 media 0.228 0.240 15.088 7.544 2.651
D283 supern. 0.435 0.443 0.442 0.44 D283 supern. 0.171 0.183 11.503 5.752 3.477
CHLA media 0.409 0.405 0.41 0.408 CHLA media 0.139 0.151 9.491 4.745 4.215
CHLA 01 supern 0.386 0.405 0.397 0.396 CHLA 01 supern0.127 0.139 8.736 4.368 4.579
CHLA 01R sup. 0.362 0.376 0.382 0.373333 CHLA 01R sup. 0.104 0.116 7.310 3.655 5.472
HDMB03 media 0.405 0.401 0.413 0.406333 HDMB03 media0.137 0.149 9.386 4.693 4.262





2.6.1 Western blotting 
To determine the baseline differential MMP-2 protein expression in 
isogenic primary and medulloblastoma cell lines, equal amounts of 
protein lysates were examined using western blotting. Briefly, equal 
amounts of protein from each cell line as determined in Bradford assays, 
were agitated with equal volumes of 4X sample buffer containing β-
mercaptoethanol and loaded into 1.5mm wells of 10% sodium dodecyl 
sulphate polyacrylamide gels (SDS-Page). The gels were 
electrophoresed within running buffer at 40 milliamps until adequate 
separation of the protein ladder was observed. The separated proteins 
were then transferred from the gels onto polyvinylidene difluoride (PVDF) 
membranes which were dried for 15 minutes before being blocked in 5% 
bovine serum albumin in TBS-T for 1 hour. The membrane was then 
incubated with 10mls of 1:1000 primary anti-rabbit MMP-2 antibody (Cell 
signalling; #4022) diluted in the blocking solution for 18 hours at 4˚C. The 
next day, the membrane was washed in TBS-T before and after being 
incubated with the secondary anti-rabbit antibody at 1:1000 
concentration in 5% BSA for 1 hour at room temperature. After incubation 
with horseradish peroxidase (HRP) solution and ECL solution, the 
membranes were imaged using chemiluminescence (LAS 4000 mini 
Biomolecular imager, GE Healthcare) and image J densitometry used to 






2.6.2 Enzyme Linked Immunosorbent Assays [ELISA] 
ELISA experiments were mainly used to determine what role the storage 
conditions of supernatants and CSF would exert on the levels of MMP-2 
protein detectable. The Quantikine total MMP-2 immunoassay kit (R&D 
systems; MMP200) was used to detect the MMP-2 levels within cell 
supernatants to determine the optimal storage conditions for CSF.  
A standard of MMP-2 concentrations was prepared by its serial dilution 
to give a standard curve for comparison to, when read by a plate reader. 
Reagents were added to the same volume of samples to be investigated 
and a substrate solution added last to the sample was observed to 
change colour depending upon the MMP-2 concentration within the 
sample. Results were then extrapolated from the correlated optical 
density to the MMP-2 standards and concentrations of our samples 
given.  
2.6.3 Protease and protease inhibitor arrays 
Forty-eight hour conditioned cell supernatants were prepared as 
previously described and tested immediately after being harvested, using 
a Human Protease/Protease inhibitor Array kit (R&D Systems; ARY025). 
Reagents and buffers required were all provided within the kit and used 
according to the volumes and times described within their manual. 
Briefly, nitrocellulose membranes were placed into a multi-well plastic 





at room temperature. During this time, samples for analysis were diluted 
to a volume of 1.5ml with array buffer 6, with the addition of 15µl of either 
the protease or protease inhibitor detection antibody cocktails. The 
membranes were then incubated in the supernatant/array buffer 6 
solution overnight at 4˚C. The next day, in a manner similar to western 
blotting, the membranes were thrice-washed before being incubated with 
2mL of Stretavidin-HRP. Further washing with the washing buffer was  
done after 30 minutes of incubation and array detection assessed using 
chemiluminescence, as previously described.  
Array correlates were localised using the transparent overlay templates 
provided and quantified using a publicly available macro for analysis of 
protein arrays (see appexndix). Densitometry performed on Image J was 
then used to compare the relative protease and protease inhibitor 
expressions within the supernatant samples, with normalisation to the 
mean of the reference controls on each membrane. Graphs were created 
on Graphpad prism.  
2.6.4 Fluorescence Resonance energy transfer (FRET) 
As previously employed in the optimisation of our MRI-MMP biosensor, 
FRET assays were used to explore specific factors prior to imaging with 
the biosensor which is expensive. Equal volumes of supernatant derived 
from samples with the same initial seeded cell numbers, were pipetted 





quenched DQ gelatin and reaction buffer. The presence of MMP-2/MMP-
9 within the supernatant sample would degrade the fluorescent 
quenched gelatin, resulting in increasing fluorescence with time, as 
detected by our FLUOstar Omega plate reader (BMG labtech) and 
plotted using graph pad prism.  
2.7 3-D cell culture 
SHH cell lines DAOY, ONS-76 and UW228-3 were the main cell lines 
cultured as unicellular spheroids. Using a protocol for the development 
of a spheroid MB model that was optimised by a colleague Dr Sophie 
Roper, the optimal cell densities of each cell line, were seeded within 
ultra-low attachment round bottom plates (Corning, 7007) and left to 
aggregate over 96 hours in 200µl of freshly prepared neurosphere 
medium. These cell lines formed tight spheroids, which could be safely 
transferred with 100µl of their older medium, to ECM coatings on flat-
bottomed 96 well plates with 100µl of fresh neurosphere medium, 
prepared every 7 days. This practice helped to ensure that the added 
factors remained active within the medium (recipe in Table 2.10).  








2.7.1 Spheroid migration across a Collagen IV matrix  
Day 4 generated spheroids of approximately ~300µm diameter, were 
transferred along with 100µl of their original neurosphere medium onto a 
dry 20µl coating of 10µg/mL of collagen IV (Cultrex mouse, 3400-010-
01) after the 96 well plate was washed with HBSS. A further 100µl of 
fresh medium was added and daily imaging of the migrating spheroids 
was performed using a camera (Canon, DS126431) attached to a 
brightfield microscope (Olympus, CKX41) at X4 and X10 magnifications. 
Images were calibrated using a graticule photographed at the same 
magnification and a macro designed by a predecessor Dr Ivanov (see 
appendix) was used to quantify spheroid volume. This was then analysed 
on excel and presented graphically using GraphPad prism.  
2.7.2 Spheroid and macrophage co-culture 
The spheroid-macrophage co-cultures were performed by Dr Sophie 
Roper with macrophages gifted by Dr Luisa Martinez-Pomares group. 
Briefly, macrophages delivered in 24-well ultra-low attachment plates on 
ice were trypsinised then harvested before being twice centrifuged at 
300g for 5mins. The pellet was washed in neurosphere medium and 
centrifuged as before twice more. Optimal cell densities of DAOY mut 
p53, ONS-76 dnp53 and ONS-76 wt. p53 cells were seeded in ultra-low 
attachment plates (Corning, 7007) with macrophages in ratios of 1:1 





experiments of the resulting 72hr conditioned supernatants performed as 
demonstrated in Figure 4.10.  
2.7.3 Transwell-migration assays 
Having been demonstrated by a colleague, Dr Macha Aldighieri to 
migrate through uncoated trans-well inserts with pores measuring 8µm 
in diameter (Greiner Bio-One Thincert, 662638), invasion assays of 
Group 3 and Group 4 MB cell lines were performed, to determine their 
differential capacities for invasion through a collagen IV/Laminin I matrix. 
Further details of the optimisation work are available here (Aldighieri 
2020). The collagen coatings were performed in the same manner 
described for the spheroid migration assays. Once completely dried in 
the cell culture hood and immediately prior to seeding the MB cells, 50µl 
of 100µg/µl of Laminin I mouse (Cultrex, 3400-010-02) was added and 
left for an hour before being aspirated.  
To create a chemokine gradient towards which MB cells would move, cell 
lines were cultured in 2% FBS for 24 hours prior to counting 104 viable 
cells for loading in the upper chamber in 2% FBS, with 10% FBS in the 
24 plate receptacle. Invasion was permitted for 48 hours following which 
the remaining cell suspension within the transwell were aspirated and 
invaded cells dissociated from the bottom receptacle-facing surface of 
the transwell by incubating them in 1X cell dissociation solution (CDS) at 





2.7.4 Determining which assay dye most accurately 
detected invasive MB cells 
While the assay had thus far been optimised using Calcein AM© for the 
quantification of the invaded HD-MB03 cells, initial experiments testing 
the slower growing metastatic Group 3 and 4 cell lines D458-Med and 
CHLA-01R-Med respectively resulted in reduced accuracy in detection 
of cell numbers below 2.5X104. Therefore comparative standard curves 
using 50,000 and 100,000 HD-MB03 cells were used, and PrestoBlue© 
compared to Calcein-AM©. Table 2.11 summarises their key distinctive 
features.   
Table 2.11 Comparison of technical differences between Calcein-AM© and 
PrestoBlue© fluorescent dyes 
 
As demonstrated in the appendix section of this thesis, the accuracy of 
detection of cell populations less than 2.5X104 was better in the 
PrestoBlue© standard curves compared to those for Calcein-AM©, at both 





of 0.9993 and 0.9752 for PrestoBlue 50,000 and 100,000 cells 
respectively; against those attained with Calcein-AM©. Subsequent 
experiments were performed using PrestoBlue© to increase the validity 
of the results attained.  
2.8 Drug treatments  
2.8.1 3-D cultured MB treatments with recombinant Tissue 
inhibitors of matrix metalloproteinases (TIMPs) TIMP-1, TIMP-2 
and Doxycycline  
The recombinant TIMP-1 (Peprotech; 410-01) and TIMP-2 (Peprotech; 
410-01) proteins were reconstituted to 10µM stock solutions in sterile 
cell-culture grade water and aliquots made and stored at -20˚C as 
specified by Peprotech. The required volumes were then added to give 
final concentrations of 10nM, 25nM, 50nM and 100nM, used in the 3-D 
experiments.  
Doxycycline a general metalloproteinase inhibitor, was obtained from 
Sigma (D9891). A fresh stock of 1mM concentration was made by 
dissolving the white powder in sterile cell-culture grade water to give a 
yellow-green solution, which was gently warmed for 5 minutes in a 37˚C 
hot water bath and filtered. This solution was freshly prepared for each 
experiment.  
As sterile cell-culture grade water was used for reconstitution of each of 






2.9 19F-Magnetic Resonance Imaging of MMPs using an 
enzymatic degradable biosensor 
The activatable enzymatic 19-fluorine MRI MMP biosensor used was 
locally synthesised through a collaboration between the Sir Peter 
Mansfield Imaging Centre and the Centre for Biomolecular Sciences at 
the School of Chemistry, University of Nottingham. It consists of a 19-
fluorine (19F) moiety that is linked to a gadolinium III-DOTA complex by 
a substrate specific to MMP-2/MMP-9 (Faas, Krupa et al. 2019). 
Biological samples of column concentrated (X30) conditioned 
supernatant from HD-MB03, CHLA-01-MED and CHLA-01R-MED were 
separately tested by addition of 5µl of the samples to 600µl of the 
biosensor contained within 5mm nuclear magnetic resonance (NMR) 
tubes that were housed in a customised sample holder. 2D transverse 
gradient echo and ultra-short echo time sequences  were performed 
using a Bruker Avance III 14.1 tesla spectrometer with an inner 19F coil, 
at room temperature and later at 37˚C. Prior to testing the biological 
samples, they were stored at -80˚C, transferred on dry ice to the scanner, 
and were slowly thawed immediately prior to the sample being added. 
Over the 18-hour experiment, spectroscopy demonstrated the initial peak 
of the biosensor at -64ppm. Once complete, results were analysed with 
the Igor Pro7 program. Prior to each experiment, the functional activities 
of the samples were confirmed in zymography and FRET experiments. 
Further details of the biosensor experiments are available in this recently 





2.10 Statistical analyses 
GraphPad Prism 8 software (https://www.graphpad.com/scientific-
software/prism/) was used to create, analyse and perform one-way 
ANOVA or paired t-test statistical analyses on all graphs where specified. 
2.11 Fluorescence resonance energy transfer (FRET) 
assays 
Fresh cell supernatants were firstly prepared by adding equal volumes 
from each cell line into Vivaspin (Vivaspin 20-50,000 MWCO, SLS 
VS2032) columns. These were centrifuged at 4000g for 40 minutes at 
4˚C. The EnzCheckTM Gelatinase/Collagenase Assay kit (ThermoFisher 
Scientific, E12055) was used for all experiments. 100µL of 1:2 dilutions 
of the resulting concentrates were added to the 80 µL of reaction buffer 
and 20 µL of fluorescence quenched (DQ) gelatin provided within the kit 
within a black-walled 96-well plate (Brandtech). Bottom reads on a 
FLUOstar Omega plate reader (BMG labtech) at absorption 
maxima~495nM and emission maxima ~515nM of fluorescence were 
recorded following digestion of the DQ gelatin over 24 hours and 
presented graphically using GraphPad Prism 8 software. 100µL of 
undiluted naïve CSF samples from patients 1-6 were examined in similar 














Biological characterisation of matrix 












3.1 Chapter outline 
 
Metastasis is recognised as the predominant cause of mortality in 
paediatric patients with medulloblastoma (MB).  As it is detected at 
diagnosis in 30%-45% of paediatric patients, it is considered to be an 
early event in the disease progression (Juraschka and Taylor 2019, 
Menyhart, Giangaspero et al. 2019). While the emergence of biological 
heterogeneity within MB improved our understanding of the disease, it 
most importantly highlighted sub-group specific distinctions in their 
frequency of metastasis, their propensities for nodular or laminar 
metastasis, and anatomical sites of recurrence, whether local or distant 
to the primary tumour (Ramaswamy, Remke et al. 2013, Zapotocky M 
2017) 
Further compounding the problem, the current methods used to detect 
MB dissemination are suboptimal, with negative neuroaxial magnetic 
resonance imaging observed in 30-70% and negative cerebrospinal fluid 
cytology in up to 50% of patients with leptomeningeal disease, 
necessitating their combined application. Thus more quantitative and 
validated techniques that more accurately determine the metastatic 
status and treatment response in paediatric patients with 
medulloblastoma, pre-operatively and at surveillance, are essential to 
improving our provision of personalised therapy (Chamberlain, Soffietti 





 While the molecular subgroups remain unchanged at recurrence 
(Ramaswamy et al. 2013), a paucity in studies investigating recurrent 
disease due to limited surgical resection and liquid biopsies in the 
affected patient population, has led to the unfounded notion that primary 
and metastatic medulloblastoma are biologically similar. This has 
culminated in failed clinical trials, in which genes and proteins 
upregulated in the primary tumour are designated as therapeutic targets 
in metastatic disease and administered to these patients (Wu, Northcott 
et al. 2012).  
The limited data from the few studies of matched primary and metastatic 
medulloblastoma tumours available, have highlighted that the latter are 
frequently derived from the clonal selection of populations of the primary 
tumour with certain metastatic virulence characteristics. Furthermore, 
their molecular, genetic and proteomic signatures are distinct, which 
could in part account for the poor treatment response in paediatric 
patients who present with disease recurrence, when therapies previously 
administered at diagnosis are given (Ramaswamy, Remke et al. 2013). 
Examples of these include transcriptional modifications in the TP53 gene 
and pathway, which are frequently observed between SHH primary and 
recurrent tumours, and enrichment in extracellular matrix associated 






3.2 Aims and hypotheses 
 
As extracellular matrix gene sets were shown to be enriched in matched 
metastatic Group 4 MB tumours (Wu, Northcott et al. 2012), it was 
postulated that these genes would be a pragmatic starting point. It was 
hypothesised that the balance between the proteases and their 
respective inhibitors would best account for the differential metastatic 
potential between the primary and recurrent cell lines. Similarly, a 
matched pair of Group 3 cell lines were also compared due to their 
increased propensity to metastasise at an earlier stage from smaller 
primary tumours (Mata-Mbemba, Zapotocky et al. 2018). To this end, the 
aims of this chapter were as follows: 
 
1. To elucidate the expression of biomarkers of increased metastatic 
potential, through protease and protease inhibitor microarray 
experiments, comparing conditioned supernatant samples from 
matched primary and recurrent medulloblastoma cell lines.  
 
2. To investigate gene and protein expression of the identified 
differentially expressed candidate proteins using real time PCR 
and western blotting in a wider panel of cell lines. Levels and 
functional activity of secreted proteins will also be examined using 






It was postulated that the levels of functional activity of the candidate 
proteases would be higher in metastatic and recurrent MB cell lines, and 
would therefore provide a valid, measurable molecular signature that 
could potentially be worthy of translation into the clinic and designated 
as a prognostic biomarker of metastasis in MB. 
 
3.3 Elucidating protein biomarkers of metastasis in 
matched primary and recurrent MB cell lines 
To elucidate potential prognostic biomarkers in metastatic 
medulloblastoma, the relative expression levels of protease and 
protease inhibitors (R&D systems) were detected from conditioned 
supernatant from matched primary and metastatic MB cell lines. 5X106 
cells of the primary Group 3 cell line, D425-MED and its metastatic 
counterpart D458-MED and the same number of the matched primary 
and metastatic Group 4 cell lines CHLA-01-MED and CHLA-01R-MED 
respectively, were cultured in in their usual growth medium in 5% CO2 at 
37˚C for 48 hours. The resulting cell suspensions were twice centrifuged 
at 100g for 7 minutes, to obtain cell free supernatant and hence reduce 
the potential for inadvertent cellular protein detection. The analytes that 
were notably differentially expressed between matched cell lines are 
shown in Table 3.1 and Table 3.2. An image of the Proteome Profiler 












Figure 3.1 Protease and protease inhibitor microarrays of conditioned supernatant following 48hrs of culture of the matched Group 3 medulloblastoma A. 
primary (D425-Med) and B. metastatic (D458-Med) cell lines. The cell lines were cultured in the same media and experiments performed simultaneously.  An overlay 
provided within the protease and protease inhibitor array kit (R&D systems) was used to locate the analytes as shown following 15 minutes of chemiluminescence 
exposure. The signal intensity of each analyte was normalised to the reference (ref) intensities on the respective membrane and their densitometry determined using a 
microarray plugin from image J software.  
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3.3.1 Differentially expressed analytes in matched 
primary (D425-Med) and metastatic (D458-Med) Group 3 
cell lines  
 
All membranes were exposed to chemiluminescence for a period of 15 
minutes. Each analyte signal was quantified using a protein array 
analyser macro from image J software and the resulting densitometry 
(see appendix) determined relative to internal reference controls allowing 
analytes that were notably differentially expressed between matched cell 
lines to be identified  (Table 3.1 and Table 3.2).  
Table 3.1 Differentially expressed proteases in matched Group 3 primary (D425-Med) 





% Increase in D458-Med 
Cathepsin B 0.153 0.159 3.73 
Cathepsin D 0.286 0.394 27.3 
Cathepsin V 0.607 0.763 20.5 
Kallikrein 5 0.001 0.021 95.0 
MMP-2 0.255 0.592 56.9 
MMP-3 0.010 0.027 62.9 
 
As shown in Table 3.1, Kallikrein 5 (KLK5) was the most highly 
upregulated protease in the metastatic Group 3 cell line in comparison to 
its primary counterpart. Kallikreins are serine proteases that are involved 





correlated to poorer outcomes in lung, pancreatic and head and neck 
squamous cell cancers. Interestingly, upregulated KLK5 expression as 
seen in the Group 3 metastatic cell line, has been correlated with 
increased mortality in urothelial bladder carcinoma (Tailor, Kodeboyina 
et al. 2018) and worse patient outcomes in ovarian cancer (Borgono and 
Diamandis 2004). 
MMP-2 and MMP-3 expression was increased by 56.9% and 62.9% 
respectively, in the Group 3 metastatic cell line D458-Med. Both matrix 
metalloproteinases have been implicated in multiple hallmarks of 
metastasis, including tissue invasion, intravasation and preparation of 
the metastatic niche (Kessenbrock, Plaks et al. 2010).   
The metastatic Group 3 cell line D458-Med also demonstrated increased 
expression of the cysteine proteases, cathepsins B, D and V as shown 
in Table 3.1. When activated, these proteases remodel the extracellular 
matrix, releasing chemokines that promote migration and invasion of 
tumour cells. Cathepsin B in particular has been shown to degrade the 
endogenous tissue inhibitors of metalloproteinases (TIMPs), resulting in 
increased MMP activity independent of levels of MMP expression (Olson 
and Joyce 2015).  
While the profile of protease expression between the matched Group 3 
cell lines were within similar ranges, the expression levels of protease 





lower than those observed in its primary counterpart.  The most 
significant changes are shown in Table 3.2 as fold decreases from the 
expression levels detected in the supernatant of the primary Group 3 cell 
line D425-Med.  
Table 3.2 Differentially expressed protease inhibitors in matched Group 3 primary 







Fold decrease in 
D458-Med 
APP 1.09 1.15E-04 9554 
Cystatin A 0.081 3.31E-06 24308 
Cystatin B 0.467 1.45E-05 32219 
Cystatin C/3 0.633 5.86E-05 10796 
Cystatin E/M/6 0.035 4.90E-07 71578 
EMMPRIN/CD147 0.667 6.14E-05 10861 
Serpin F1 0.165 1.10E-05 14986 
SPOCK 1 0.516 5.65E-05 9137 
TFPI-2 1.69 6.30E-05 26810 
TIMP-1 0.818 3.05E-05 26805 
TIMP-2 0.525 3.83E-07 1372159 
 
Being the endogenous inhibitors of cysteine proteases-cathepsins, the 
downregulation of cystatins A, B, C and E occurs in the metastatic Group 








Figure 3.2), resulting in unchecked cathepsin activity. SPOCK1 is an 
isoform of the SPARC (secreted protein acidic and rich in cysteine) 
protein family that has been shown to be upregulated in cancers where 
it promotes proliferation, metastasis and invasion. However, as seen in 
Table 3.2, it is downregulated in the metastatic Group 3 cell line, D-458-
Med, a common finding in brain tumours. This conundrum is in part 
postulated to be dependent on their concentrations which determine 
whether their overall effects are pro-metastatic and anti-migratory 
(Gerarduzzi, Hartmann et al. 2020). 
Meanwhile, TFPI-2 (tissue factor pathway inhibitor 2) is a protein that 
inhibits tissue factor, plasmin and kallikreins all of which when inhibited, 
result in the downregulation of activated MMP-2 protein levels. It is 
therefore unsurprising that its secreted levels are much higher in the 
primary Group 3 cell line D425-Med in comparison to the metastatic line 
D458-Med (Table 3.2, Figure 3.2). 
Significant downregulation of the tissue inhibitors of metalloproteinases 
(TIMPs) -1, -2 and -3 is also observed in the metastatic cell line D458-
Med (Figure 3.2), suggesting a pro-metastatic niche in its secretome, as 


















Figure 3.2 Densitometry of protease and protease inhibitor microarrays of the matched Group 3 medulloblastoma A. primary (D425-Med) and B. metastatic 
(D458-Med) cell lines. Analytes were quantified using an Image J plugin. While their levels of protease expression were comparable, the metastatic cell line secreted 




3.3.2 Differentially expressed analytes in matched 
primary (CHLA-01-Med) and recurrent (CHLA-01R-Med) 
Group 4 cell lines  
 
An image of the Proteome Profiler Array obtained for the Group 4 
matched pair is shown in Figure 3.3. Each signal was then quantified 
using a protein array analyser macro from image J software and the 
resulting densitometry determined relative to internal reference controls 
allowing analytes that were notably differentially expressed between 
matched cell lines to be identified.  
In comparison to the expression profile of proteases and protease 
inhibitors in the matched Group 3 cell lines, more differentially expressed 
analytes were detected in the matched Group 4 pair. As demonstrated in 
Table 3. 3 and Figure 3.4, the kallikreins and matrix metalloproteinases 
were the most upregulated proteases in the recurrent Group 4 cell line 
CHLA-01R-Med compared to its primary counterpart. CHLA-01R-Med 
also depicted increased MMP-1 and MMP-2 expression by 90.7% and 
97.3%  respectively from the levels detected in the primary Group 4 cell 
line, as well as upregulated levels of more MMPs (-3,-7, -8, -10 and -12) 
compared to the Group 3 metastatic cell line D458-Med, in which MMP-
2 was upregulated by 56.9%. This suggests that MMPs could play a more 
pivotal role in progression in Group 4 medulloblastoma in comparison to 





The Group 4 metastatic cell line also exhibited higher levels of kallikreins 
(KLKs) which have been reported to digest plasminogen to plasmin 
(Dong, Loessner et al. 2014), one of the key activators of pro-MMP-2.  
CHLA-01R-MED demonstrated 4-29X higher levels of kallikreins -6, -7 
and -10 compared to its primary counterpart. In addition, cathepsins B 
and C were also overexpressed in the metastatic line CHLA-01-R-Med 
by 78.9% and 54% respectively.  
The most striking decrease in the levels of protease inhibitors secreted 
in the metastatic compared to its primary counterpart, were the tissue 
inhibitors of metalloproteinase 1 (TIMP-1) with almost no TIMP-1 
detected in the metastatic cell line (Table 3.4, Figure 3.4). Additionally, 
SPOCK2 expression was downregulated to a similar degree as were 












Figure 3.3 Protease and protease inhibitor microarrays of conditioned supernatant following 48hrs of culture of the Group 4 medulloblastoma primary A. 
(CHLA-01-Med) and metastatic B. (CHLA-01R-Med) cell lines. The cell lines were cultured in the same serum-free media and experiments performed simultaneously. 
The intensity of each dot was normalised to the reference (ref) dots on the respective membranes and their intensity was determined using a microarray plugin from 
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Table 3. 3 Differentially expressed proteases in matched Group 4 primary (CHLA-01-





% Increase in 
CHLA-01-Med 
Cathepsin B 0.007 0.034   78.9  
Cathepsin C 0.016 0.034 54.0  
Cathepsin S 0.034 0.072 52.9  
Cathepsin V 0.059 0.084      30.2  
Kallikrein 5 0.015 0.039   62.5  
Kallikrein 7 0.021 0.096  78.4  
Kallikrein 10 0.015 0.118 87.7  
Kallikrein 11 0.004 0.109 96.0  
Kallikrein 13 0.003 0.085 96.6  
MMP-1 0.015 0.157 90.7  
MMP-2 0.014 0.516 97.3  
MMP-3 0.016 0.119    86.6  
MMP-7 0.003 0.016 81.8  
MMP-8 0.009 0.019 55.0  
MMP-10 0.016 0.027 42.4  
MMP-12 0.021 0.052 58.7  
 
As shown in Table 3.4, the group 4 pair demonstrated decreased levels 
of Serpins A9, A12, B5, B6 B8 and E1 in the recurrent cell line, CHLA-
01R-MED. Recognised to inhibit angiogenesis, the reduced expression 
of these protease inhibitors would likely promote unregulated 






Table 3.4 Differentially expressed protease inhibitors in matched Group 4 primary 







Fold Decrease in 
CHLA-01R-Med 
CSTA 0.025 0.007 3.77 
CSTB 0.168 0.012 13.6 
CST6 0.029 0.000 0.029 
EMMPRIN/CD147 0.545 0.515 1.06 
Serpin A9 0.066 0.024 2.69 
Serpin A12 0.064 0.028 2.29 
Serpin B5 0.070 0.022 3.10 
Serpin B6 0.070 0.037 1.90 
Serpin B8 0.097 0.035 2.79 
Serpin E1 0.057 0.036 1.57 
SPOCK 1 0.056 0.025 2.25 
SPOCK 2 0.055 0.000 0.055 
TIMP-1  0.077 0.000 0.077 
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Figure 3.4  Densitometry of protease and protease inhibitor microarrays of the matched Group 4 medulloblastoma cell lines. A. Primary (CHLA-01-Med) and 
B. metastatic (CHLA-01R-Med) cell lines. Signal intensities were quantified using a microarray plugin from Image J software, demonstrating differential expression of 
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Having been shown to correlate with aggressiveness, higher grade and 
poor patient outcome in multiple solid cancers (Isaacson, Jensen et al. 
2017), it was hypothesised that matrix metalloproteinases (MMPs), a 
large proportion of the proteases involved in modulation of the tumour 
microenvironment, would be upregulated in the metastatic compared to 
the primary MB cell lines. As they have been widely demonstrated to be 
instrumental in metastasis, MMP-2 and MMP-9 were thought to be the 
most likely of the extracellular proteases, to be amplified in the 
metastatic/recurrent MB counterparts (Isaacson, Jensen et al. 2017) 
Homeostasis of the tumour microenvironment is a complex and dynamic 
landscape in which matricellular proteins such as matrix 
metalloproteinases, released into the extracellular matrix may not be as 
strictly controlled as in physiological conditions. As alluded to earlier, the 
very concentrations and co-localisations of these matricellular proteins 
may determine their context specific effects. To complicate issues 
further, the pathways of expression or upregulation of pro-metastatic 
factors may also activate pathways with opposing effects. Thus, it would 
be presumptuous to conclude that increased secretion of matrix 
metalloproteinases would be the sole mechanism that results in the 
increased metastatic potential in the recurrent Group 3 and 4 cell lines.  
Therefore, to gain a comprehensive understanding of the landscape of 
metalloproteinases and their inhibitors in promoting metastasis in 





expression, as well as functional activity was investigated, to determine 
the point of upregulation in the metastatic cell lines.  
 
3.4 MMP-2 gene expression in medulloblastoma 
cell lines 
 
To investigate the gene expression of MMP-2 in a panel of 9 sub-grouped 
medulloblastoma cell lines, real time PCR experiments using SYBR 
green I were performed and results normalised to their relative 
expression of GAPDH, to enable comparison of MMP-2 gene expression 
between the different MB cell lines.  
As shown in Figure 3.5, MMP-2 gene expression varied between and 
within the subgroups. While the highest MMP-2 gene expression was 
observed in the most aggressive cell lines within each subgroup, HD-
MB03 in Group 3, DAOY and ONS in SHH and CHLA-01R-Med in Group 
4, there was a statistically significant increase in MMP-2 gene expression 
in the metastatic Group 4 cell line, CHLA-01R-Med, compared to its 
primary counterpart (p=0.0215). The low levels of MMP-2 gene 
expression in the metastatic Group 3 cell lines, D458-Med and D283 was 




















Figure 3.5 MMP-2 gene expression by qRT-PCR of 9 sub-grouped medulloblastoma 
cell lines. For each cell line, the mean of the quantitation cycles of MMP-2 expression was 
normalised to that of GAPDH expression and analysed using Graphpad prism. *indicates 
the statistically significant difference in the gene expression of MMP-2 between the primary 
and recurrent Group 4 cell lines. (ANOVA; p=0.0215) Error bars represent SD. 
 
 
3.5 MMP-9 gene expression in medulloblastoma 
cell lines 
 
While the multilevel regulation of MMP-9 was attempted, the MMP-9 
gene expression in the MB cell lines could not be determined due to 






3.6 MMP-2 protein expression in medulloblastoma 
cell lines 
To determine the baseline differential MMP-2 protein expression in 
isogenic primary and medulloblastoma cell lines, protein extraction was 
performed from the same cell pellets used in the MMP-2 gene expression 
experiments. Equal amounts of protein were examined using western 
blotting as described in detail in the methodology section of this thesis. 
Image J densitometry was performed on the resulting chemiluminescent 
images to quantify the differential levels of MMP-2 protein expressed by 
each cell line.  
As shown in Figure 3.6, the protein expression in the control neural stem 
cell line H1-NSC was present but at very low levels, supporting the 
hypothesis that MMP-2 is constitutively expressed. Though the 
differential MMP-2 protein expression between the paired Group 3 cell 
lines D425-Med (M0) and D458-Med (M+) as well as the paired Group 4 
cell lines CHLA-01-Med (M0) and CHLA-01R-Med (M2) did not reach 
statistical significance, the metastatic cell lines expressed considerably 
more MMP-2 protein. This result was in contrast to the pattern of gene 
expression in the Group 3 pair, where the primary cell line D425-Med 
exhibited higher MMP-2 gene expression than its metastatic counterpart. 
The highest MMP-2 protein expression was observed in the metastatic 
ONS-76 (wt p53) cell line, in stark contrast to the ONS-76 dnp53, in which 

















Figure 3.6 MMP-2 protein expression by Western blotting of cell lysates from 10 sub-
grouped medulloblastoma cell lines (n=5).  A. Representative western blot of 8 MB 
cell lines alongside a foetal stem cell control H1-NSC. B. MMP-2 protein expression 
was normalised to expression of the housekeeping protein, GAPDH and plotted in 
Graphpad prism as shown above. Error bars indicated standard deviations from the 
mean (SD).  
 
This suggests that an intact tumour suppressor p53 gene may be 
essential to the gene transcription and therefore protein expression of 
MMP-2. This is supported by the finding that the MMP-2 promoter 








































































Having determined the relative protein expression between the MB cell 
lines, their levels of secreted MMP-2 protein into conditioned media was 
investigated. Briefly, supernatant from 5X106 cells of 6 MB cell lines was 
harvested following 48 hours of incubation in their respective optimal 
culture medium in 5% CO2, 37˚C. After centrifugation at 100g for 7 
minutes, the supernatant samples were snap frozen, stored at -80 ̊ C and 
slowly de-frosted on ice immediately prior to the experiment. The 
Quantikine ELISA Total MMP-2 immunoassy kit from R&D systems (cat. 
MMP200) was used to quantify the levels of total MMP-2 protein 








Figure 3.7  Levels of secreted MMP-2 protein as detected with the total MMP-2 
Quantikine ELISA immunoassay (R&Dsystems). Screening ELISA experiments were 
performed to determine whether the MB cell lines secreted differential levels of MMP-2 into 
their conditioned medium, following a 48 hour incubation in 37˚C and 5% CO2 conditions. 
The resulting protein levels were compared to MMP-2 standards ranging from 0.5ng/mL to 






As shown in Figure 3.7, the levels of secreted MMP-2 protein follow a 
similar pattern as that observed for gene expression of the same MB cell 
lines (see Figure 3.5). Notably, the Group 4 metastatic cell line CHLA-
01R-Med appeared to secrete 2.7 times more MMP-2 protein compared 
to the primary CHLA-01-Med. However, as these experiments were not 
repeated, this data supported the likelihood that the levels of MMP-2 
protein secreted by each MB cell line might be detectable using Gelatin 
Zymography.  
To determine the best storage conditions for the supernatant and later, 
patient cerebrospinal fluid that would maximise the functional activity of 
the MMP-2 and MMP-9 therein, ELISA experiments were performed on 
supernatants harvested from the Group 4 paired cell lines that were 
stored at 4˚C for 7-day intervals. As shown in  
Figure 3.8, levels of MMP-2 protein secretion from the metastatic group 
4 cell line CHLA-01R-Med, decreased in a stepwise manner over the 2-
week period, but at all times, secreted between 5-10 times the amount of 
MMP-2 protein detected in its primary counterpart. 
Following this experiment, supernatant and patient cerebrospinal fluid 
destined for zymography experiments were snap frozen in liquid 
nitrogen, stored at -80˚C and thawed on ice immediately prior to 
experimentation, to maximise the functional activity of the MMP-2 and 













Figure 3.8 Levels of secreted MMP-2 protein as detected with the total MMP-2 
Quantikine ELISA immunoassay (R&Dsystems). Screening ELISA experiments were 
performed to determine whether the paired Group 4 MB cell lines secreted differential levels 
of MMP-2 into their conditioned medium, following a 48hour incubation in 37˚C and 5% CO2 
conditions. The resulting protein levels were compared to MMP-2 standards ranging from 
0.5ng/mL to 32ng/mL of MMP-2 protein and quantified using a microplate reader, in a similar 
manner as the prior experiment. 
 
3.6 MMP-9 protein expression in medulloblastoma 
cell lines 
 
MMP-9 has been shown to play a substantial role in multiple facets of the 
metastatic process including angiogenesis by catalysing the release of 
vascular endothelial growth factor (VEGF) from the extracellular matrix, 
as well as priming the metastatic niche by activating cancer associated 
immune cells and astrocytes to release pro-metastatic factors that further 
modulate the tumour microenvironment (Shimoda and Khokha 2017, 


















Figure 3.9 MMP-9 protein expression by Western blotting of nine sub-grouped 2-D 
cultured medulloblastoma cell lines alongside a control cell line (H1-NSC). A. 
Representative western blot of (n=4) MMP-9 and GAPDH (housekeeping protein) 
expression in MB. B. Image J densitometry of MMP-9 protein expression normalised to 
expression of the housekeeper, GAPDH and plotted in GraphPad prism as shown above.  
 
As one of the most commonly implicated MMPs in metastatic tumours 
including medulloblastoma, it was felt that a further look at the protein 
expression of MMP-9 in MB would be worthwhile, in spite of their low 
expression at the genetic level. This was determined by performing 








































































MMP-2. The main differences were that the concentration of the MMP-9 
primary antibody (Cell Signalling #13667) used was 1:500 diluted in 5% 
BSA, twice that of MMP-2. In addition, ECL signal fire elite (Cell 
signalling, 12757P) a stronger chemiluminescence imaging solution, was 
used to maximise the signal intensity obtained.  
MMP-9 protein expression varied between the medulloblastoma cell lines 
with considerable variation within the replicates of the sample. This was 
postulated to be as a result of the low overall protein expression of MMP-
9 in MB in comparison to their MMP-2 protein expression. As primary cell 
lines appeared to express similar MMP-9 protein to their metastatic 
counterparts, it seemed unlikely that MMP-9 protein expression could 
serve as a robust biomarker of metastasis.  
While perturbing the gene and protein expression of MMP-2 and MMP-9 
in the primary and metastatic medulloblastoma cell lines suggested that 
MMP-2 may serve as a robust biomarker at protein levels in matched 
recurrent cell lines, their secretion into the tumour microenvironment 
represented by their conditioned supernatant, was thought to be the most 
physiologically relevant. This is because of the observation that the 
specific biological roles played by MMPs is determined by their 
localisation (Kessenbrock, Plaks et al. 2010). This enables their strict 
homeostasis in a vast array of physiological and pathological states 
including carcinogenesis and metastasis.  Thus in their roles as 





MMP-2 and MMP-9 secreted into the MB cell supernatants were 
examined using gelatin zymography.  
3.7 Gelatin zymography for the detection of 
functionally active MMP-2 and MMP-9 in 
medulloblastoma cell lines 
 
While MMP-2 and MMP-9 are regulated at multiple levels, a key 
determinant of specific role is dependent upon their localisation within 
the intracellular or extracellular compartments. This enables their wide 
range of functions including extracellular matrix remodelling, lysosomal 
digestion of microbes and preparation of the metastatic niche. In these 
different contexts, their effects can vary based on their cellular source i.e. 
tumour cells, endothelial cells, tumour-associated immune cells or 
astrocytes for example, as well as the physiological or pathological 
situation (Kessenbrock, Plaks et al. 2010). While majority of MMPs are 
secreted, some such as MMP-2 are both membrane-bound and secreted 
within exosomes which are nanometre-sized, membrane-bound vesicles 
that are thought to be involved in autocrine and paracrine signalling 
between tumour cells, their cellular microenvironment and their distant 
pre-metastatic niche (Shay, Lynch et al. 2015). As such, investigating the 
levels of functionally active, secreted MMP-2 and MMP-9 in the 
supernatants of the MB cell lines, may provide a pertinent indicator of 





Gelatin zymography is a gel electrophoresis technique in which the levels 
of the zymogens and their active forms can be detected by their 
enzymatic digestion of gelatin incorporated into the gel. Having not 
previously been performed in our lab, optimisation of the technique for 
the detection of pro- and active MMP-2 and MMP-9 in the MB cell line 
supernatants was necessary.  
3.7.1 Optimisation of Gelatin Zymography 
With the exception of the 10X zymography development buffer (Biorad, 
1610766), all other material were made up in the lab. Table 3.5 shows the 
steps taken in the optimisation of this technique. Annotations of the 
reasons resulting in experimental technical failure and the resolutions at 
each stage were annotated alongside each zymogram. As shown in Table 
3.5 zymograms A and B were the first two unsuccessful experiments with 
no detectable evidence of functional MMP2 or MMP9 activity despite 
using concentrated FBS, a well-established, strongly positive control. 
This technical challenge was addressed by re-constituting the assay 
buffers according to the aforementioned instructions in the methods and 
storing the gel buffers at 4˚C. With slight modifications to the order in 
which the reagents were incorporated into the Gelatin-SDS-PAGE 
mixture, positive results were obtained as shown in zymograms C 











Table 3.5 Gelatin zymography optimisation experiments 
Zymogram Altered experimental conditions Main result 
A       
Gel thickness:                                1.5 mm 
Volume of sample loaded:             20 µL 
Staining time:                                 1 hour 




Gel thickness:                                1.5 mm 
Volume of sample loaded:             20 µL 
Staining time:                                 1 hour 




Gel thickness:                                0.75 mm 
Volume of sample loaded:             20 µL 
Staining time:                                 30 mins 
De-staining time:                            45 mins 
 
Successful but overflow of FBS into other adjacent wells 
D  
Gel thickness:                                0.75 mm 
Volume of sample loaded:             20 µL 
Staining time:                                 30 mins 
De-staining time:                            45 mins 
 
Successful but contamination of FBS into other adjacent 
wells. This was the first experiment in which supernatant 
from the matched primary CHLA-01-Med (lime green) and 
metastatic (dark green) cell lines were loaded.  
E  
Gel thickness:                                1.0 mm 
Volume of sample loaded:             40 µL 
Staining time:                                 30 mins 
De-staining time:                            45 mins 
 
Successful, clear lane separation of different loaded 
samples with introduction of Hamilton pipette for more 
accurate loading of gel 
F  
Gel thickness:                                1.0 mm 
Volume of sample loaded:             40 µL 
Staining time:                                 15 mins 
De-staining time:                            90 mins 
 
Successful with better contrast between digested gelatin 





The cosmetic appearances of the zymograms was improved by 
incubating the gels for a shorter period of 15 minutes in the 0.5% 
coomassie blue staining solution (zymograms E and F) and longer 
incubation in the de-staining solution. This was postulated to be due to 
the binding affinity of the freshly made staining solution. In addition, the 
accuracy of loading conferred by using a Hamilton pipette (Hamilton, 
80600) instead of using the standard pipettes was greatly enhanced as 
the slim needle easily accessed the bottoms of the wells within the 
1mm/0.75mm gels, in comparison to the standard pipette tips with a 
considerably larger diameter. 
The optimal gel thickness of 1mm allowed for easier manipulation 
compared to the 0.75mm gels which were fragile, especially on handling 
and transfer between the various buffers. When compared to the 1.5mm 
gel spacers commonly used in Western Blotting, poor penetration of the 
renaturing and developing buffer due to the thicker gel may have 
prevented the activation of MMP-2 and MMP-9 proteins expressed by 
the cell supernatants in these particular gels.    
3.7.2 Gelatin zymography detection of pro- and active- 
MMP-2 and MMP 9 from medulloblastoma cell lines 
 
5X106 cells of each cell line were cultured in their optimal media and 
incubated for 48 hours in 5% CO2 at 37˚C. Following cell dissociation of 





twice centrifuged at 100g for 7 minutes to obtain cell-free supernatant. 
These samples were either snap frozen and stored at -80 ˚C or used 
immediately in zymography experiments. A key important difference 
between zymography and western blotting is that the samples in the 
former are not denatured to enable their enzymatic functions by 
preserving their 3-dimensional structures. After gel electrophoresis of the 
loaded samples, the gels were incubated in renaturing buffer on a rocker 
for 1 hour at room temperature, before incubation in zymogram 
developing buffer (Biorad, 1610766) overnight. After washing the gels in 
dH2O, they were stained in a 0.5% coomassie blue solution for 15 
minutes and de-stained for 2 hours. Zymograms were photographed and 
quantified using Image J densitometry.  
As shown in Figure 3.10, the highest levels of MMP-2 were seen in the 
metastatic cell lines with the exception of D283. Within each subgroup, 
the cell lines with the highest metastatic status secreted the highest 
levels of functionally active MMP-2. While the difference in active MMP-
2 detected in the Group 3 matched pair (primary D425-Med and 
metastatic D458-Med cell lines) was not statistically significant, the 
difference between the levels detected in the Group 4 matched pair, 
CHLA-01-Med (primary) and CHLA-01R-Med (metastatic) cell achieved 











Figure 3.10 Gelatin zymography of supernatant from a panel of 9 medulloblastoma sub-grouped cell lines A. Representative zymograms showing endogenous 
MMP-2 and MMP-9 signals alongside equal volumes of their respective media controls. Image J densitometry was performed to determine the differential levels of 





In keeping with the low levels of MMP-9 expression observed at both 
gene and protein levels, the levels of functionally active MMP-9 secreted 
by the medulloblastoma cell lines 100 times less than the levels of MMP-
2. As depicted in Figure 3.10 the highest levels of functionally active 
MMP-9 were observed in the SHH cell lines, in contrast to the pattern 
seen in the protein expression from the same lines. In addition, while the 
matched Group 4 cell lines CHLA-01-Med (M0) and CHLA-01R-Med 
expressed comparable levels of MMP-9 to those seen in HD-MB03, their 
levels of secreted MMP-9 were significantly low and undetectable in the 
primary cell line.  
These results suggest that functionally active MMP-2 is secreted by all 
medulloblastoma cell lines and is present at much higher levels in the 
extracellular compartment in comparison to levels of active MMP-9. 
These results suggest that functionally active MMP-2 may be the most 
clinically relevant biomarker in predicting the metastatic potential of 
medulloblastoma. As both are detectable using gelatin zymography, this 
technique was taken forward for the determination of whether levels of 
functionally active MMP-2 in cerebrospinal fluid from paediatric patients 









 Screening protease and protease inhibitor microarray 
experiments used to elucidate potential biomarkers of increased 
metastatic potential in medulloblastoma cell lines, revealed an 
imbalance in the secretion of proteases in the primary Group 3 
(D425-Med) and Group 4 (CHLA-01-MED) cell lines in 
comparison to the scarcity of protease inhibitors in their respective 
metastatic counterparts. This likely results in a tumour 
microenvironment that is more conducive to migrating 
metastasizing tumour cells.  
 
 The most striking differences involved the levels of MMP-2 
secreted by the recurrent cell lines, thus further determination of 
its potential as a valid and robust prognostic biomarker was 
performed. While the secretion levels of MMP-9 were less 
dramatic, it is well-documented to be highly expressed at the 
invasive margins of solid tumours as well as play a synergistic role 
with MMP-2. We therefore proceeded to focus on these 
proteases.  
 
 At the level of gene expression, MMP-2 was expressed at higher 
levels in the metastatic MB cell lines, especially in the Group 4 
recurrent cell line CHLA-01R-MED in comparison to its primary 





complicated, likely due to the low expression levels in MB cell 
lines.  
 
 Given its enzymatic functions, ELISA experiments were 
performed to determine the optimal storage and handling of the 
supernatant samples from the MB cell lines and patient 
cerebrospinal fluid. A stepwise reduction in the MMP-2 protein 
was detected by ELISA in the matched Group 4 MB cell lines, 
emphasizing the importance of storage of the samples at -80˚C.  
 
 The levels of functional activity as determined using gelatin 
zymography further confirmed the higher levels of functionally 
active MMP-2 in the recurrent Group 4 cell line (CHLA-01R-MED) 
compared to the primary, while similar levels of MMP-2 and MM-
9 were observed in the Group 3 matched pair. The highest levels 
of MMP-9 were secreted by the most aggressive group 3 cell line 
and the SHH cell lines, suggesting subgroup specific differences 


















Functional characterisation of matrix 













4.1 Chapter outline 
Though metastasis has remained the leading cause of mortality and 
morbidity in paediatric patients with medulloblastoma (MB), its precise 
mechanisms are poorly understood. This is in part due to the 
inaccessibility of biological samples from paediatric patients with 
advanced disease, in whom surgical intervention would be unethical and 
detrimental to their survival. For this reason, the development of relevant 
translational biological models in which the mechanisms of 
medulloblastoma dissemination can be examined, is invaluable to our 
understanding of metastatic disease.  
While aspects of the pathophysiology of MB metastasis can be 
investigated in animal models, they are expensive, and have limited 
survival; at times curtailing the study duration to less than that required 
to establish disseminated disease. In addition, the animals are often 
immune suppressed, which impedes the elucidation of interactions 
between the host immunological response and disseminating tumour 
cells, a key feature of the tumour microenvironment (Van Ommeren, 
Garzia et al. (2020). Considering the increasing evidence of the 
fundamental role played by the tumour milieu in all aspects of metastasis 
and drug resistance (Boire, Brastianos et al. 2019, Morad and Moses 
2019), 3-dimensional models present an exciting opportunity in which the 
interactions between MB and aspects of their in vivo tumour 





While the molecular subgrouping of MB is maintained at relapse 
(Ramaswamy, Remke et al. 2013), there are subgroup-specific 
distinctions in their preferred sites of recurrence and morphology of 
metastases. SHH MB tumours preferentially arise within the cerebellar 
hemispheres and recur locally in nodular metastases, whereas the 
midline cerebellar Group 3 and 4 medulloblastoma tend to metastasise 
to the leptomeninges, where they radiologically appear as laminar and 
laminar-nodular metastases respectively (Zapotocky M 2017). These 
inherent differences may also extend to their primary and metastatic 
tumour microenvironments, which may explain the Group 4 MB 
predilection for suprasellar metastases, or why greater immune cell 
infiltration is observed in SHH tumours (Zapotocky M 2017, Mata-
Mbemba, Zapotocky et al. 2018, Van Ommeren, Garzia et al. 2020).  
Thus, cancer cells can adapt the biochemical, physical and 
immunological properties of their microenvironments, to secure their 
survival in their chosen pre-metastatic niche by various mechanisms 
(Cacho-Diaz, Garcia-Botello et al. 2020). Through reciprocal 
interactions, disseminating metastatic cells modulate their milieu by 
secreting growth factor liberating proteases, chemokines and immune 
mediators, enabling their evasion from immune detection and initiating 
signalling pathways that augment their proliferation, motility and survival 
(Novak and Kaye 2000).  Dysregulation of MMP-2 and MMP-9 secretion 





Constituents of the brain tumour microenvironment include cells such as 
neurons, astrocytes, microglia, endothelia and macrophages, as well as 
non-cellular components embedded within the extracellular matrix (ECM) 
(Van Ommeren, Garzia et al. 2020).  
The ECM of the brain is defined by the parenchymal interstitial matrix in 
which glycosaminoglycans (GAGs) such as hyaluronan and 
proteoglycans like tenascin C are present in abundance, as well as the 
basal lamina that encapsulates the vascular endothelium and is mainly 
composed of collagen IV, laminin and fibronectin. The ubiquity of 
hyaluronan in the brain ECM facilitates its role as a key anchor of many 
matricellular proteins and modulator of cell migration. This may explain 
its higher prevalence within the brain tumour microenvironment in 
comparison to normal brain, where its overexpression is advantageous 
to migrating tumour cells (Richard, Kortei et al. 2020). In addition, its 
receptors CD44 and receptor for hyaluronan-mediated motility 
(RHAMM), have been detected at higher expression levels and observed 
to co-localise with MMP-2 and -9 at the invasive margins of gliomas, 
breast and other solid tumours (Novak and Kaye 2000, Yu, Chen et al. 
2017, Richard, Kortei et al. 2020, Toole 2020).  
This observation could support the theory that CD44-mediated activation 
of MMP-9 (Novak and Kaye 2000) and subsequent activation of MMP-2 
at the leading edge of metastasizing tumours, could result in digestion of 





initiating the haematogenous dissemination of MB cells (Novak and Kaye 
2000, Boire, Zou et al. 2017). The re-modelling of the tumour 
microenvironment initiated by the hyaluronan-CD44 dependent MMP-9 
activation, may also result in the concomitant release of previously 
sequestered pro-angiogenic factors (Bauvois 2012), culminating in neo-
angiogenesis and further permeability of the blood-tumour barrier, a 
phenomenon radiologically observed in Group 3 MB which also express 
higher levels of angiogenesis-related genes (Thompson, Keir et al. 
2017).  
As shown in chapter 3 of this thesis, MB cells secrete functionally active 
MMP-2 and MMP-9 that may enable them to remodel their 
microenvironment by modifying the stiffness of the extracellular matrix, 
as well as liberating growth factors and chemokines that drive their 
proliferation, migration and invasion. As the experiments performed thus 
far concerned medulloblastoma cells cultured in 2-dimensional methods, 
it was postulated that their secreted proteome would be altered in 3-
dimensional culture, in a manner that would better recapitulate the in vivo 
setting.  
4.2 Aims and Hypotheses 
Therefore, to explore the effects that different aspects of the tumour 
microenvironment may exert on the levels of functionally active MMP-2 





models that replicated interactions between MB and their architectural or 
cellular milieu were used. Aims for this chapter were as follows:  
1) To better re-capitulate the tumour microenvironment of SHH 
MB micrometastases, a spheroid model was employed. The 
SHH MB spheroids were generated over 96 hours and on day 
4 seeded on top of collagen IV and hyaluronan-based 
matrices, alongside media controls; and their levels of 
functionally active MMP-2 and MMP-9 correlated to their 
migration across the matrices. It was hypothesised that the 
increased cell-cell interactions within the spheroids, as well as 
their adhesion to and the presence of a digestible matricellular 
protein, would result in higher levels of secreted functionally 
active MMP-2 and MMP-9, which would correlate with their 
extent of migration across the matrices.  
 
2) To determine whether the migration of SHH spheroids across 
extracellular matrices was MMP-2/-9 dependent, 
pharmacologic inhibition using recombinant tissue inhibitor of 
metalloproteinases 1 (TIMP-1), TIMP-2 and Doxycycline, was 
used to inhibit the tumour-derived functionally active MMP-
2/MMP-9. Sequential imaging of the spheroids was then 
performed every 24 hours over a 48-72-hour period. It was 
postulated that the extent of migration would be limited 





3) To explore the effect that immune cell infiltration may have on 
the levels of functionally active MMP-2 and MMP-9 secreted 
by medulloblastoma, SHH spheroids were co-cultured with 
macrophages. The supernatants were thereafter harvested, 
and levels of functionally active MMP-2 and MMP-9 
determined by gelatin zymography.  
4) To determine whether the observed differential levels of 
functionally active MMP-2 and MMP-9 secreted by the 
matched primary and metastatic Group 3 (D425-Med and 
D458-Med) and Group 4 cell lines (CHLA-01-MED and CHLA-
01R-MED) would correlate with their invasiveness in a 3-D 
model of the basal lamina, transwell invasion assays were 
performed. It was thought that the increased levels of 
functionally active MMP-2 and MMP-9 secreted by the 
matched primary and recurrent cell lines, would correlate with 
their invasive capacity.  
5) To explore the effect of hyaluronan on the levels of functionally 
active MMP-2 and MMP-9 secreted by MB cell lines, 
conditioned supernatants from SHH, Group 3 and Group 4 
medulloblastoma were examined using gelatin zymography, 
following the 3-D culture embedded within a hyaluronan-based 
hydrogel. It was postulated that the presence of hyaluronan 






4.3 The effect of 3-dimensional spheroid culture of 
medulloblastoma cell lines on their secreted levels 
of functionally active MMP-2 and MMP-9 
4.3.1 Generation of medulloblastoma spheroids 
To ascertain whether 3-D culture of MB cell lines would impact their 
secretion of MMP-2 and MMP-9, a spheroid model optimised in MB by a 
former PhD colleague, Dr Roper was used (Roper 2019). SHH cell lines, 
which form an adherent monolayer in 2-D culture, formed tight spheroids 
within 24 hours of seeding, while the Group 3 cell lines, which were semi-
adherent in 2-D culture, produced very loose spheroids in 3-D. 
Meanwhile, the matched pair of Group 4 cell lines that were cultured in 
suspension did not form suitable spheroids, despite forming a mixture of 
large cell clusters and single cells in suspension culture. Thus, it 
appeared that the MB cell line phenotype in 2-D culture gave some 
indication of the cell lines predicted suitability for the spheroid model 
(Kramer, Walzl et al. 2013, Roper 2019).  
MB spheroids with an approximate diameter of 300µm were generated 
96 hours after seeding ( 
Figure 4.1 A). While initial experiments included the Group 3 cell line HD-
MB03, its loose spheroids resulted in unacceptable variation in 
subsequent functional assays in which the transfer of these delicate 





spheroid work. The initial 7-day experiments (involving HDMB-03 cells) 
of spheroid culture within serum-free neurosphere media versus seeded 





Figure 4.1Growth of medulloblastoma spheroids  
A. Schematic showing the generation of medulloblastoma spheroids.   
The previously optimised cell seeding densities of each cell line as determined by Dr S. 
Roper were seeded into ultra-low attachment plates and allowed to grow for 72 hours. On 
day 4, the spheroids were ~300µm in diameter and therefore suitable for functional 
experiments. Image created with BioRender.com.  
B. Graphical representation of the growth of the SHH spheroids over 72 hours from 
Day 4 to Day 7. Spheroid volume was measured using an image J macro designed by a 
previous lab colleague Dr Ivanov and plotted within Graphpad prism from day 4 to day 7. 
While DAOY and ONS-76 cell lines remained spherical at Day 7, the UW228-3 spheroids 
began to adopt an ovoid phenotype from day 4 onwards. All spheroids measured over 300 
µm at the beginning of the experiment and continued to grow over the 72 hours period. 
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Figure 4.2 Spheroid culture in neurosphere medium and on top of a collagen IV matrix. As shown above, all except HD-MB03 form spherical spheroids. 





4.3.2 The effects of variations in the tumour 
microenvironment on the levels of functionally active 
MMP-2 and MMP-9 secreted by medulloblastoma 
4.3.2.1 3-D spheroid culture of MB spheroids on top of a Collagen 
IV matrix 
To determine whether the culture of SHH and Group 3 spheroids on 
various extracellular matrix components would stimulate higher levels of 
secreted functionally active MMP-2 and MMP-9; DAOY, ONS-76, 
UW228-3 and HD-MB03 spheroids were seeded on top of collagen IV-
coated 96 well plates. Fresh serum-free neurosphere medium was then 
added and the spheroids allowed to migrate for 72 hours, following which 
images as shown in Figure 4.2 were taken, and conditioned supernatant 
harvested for gelatin zymography.  A representative zymogram is shown 
in Figure 4.3.  At 48 hours, the intensity of the MMP-2 signal modestly 
increased in all the cell lines seeded on the collagen IV matrix in 
comparison to their media-cultured counterparts as shown in Figure 4.3 
B (i). Only DAOY and ONS-76 spheroids secreted detectable levels of 
functionally active MMP-9 at 48 hours, with increased signal observed in 
those seeded onto the collagen IV matrix (Figure 4.3 B (ii)). While the 
levels of functionally active MMP-2 and MMP-9 were easily detectable 
after 48 hour conditioned supernatant from 2-D culture of the MB cell 





MMP-2 and MMP-9 signal intensity from spheroid 48 hr conditioned 











Figure 4.3 Levels of functionally active MMP-2 and MMP-9 from initial SHH and 
Group 3 MB spheroid experiments.    
A. Gelatin zymograms of conditioned supernatant following 48 hour culture of MB SHH and 
Group 3 MB spheroids on top of a collagen IV coating (10µg/mL). 15µl of each sample were 
loaded alongside serum-free neurosphere media (N/S medium) and recombinant MMP-2 
(rMMP-2) and MMP-9 (rMMP-9) controls and the resulting percentage change in signal 
intensity quantified with Image J densitometry where detectable. (M)-Media, (C)-collagen IV 
B.  Graphical representation of the percentage change in the signal intensity of detectable 
MMP-2 (i) and MMP-9 (ii) secreted by spheroids cultured for 48 hours in neurosphere media 
versus on top of a collagen IV matrix. As shown, n=3 experiments for DAOY and ONS-76 
spheroids demonstrated consistently higher MMP-2 in the collagen cultured spheroids at 24 
and 48 hours, while UW228-3 and HD-MB03 showed MMP-2 levels lower than the media 
controls at 24 hours but more MMP-2 at 48 hours. MMP-9 signals from 48-hour spheroid 





4.3.2.2 3-D spheroid culture of SHH spheroids on top of a 
hyaluronan based hydrogel 
To explore the effect of a hyaluronan (HA) microenvironment on the 
levels of secreted functionally active MMP-2 and MMP-9 from 
medulloblastoma, day 4 DAOY and ONS-76 spheroids were seeded by 
Dr S. Roper (Roper 2019), on top of a hyaluronan-based matrix 
(Hystem©) along with different combinations of extracellular protein 
components. The spheroids were incubated in neurosphere medium for 
72 hours before their supernatant was extracted, centrifuged and stored 
at -80˚C, allowing for simultaneous zymography experiments to be 






Figure 4.4 The effect of SHH spheroid culture on a hyaluronan-based matrix on the 
secreted levels of functionally active MMP-2 and MMP-9. 
Day 4 DAOY and ONS-76 spheroids were seeded on top of a customisable 1% hyaluronan 
hydrogel (Hystem©) combined with different matricellular protein combinations to final 
concentrations of 50 µg/mL-as optimised by our post-doctoral fellow, Dr Franziska Linke. 
Equal volumes of 72 hr conditioned supernatant were examined with gelatin zymography. 
Zymograms shown above were representative of n=2 experiments, with ONS-76 spheroids 
MMP-9 signal intensity more visible than MMP-2 while DAOY MMP-9 signal was difficult to 





While DAOY spheroids migrated to similar extents across all matrix 
combinations (Roper 2019),  their differential levels of functionally active 
MMP-2 (p=0.0004) and MMP-9 (p=0.0333) were statistically significant 













 Figure 4.5 Levels of functionally active MMP-2 and MMP-9 secreted by DAOY 
spheroids migrating across different matrices. 
DAOY spheroids were generated and after 96 hours, seeded on top of either collagen IV 
(10µg/mL) or 1% hyaluronan hydrogel alone or supplemented with collagen I, laminin I, 
vitronectin, fibronectin or a combination of 1% hyaluronan supplemented with the latter 4 
factors to resulting concentrations of 50µg/mL, and allowed to migrate for 72 hours. 
Conditioned supernatant was harvested and gelatin zymography performed as shown (n=2). 
Image J densitometry was used to determine the MMP-2 and MMP-9 content of each sample 
relative to loaded controls of MMP-2 (3.33ng/µl) and MMP-9 (1:100 of 6.66ng/µl),and 
analysed using GraphPad prism. DAOY spheroids migrating across a collagen IV matrix 





Similarly, ONS-76 spheroids migrated across all matrix combinations, but 
exhibited the most dramatic migration pattern on hyaluronan 
supplemented with fibronectin (Roper 2019). While the differential levels 
of functionally active MMP-2 and MMP-9 secreted by the ONS-76 
spheroids cultured on the various were not statistically significant, the 
highest levels of MMP-9 seemed to emanate from ONS-76 spheroids on 
HA hydrogels supplemented with laminin I or vitronectin (Figure 4.8).  
 
Figure 4.6 Levels of functionally active MMP-2 and MMP-9 secreted by DAOY 
spheroids migrating across different matrices.  
Following 72 hour migration of ONS-76 spheroids across pure collagen IV (10µg/mL), pure 
1% hyaluronan or hyaluronan (HA) supplemented with collagen I, laminin I, fibronectin I, 
vitronectin or a combination of all 4 factors, supernatant was examined using gelatin 
zymography as shown and analysed using image J densitometry and ANOVA statistical test 
on Graphpad prism. The strongest MMP-9 signal intensities were apparent in the HA + 





Further experiments to explore this differential secretion of functionally 
active MMP-2 and MMP-9 from SHH MB cultured on different ECM 
components and conditions are required to make definitive conclusions. 
While DAOY and ONS-76 spheroids migrated across each 
representative ECM surface, they were not found to be invasive when 
embedded within pure or supplemented hyaluronan based hydrogels 
(Roper 2019). We therefore explored whether hyaluronan-embedded 
single MB cells would secrete stronger levels of functionally active MMP-
2 and MMP-9.    
 
4.3.2.3 The effect of 3-dimensional culture of medulloblastoma 
cell lines embedded in a Hyaluronan hydrogel on their secreted 
levels of functionally active MMP-2 and MMP-9 
 
MB cells were embedded within a pure hyaluronan hydrogel by our post-
doctoral fellow, Dr Franziska Linke. Forty-eight hour conditioned media 
was harvested after 20 days of extended culture and examined using 
gelatin zymography.  










Figure 4. 7 Schematic diagram of 3-dimensional hydrogel culture of medulloblastoma 
Medulloblastoma cell lines were seeded in a pure hyaluronan (HA) hydrogel and established 
in extended culture with media changes performed every 48 hours. Supernatant from 
embedded 20-day old cells was centrifuged and their levels of functionally active MMP-2 
and MMP-9 examined using gelatin zymography. Image created with BioRender.com 
 
As shown in Figure 4.8, the levels of functionally active MMP-2 and to a 
lesser extent MMP-9 expressed by the MB cell lines embedded within 
the pure hyaluronan gel, are drastically stronger than those previously 
seen from their 2-D cultured counterparts (Figure 3.10). This is especially 
clear when the initial numbers of seeded cells are considered, i.e. less 
than 1000 cells per well in the hydrogel compared to the 5 million cells 
seeded in the 2-D cultures.  
In comparison to the signal intensity (Figure 4.8)  of the functionally active 
MMP-2 and MMP-9 detected in the supernatants derived from the 2-D 
monolayer cultures of 5X106 MB cells, higher levels of functionally active 
MMP-2 and MMP-9 were derived from considerably fewer cells 
embedded within the hyaluronan hydrogel. While the concomitant 





replicate experiments, this data suggests that the encapsulation and 
interactions with components of their extracellular matrix, may stimulate 





Figure 4. 8 Gelatin zymography of supernatant from 3-D embedded medulloblastoma 
cell lines. 
Equal volumes of 48-hour conditioned supernatant (S) from 20 day hydrogel embedded 
medulloblastoma cells were loaded alongside serum containing media (M) controls into a 
gelatin impregnated SDS-gel and examined for their levels of functionally active MMP-2 and 
MMP-9 using zymography. Reference controls of recombinant MMPs (rMMPs) loaded were 
33.3ng of rMMP-2 and 0.66ng of rMMP-9 in this experiment. As shown, the signal intensity 
of MMP-2 and MMP-9 from the embedded cells are comparable to those from millions of 
single MB 2-D cultured cells.  
 
4.3.2.4 Investigating the effect of spheroid and macrophage co-
culture and p53 status of SHH medulloblastoma on their secreted 
levels of functionally active MMP-2 and MMP-9 
In addition to being the MB subgroup with the highest immune cell 
infiltration, the p53 status in SHH medulloblastoma is a well-known 
prognostic indicator as highlighted by the WHO (Louis, Perry et al. 2016) 
While we primarily sought to evaluate whether co-culture with 
macrophages would increase the levels of functionally active MMP-2 and 





forming SHH cell lines with different p53 statuses and previously 
published data suggesting p53 regulates MMP-2 activation at the 
transcriptional level,  drove us to explore whether the p53 gene status 
would have any effect upon the secreted levels of functionally active 
MMP-2 and MMP-9 from SHH spheroid-macrophage co-cultures.  
To this end, previously optimised cell densities of DAOY mut p53, ONS-
76 dnp53 and ONS-76 wt. p53 were co-cultured with macrophages 
graciously donated by Dr Luisa Martinez-Pomares group (see Methods 
2.7.2). Tumour cells were seeded in ultra-low attachment plates 
(Corning, 7007) with macrophages in ratios of 1:1 ratio, 1:0.5 and 1:0.25 
by Dr S. Roper (Roper 2019) and zymogram experiments of the 
supernatants performed as demonstrated in Figure 4.10.  
 
Figure 4.9 Generation of ONS-76 wild 
type TP53 and ONS-76 dnp53 spheroids.  
To generate spheroids of approximately 
300µm diameter at day 4, 1000 ONS-76 
dnp53 cells were required in comparison to 
250 cells of the wild type p53 counterpart. 
As shown, the resulting in the ONS-76 wt. 
TP53 spheroid was much tighter in 
appearance with a more well-defined 





While the doubling time in 2-D culture of ONS-76 dnp53 was similar to 
that of its wt. p53 counterpart, more than 4 times the number of dnp53 
ONS-76 cells were required to obtain spheroids of suitable size as shown 
in Figure 4.8. In addition, the ONS-76 dnp53 spheroids secreted less 
functionally active MMP-2 compared to its wild-type p53 counterpart, 










Figure 4.10 Zymography of supernatant from SHH MB spheroid and macrophage 
culture 
Equal volumes of supernatant following 72-hour co-culture of macrophages in the ratios 
given above to the respective cell lines were examined using gelatin zymography. 
Surprisingly, in the absence of macrophages, little to no MMP-9 signal was seen in any of 
the spheroid supernatants with the exception of possible artefact in the DAOY sample. In 
the co-culture samples, the MMP-2 signal appeared to emanate predominantly from the 
spheroids while the MMP-9 signal appeared to be proportional to the ratio of macrophages 






As depicted in Figure 4.10, the levels of functionally active MMP-2 signal 
remained constant between the MB spheroids of the same cell line 
irrespective of whether macrophages were added, suggesting the 
secreted MMP-2 was mainly tumour-derived. The MMP-2 signal intensity 
was easily detectable in the supernatant from the DAOY and ONS-76 wt. 
p53 spheroids but substantially reduced in the ONS-76 dnp53 spheroids. 
This data supports findings from the earlier works of Bian and Sun, 1997 
that demonstrated p53 regulation of MMP-2 at the transcriptional level.  
Meanwhile, the MMP-9 signal intensities decreased in a manner 
proportional to the ratio of macrophages seeded within the co-cultured 
spheroids. While preliminary, this exciting data suggests that majority of 
the functionally active MMP-9 in the SHH MB tumour microenvironment 
originates from the tumour cellular microenvironment. As both MMP-2 
and MMP-9 have been correlated with increased invasive capacity in MB, 
it is possible that these paracrine interactions with surrounding tumour 
associated immune cells, may be an additional mechanism by which 
SHH MB metastasize, given their predominance for immune cell 
infiltration (Margol AS 2015). Further work is needed to elucidate the 
autocrine and paracrine signalling involved in the medulloblastoma: 
immune cell interface, and determine their resulting effects on migration 






4.3.3 Effects of pharmacological inhibition of MMP-2 and 
MMP-9 on the migration patterns of 3D SHH 
medulloblastoma spheroids seeded on collagen IV 
matrices 
Choosing an appropriate matrix metalloproteinase inhibitor 
 
To determine whether the migration of SHH spheroids across ECM 
coatings would be altered by inhibition of their secreted MMP-2 and 
MMP-9, we selected a synthetic MMP inhibitor (MMPI)  Doxycycline 
(Figure 4. 11) (Li K 2020), to test alongside human recombinant forms of 
the endogenous tissue inhibitors of metalloproteinases (TIMPs).    
 
4.3.3.1 Medulloblastoma spheroid treatment with Doxycycline 
Hyclate 
 
Doxycycline is a well-tolerated tetracycline antibiotic that inhibits MMPs 
by chelating their calcium and zinc ions, key co-factors that enable their 
functional activity. As Vandenbroucke et al reported that the IC50 at which 
in vitro MMP-2 inhibition is achieved was 56µM, a range of 
concentrations centred around this figure, were trialled to ascertain which 
effectively inhibited the secreted MMP-2 and MMP-9 from the spheroids 
but did not result in concomitant toxicity (Vandenbroucke RE 2014, 













Day 4 DAOY, ONS-76 and UW228-3 spheroids were then treated with 
freshly re-constituted Doxycycline at 10µM, 25µM, 50µM and 100µM 
concentrations over a 72-hour period. After photomicrographs were 
captured, the supernatants were harvested and examined for the 
secreted levels of functionally active MMP-2 and MMP-9 from the 
respective spheroids and compared to their matched controls, using 
gelatin zymography as shown in Figure 4.12. 
Replicated experiments of all three SHH cell line spheroids were 
performed and their supernatants examined with gelatin zymography to 
determine the lowest effective concentration of Doxycycline that inhibited 
the secreted MMP-2 and MMP-9, without conferring spheroid toxicity. 
However, it soon became evident that above concentrations of 10 µM, 
the spheroids looked less viable after 24 hours and began to disintegrate 
by 48 hours. On the other hand, the data demonstrated that complete 
inhibition of the spheroid-derived MMP-2 and MMP-9 only occurred at 





these high toxicities, doxycycline was found unsuitable for functional 
studies and instead recombinant TIMPs were favoured for further MMP 
inhibition experiments. Additional data from the Doxycycline experiments 









Figure 4.12 Gelatin zymography of 72hr conditioned supernatant from 10µM and 
100µM Doxycycline treated spheroids alongside matched DAOY and ONS-76 
spheroids cultured in their usual neurosphere medium.  
Day 4 DAOY, ONS-76 and UW228-3 spheroids were cultured in neurosphere media 
(spheroid N/S) or neurosphere media supplemented with sterile water (vehicle) or 
Doxycycline at 10 µM and 100 µM concentrations. Gelatin zymography of the 72hr 
supernatant from spheroids treated as described, demonstrated Doxycycline 100 µM 
inhibited both spheroid-derived gelatinases but at the cost of spheroid viability. 
 
4.3.3.2 Medulloblastoma spheroid treatment with recombinant 
TIMP-1 and TIMP-2 
In physiological states, homeostasis between the levels of MMPs and 
TIMPs modulates the extracellular environment. In cancer however, 
many authors attribute the unchecked migration, invasion and cultivation 





in disproportionate upregulation of MMPs in comparison to TIMPs (Li K 
2020), as demonstrated in the protease/protease inhibitor array 
experiments in Chapter 3 of this thesis. This pattern was also suggested 
by data from DNA methylation profiling of 276 MB and 8 normal 
cerebellar samples from the Hovestadt dataset analysed on the R2 








Figure 4.13 DNA methylation profiling of TIMP-1 in normal cerebellum and sub-
grouped medulloblastoma. 
DNA from fresh frozen and paraffin-embedded samples of normal cerebellum and 
medulloblastoma from the Hovestadt dataset was examined using the Illumina 450K 
methylation array and resulting TIMP-1 gene methylation data accessed and analysed on 
the R2 Genomic Analysis and Visualisation platform. Box and whisker plots representing 
each group are shown with the median and interquartile ranges demonstrated. One way 
ANOVA analysis demonstrated statistical significance (p=0.015) of the TIMP-1 
hypomethylation in the MB samples in comparison to the cerebellum.  
 
The 4 members of the TIMP family TIMP-1, -2, -3 and -4, form irreversible 
inhibitory complexes with MMPs in 1:1 stoichiometric ratios via non-
covalent mechanisms (Laronha H 2020, Raeeszadeh-Sarmazdeh M 





constitutively expressed. In addition to their inhibition of most MMPs, 
TIMPs have also been shown to inhibit other matricellular proteases such 
as disintegrin metalloproteinases (O'Connor, Aboagye et al.). (Jackson, 
Defamie et al. 2017).  
Following their secretion into the extracellular matrix, the actions of 
TIMPs and where they exert them, is determined by their glycosylation 
and interactions with largely non-protease ligands (Table 4. 1). TIMP3 is 
the only member that remains integrated within the extracellular matrix 
as a result of its glycosylation (Jackson, Defamie et al. 2017). 
Conversely, the extracellular levels of the other TIMPs and non-
glycosylated TIMP-3, are regulated by their endocytosis which is 
facilitated by proteins such as plasma α2-macroglobulin and low density 
lipoprotein receptor-related protein (LRP-1), when the TIMPs are bound 
to zymogen forms of the MMPs (Jackson, Defamie et al. 2017). 
Table 4.1 summarises their other key features. While the TIMP-1: MMP-
9 complex impedes the activation of pro-MMP-9 and mediates its 
elimination from the tumour microenvironment; the complex formed 
between TIMP-2 and MMP-2, in the presence of MMP-14, results in the 
activation of pro-MMP-2 (Raeeszadeh-Sarmazdeh M 2020). Thus, the 
resulting effects of TIMPs can be contradictory to what they are initially 
assumed to be. The understanding of the effects of TIMPs in the tumour 
microenvironment is further complicated by their ability to initiate, induce 
and trigger proliferative, migratory and survival pathways that culminate 


















To gain an indication into which TIMP would most effectively inhibit the 
MB spheroid-derived MMP-2 and MMP-9, survival analyses of their gene 
expression from the publically available Cavalli dataset of 763 MB 
patients, were performed using the R2 genomic analysis and 
visualisation platform (http://r2.amc.nl). Over 10 years of survival data 
was available in 612 fresh frozen primary MB samples as shown in Figure 
4.14.  
In contrast to other tumours including glioblastoma (Jackson, Defamie et 
al. 2017), high gene expression of TIMP-1 in medulloblastoma conferred 
a statistically significant survival benefit [p=0.011], as shown in the 
Kaplan Meier curves below, albeit in a select proportion-3.27% of MB 
patients. While the survival analyses for TIMP-2 also demonstrated a 
statistically significant survival advantage of high TIMP-2 expression, this 
difference was much less compared to that of TIMP-1. As shown by the 
Kaplan Meier curves for TIMP-3 and TIMP-4, neither proved to be 
statistically significant within this patient dataset. We therefore chose to 
trial both recombinant forms of TIMP-1 and TIMP-2 to ascertain which 
would most effectively inhibit the endogenous MMP-2 and MMP-9 








Figure 4. 14 Kaplan Meier survival analyses of MB patient gene expression data of TIMP-1, -2, -3, and -4.  
RNA extracted from a total of 612 fresh-frozen medulloblastoma patient samples in the Cavalli dataset was hybridised by Affimetrix array profiling and the gene 
expression of all TIMPs were quantified and correlated to survival data of the same patients (Cavalli, Remke et al. 2017).  The most striking difference in survival was 
observed in the MB patient samples with high TIMP-1 expression, followed by TIMP-2. As the Kaplan Meier curves for high and low gene expression of TIMP-3 and 





To recapitulate the complexity of the MMP-TIMP in vivo interactions, 
SHH MB spheroids were generated as previously described and treated 
with different nanomolar concentrations of recombinant TIMP-1 and 
TIMP-2 proteins over a 72-hour period. Their phenotype, levels of 
functionally active gelatinases and growth were thereafter examined with 
microscopy, gelatin zymography and volumetric analyses, respectively.  
Initial experiments were performed using recombinant TIMP-1 and TIMP-
2 at 10nM and 100nM concentrations, which were based on previous 
publications (Junseo Oh 2004, Stetler-Stevenson 2008).  At 10nM TIMP-
1 and TIMP-2 treatments, there was very little detectable change in the 
signal intensity of the DAOY, ONS and UW228-3 spheroid-derived MMP-
2 and MMP-9; while at 100nM, spheroid viability was affected.  These 
experiments were therefore repeated using 25 and 50 nanomolar 
concentrations of TIMP-1 and TIMP-2 as shown in Figure 4.15. 
DAOY, ONS-76 and UW228-3 spheroids remained viable following 72 
hours of treatment with the recombinant TIMP-1 and TIMP-2 proteins at 
both 25nM and 50nM concentrations.  Since TIMP-1 strongly inhibited 
both MMP-2 and MMP-9 as confirmed in the gelatin zymography of ONS-
76 treated spheroids (Figure 4.18), and did not appear to result in 
concomitant activation of either gelatinase, it was decided that it would 
be the best endogenous MMP inhibitor to determine whether inhibition of 
MMP-2 and MMP-9 would alter the extent or pattern of migration of the 
















Figure 4.15 72-hour treatment of SHH MB spheroids with 25nM and 50nM concentrations of TIMP-1 and TIMP-2 recombinant proteins.  
As shown above, the spheroids remained viable following TIMP-1 and TIMP-2 treated spheroids at the given concentrations over the 72 hours period. With the 
exception of UW228-3 which adopted an ovoid shape after 4-5 days following their generation, DAOY and ONS-76 remained spherical throughout the 72-hour 




As 72-hour conditioned supernatant from ONS-76 spheroids 
demonstrated high levels of functionally active MMP-2 and MMP-9, ONS-
76 spheroids were used to determine the right TIMP-1 inhibitor 
concentrations and treated with recombinant TIMP-1 at 10, 25, 50 and 









Figure 4. 16 Representative gelatin zymogram of supernatant from ONS-76 spheroids 
after 72-hour rTIMP-1 and rTIMP-2 treatment at 25 and 50 nanomolar concentrations. 
As shown in the zymogram, the MMP-2 and MMP-9 signal intensities within the supernatant 
harvested from ONS-76 spheroids treated with both rTIMP-1 and rTIMP-2 at both 
concentrations of 25 and 50nM were drastically reduced in comparison to their 
corresponding vehicle treated counterparts.  Interestingly, the MMP-2 and MMP-9 signal 
intensities in the vehicle-treated spheroids were stronger than the media controls.  As both 
rTIMP-1 and rTIMP-2 appeared to inhibit the ONS-76 spheroid derived MMP-2 and MMP-9 
to a similar extent, rTIMP-1 was selected for future experiments to reduce the possibility of 








As shown in Figure 4.17, volumetric analyses of the DAOY, ONS-76 and 
UW228-3 spheroids demonstrated their continual cell proliferation and 
viability over the 72-hour course of TIMP-1 50nM treatment. In addition, 
gelatin zymography (Figure 4.19) and densitometry of replicated ONS-
76 experiments treated with both rTIMP-1 and rTIMP-2 at concentrations 
of 25nM and 50nM confirmed that rTIMP-1 and rTIMP-2 had a similar 
inhibitory effect at both concentrations. At 25nM, rTIMP-1 treatment 
resulted in a mean 64.0% decrease in MMP-2 signal and a mean 88.2% 
decrease in the MMP-9 signal, compared to its vehicle control. At the 
same concentration, rTIMP-2 treatment resulted in a 60.9% decrease 
and a 92% decrease in functionally active MMP-2 and MMP-9, 
respectively. At 50nM, a similar pattern of reduced MMP-2 and MMP-9 
signal intensities were detected in the supernatant from both TIMP 




























Figure 4.17 Volumetric comparison of SHH MB spheroids following 24-72 hours of 
TIMP-1 50nM treatment alongside media and vehicle controls. 
Volumetric analysis of DAOY (A), ONS-76 (B) and UW228-3 (C) spheroids were cultured 
for 72 hours in either the standard neurosphere media (media), vehicle control or TIMP-1 
50nM treated media. The spheroids remained viable and continuously grew over the 




To determine whether treatment with recombinant TIMP-1 (rTIMP-1) 
would affect SHH spheroid migration across a collagen IV matrix, DAOY, 
ONS-76 and UW228-3 spheroids were generated in the usual fashion 
and seeded onto a collagen IV matrix with fresh pure neurosphere media 
or neurosphere media supplemented with the vehicle (sterile water) or 
rTIMP-1 50nM.  
Figure 4.18 shows the effect of rTIMP-1 treatment on DAOY cell 
migration across the collagen IV matrix. In comparison to media and 
vehicle treated controls, there are fewer areas of confluent collective 
migration seen in the rTIMP-1 treated spheroids over the 72-hour period. 
Whereas in ONS-76, rTIMP-1 treatment did not appear to have any effect 
on the extent of migration as shown in Figure 4.19. However, the rTIMP-
1 treated ONS-76 spheroid appeared to be slower to disseminate across 
the collagen IV as by 24 hours, its vehicle counterpart had migrated to 
the extent that a central spheroid body was not visible. On the other hand, 
UW228-3 spheroids that seldom migrate over collagen IV matrices, did 
not demonstrate any overt changes in their phenotype following 











Figure 4.18 DAOY Coll. IV migration assay 
At 24 and 48 hours, the extent of migration across the collagen IV matrix appeared restricted 
in the rTIMP-1 treated DAOY spheroids compared to the media and vehicle controls. This 
effect appeared to be lost at 72 hours where the DAOY cells had migrated from the central 
spheroid body beyond the microscopy field of view, similar to the migration seen in the media 









Figure 4.19 ONS-76 Collagen IV migration assay 
While the ONS-76 spheroid appeared to favour a collective mode of migration across the 
collagen IV matrices, in comparison to the DAOY spheroids, rTIMP-1 treatment did not 












Figure 4.20 UW228-3 Collagen IV migration assay 
In contrast to DAOY and ONS-76  spheroids, single cell migration was inconsistently 
observed in UW228-3 spheroids after 48 hours of seeding on top of the collagen IV matrix. 
In comparison to the other SHH spheroids, UW228-3 were the only cell line whose 
morphology changed over 7 days of culture. However when seeded  on Collagen IV 
matrices, the migrating single cells appeared to emerge from the polar ends of the ovoid 
spheroids. 
 
This data suggests that rTIMP-1 mediated MMP-2 and -9 inhibition, may 
cause cells to adapt their migratory mechanisms in an autocrine manner 
that circumvents the need for increased secretion of functionally active 
MMP-2 and MMP-9; or that MMPs are not essential to the spheroid 
migration across a collagen IV matrix, hence their inhibition had little 




4.4 Migration of Group 3 and 4 medulloblastoma 
cell lines through trans-well assays 
 
While the spheroid migration model sufficiently demonstrated the 
migratory patterns of 3 SHH cell lines across a collagen IV matrix, it 
proved unsuitable for the correlation of their respective secretion levels 
of functionally active MMP-2 and MMP-9 to their expected metastatic 
potential, due to the presence of many confounding factors including the 
ECM components the spheroids were seeded upon, and the finding that 
their extent of migration was unaffected by TIMP-1 mediated inhibition of 
their secreted gelatinases.  
While this conundrum may mimic the complex and dynamic in vivo 
tumour microenvironment, we postulated that a different 3-D invasion 
model may be more suitable to answer our question. As migration across 
a matrix will depend heavily on cell adhesion to the matrix it can occur by 
protease-independent mechanisms. However, invasion through a matrix 
necessitates proteolysis and consequent re-modelling of the barrier 
environment (Kramer, Walzl et al. 2013) 
Having been recently shown to metastasize to the leptomeninges via 
haematogenous and CSF routes (Boire, Zou et al. 2017), the 
transmigratory capacity of MB cells across the BBB would an important 
consideration especially in Group 3 and 4 MB, which disseminate further 
from their primary tumour cavity (Zapotocky M 2017). The transwell 




capacity of cancer cells through perforated wells with pores measuring 
less than 10m. At this pore diameter, cancer cells commonly of 20m, 
must actively migrate through the pores towards a chemokine. 
Additionally, coatings of different permutations of basal lamina proteins 
can be applied, to recapitulate the in vivo cell adhesion interactions that 
allow the invading cancer cells to anchor to the basement membrane, 
prior to their protease mediated transmigration into the brain vasculature 
(Justus, Leffler et al. 2014). Thus, to recapitulate the BBB, the 
permutation of ECM proteins had to be determined. 
While ex vivo basement membranes originating from peritoneal and 
placental tissues have been used to investigate the transmigration of 
other tumour types (Touboul, Lis et al. 2013), the unique features of the 
BBB render these substitutes inadequate for determination of migration 
and invasion of medulloblastoma.  
4.4.1 Choosing the right transwell barrier  
While hyaluronan is most predominant component of the cerebellar 
parenchyma (Novak and Kaye 2000), collagen IV and laminin isoforms 
constitute the bulk of the basal lamina, a layer of the BBB formed by two 
layers distinguished by their cells of origin and laminin-isoform 
components. The endothelial derived basal lamina contains laminin 111 
and -211 while its parenchymal counterpart is constituted by laminin -411 
and -511 isoforms (Ferro, Heilshorn et al. 2020). 
Although synthetic substitutes such as Matrigel which contain collagen 




used in previously described BBB models, these polymers do not 
produce the endogenous architectural structures that would limit their 
permeation by disseminating tumour cells. Thus, collagen IV and laminin 
I isoforms that more closely recapitulated the in vivo basal lamina 
backbone were employed in the following experiments (Ferro, Heilshorn 
et al. 2020).  
As collagen I is a commonly employed barrier in published trans-well 
migration models due to its scaffold structure, experiments were set up 
to determine whether the MB invasive capacity would be altered in the 
presence of a collagen I gel barrier in comparison to a collagen IV coating 
(Figure 4.21).  
Building upon work done by a colleague Dr Macha Aldighieri in the 
optimisation of this transwell assay (Aldighieri 2020), initial experiments 
using the most aggressive Group 3 MB metastatic cell line available in 
our lab, HD-MB03 were performed, to determine the optimal trans-well 
coating for the investigation of the migratory and invasive capacities of 
matched primary and recurrent Group 3 (D425-Med and D458-Med) ( 
and Group 4 (CHLA-01-Med and CHLA-01R-Med) MB cell lines. As Dr 
Aldighieri had already demonstrated a barrier function using collagen IV 
and collagen IV/laminin transwell coatings in her work, this was not 
tested further.  
As shown in Figure 4.21, 25% of seeded HD-MB03 cells invaded within 
24 hours with no significant differences observed between the different 




had a doubling time of approximately 48 hours, therefore to minimise the 
confounding effects of concomitant proliferation, a shorter duration of 24 








Figure 4.21 24 hour invasion assays of an aggressive Group 3 cell line through 
different barrier coatings. 
100,000 HD-MB03 cells were seeded into trans-wells and allowed to invade through 
Collagen I (1.5mg/mL), Collagen IV (10µg/mL) and Collagen IV (10µg/mL)/Laminin I (100 
µg/mL) coatings (n=3). Invaded cells were dissociated and numbers determined using a 
Presto blue© standard curve. Similar proportions of seeded HD-MB03 cells invaded through 
the three transwell coatings. 
 
As similar numbers of HD-MB03 cells invaded through the different 
transwell coatings (Figure 4.21) and collagen IV/laminin I are well 
described in the literature as key components of the basal lamina 
(Hoarau-Véchot J et al, 2014), this combination transwell coating was 
adopted for all subsequent transwell invasion experiments, to 
recapitulate invasion through the BBB-a key step in the haematogenous 




















4.4.2 The effect of pharmacologic inhibition of MMP-2 and 
MMP-9 on the rate of transwell invasion across a collagen 
IV/Laminin I barrier 
Having observed that rTIMP-1 treatment of SHH MB spheroids had little 
effect on the extent of migration of SHH spheroids across extracellular 
matrices (Figure 4.18, Figure 4.19 and Figure 4.20), it was postulated 
that TIMP-1 may alter the invasive potential of the aggressive Group 3 
HD-MB03 cells. However as previous rTIMP-1 experiments were 
performed on 3-dimensional spheroid cultures, baseline confirmation of 
the viability of 2-d cultured cells treated with rTIMP-1 50nM was 
necessary, to ensure that any changes in the levels of secreted MMP-2 
and MMP-9 would be due to the pharmacological inhibition by TIMPs 
rather than cytotoxicity. To this end, PrestoBlue© was added to matched 
HD-MB03 cell populations following 72 hours of  rTIMP-1 treatment, at 
10nM, 25nM, 50nM and 100nM concentrations, alongside vehicle 
controls Figure 4.22.  
As shown in Figure 4.22, HD-MB03 cell viability was preserved in the 











Figure 4.22 PrestoBlue cytotoxicity experiment in 2-dimensional culture of HD-MB03 
Group 3 MB cells treated with varying concentrations of rTIMP-1 
In comparison to the media control, less than 10% reduction in cell viability was observed 
after rTIMP-1 treatment of HD-MB03 cells.  
 
Equal numbers of HD-MB03 cells were treated with rTIMP-1 for 48 hours 
and allowed to invade for 24 hours (Figure 4.23).  Interestingly, rTIMP-1 
treatment of the Group 3 HD-MB03 cells did not significantly alter their 
invasive capacity and in the case of Collagen IV trans-well assays, it 
appeared to slightly increase their migration through the Collagen IV 
matrix as seen in Figure 4.23. While unexpected, these findings could be 
due to the effect of increased secreted levels of MMP-2 and MMP-9 
stimulated by the presence of their substrate collagen IV, which may 
counteract the inhibitory effects of rTIMP-1. As observed in the spheroid 
rTIMP-1 migration experiments, the rTIMP-1 may also cause the cells to 





























Figure 4.23 Effect of rTIMP-1 treatment on the invasive capacity of HD-MB03 cells 
(n=3) 
Following 48 hours of pre-treatment with rTIMP-1 at 100nM, 100,000 HD-MB03 cells were 
seeded into trans-wells and allowed to invade through Collagen I, Collagen IV and Collagen 
IV/Laminin I coatings. The number of rTIMP-1 treated cells that invaded through the barriers 
were normalised to the numbers of vehicle controls for each corresponding trans-well 
coating and analysed using GraphPad prism. One-way ANOVA analysis of the mean 
revealed no statistically significant differences between the three transwell coatings.  
 
4.4.4 Comparison of transwell invasion assays of matched 
primary and metastatic Group 3 and Group 4 cell lines 
across a collagen IV/Laminin I barrier 
 
To determine whether the secreted levels of functionally active MMP-2 
and MMP-9 would correlate with the postulated increased invasive 
potential of metastatic Group 3 and Group 4 medulloblastoma, trans-well 
invasion assays of the matched primary and metastatic Group 3 (D425-
Med and D458-Med)  and Group 4 (CHLA-01-MED and CHLA-01R-
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(as denoted by the origin from lower graded M status tumours) and had 
longer doubling times in comparison to HD-MB03, the duration allowed 
for the invasion assays was doubled to 48 hours.  
As demonstrated in Figure 4.24, nearly a third of the seeded cells from 
the matched primary and metastatic Group 3 (D425-Med and D458-Med) 
cell lines invaded through the Collagen IV/Laminin I matrix, over 48 
hours. This finding correlated well with the detected levels of functionally 
active MMP-2 and MMP-9 by gelatin zymography, which were 






Figure 4.24 Invasion assays (n=3) of matched primary and metastatic Group 3 (D425-
Med and D458-Med) cell lines. 
Equal cell numbers were seeded into trans-wells coated with Collagen IV/Laminin I and 
incubated for 48 hours. Invaded cells were dissociated and numbers determined using 
a Presto blue© standard curve (n=3) and analysed using Graphpad prism. As shown, 




When equal cell numbers of the matched Group 4 primary and metastatic 
(CHLA-01-MED and CHLA-01R-MED) cell lines were seeded, a 
statistically significant difference (p<0.05) in the invasive capacity was 
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observed as shown in Figure 4.23. While a third of the original number of 
primary cells invaded across the Collagen IV/Laminin I matrix, almost 
50% of the number of metastatic cells invaded within the same 48-hour 
period. This increased invasive capacity in the metastatic Group 4 cell 
line CHLA-01R-Med compared to its primary counterpart mirrored the 
previously demonstrated pattern of increased levels of functionally active 







Figure 4.25 Invasion assays (n=3) of matched primary and metastatic Group 4 (CHLA-
01-MED and CHLA-01R-MED) cell lines. 
Equal cell numbers were seeded into trans-wells coated with Collagen IV/Laminin I and 
incubated for 48 hours. Invaded cells were dissociated and numbers determined using a 
Presto blue© standard curve. The difference in the numbers of invaded cells between the 
primary and recurrent Group 4 cell lines was statistically significant. (n=3+SD t-test*=p<0.05) 
 
These replicate invasion assays appeared to correlate with the 
differential levels of secreted MMP-2 and MMP-9 by the matched Group 
3 and Group 4 cell lines, supporting the hypothesis that the levels of 
functionally active MMP-2 and MMP-9 could be predictive of the 
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In conclusion, the data from the 3-D functional assays of SHH, Group 3 
and Group 4 medulloblastoma suggest that: 
 
 A hyaluronan-rich tumour microenvironment may stimulate increased 
levels of secreted functionally active MMP-2 and MMP-9 from embedded 
medulloblastoma cells.  
 
 The spheroid model proved to be an optimal model for the elucidation of 
the SHH spheroid migration across a range of extracellular matrices, and 
their secreted levels of functionally active MMP-2 and MMP-9 in each 
condition. Interestingly, when seeded on a hyaluronan matrix, the wtp53 
SHH ONS-76 cell line consistently secreted higher levels of MMP-2 and 
MMP-9 compared to its p53 mutant SHH counterpart DAOY when both 
were seeded on top of Collagen IV. The converse was seen in the 
mut.p53 SHH cell line DAOY, which secreted higher levels of MMP-2 and 
MMP-9 when seeded on top of the collagen IV compared to hyaluronan. 
This may be as a result of their differential HA/collagen IV receptor 
densities.  It was also observed that the levels of secreted functionally 
active MMP-2 and MMP-9 increased when the spheroids were cultured 
on top of a matrix compared to neurosphere medium.  
 
 While the mode of migration across the matrix may be altered following 
endogenous MMP-2 and MMP-9 inhibition with TIMPs (as seen in the 




mediated MMP-2/-9 inhibition. This suggests that, as in vivo, the tumour 
cells adapt their migratory behaviour/mechanisms to circumvent the 
MMP inhibition as seen in the change of collective to more single cell 
migration in ONS-76 spheroids; or that migration across a matrix does 
not depend upon proteolysis (Dauth, Grevesse et al. 2016).  
 
 A collagen IV/Laminin I transwell invasion model demonstrated that the 
invasive capacities of the MB cell lines that secreted higher levels of 
functionally active MMP-2 and MMP-9, correlated with their differential 
invasive capacities. This pattern was clearly demonstrated in the 
matched primary and recurrent Group 4 cell lines (CHLA-01-MED and 
CHLA-01R-MED) but was not as distinctive in the Group 3 matched 




















Validation of MMPs as prognostic 
biomarkers in tissue and CSF from 













5.1 Chapter outline 
 
From epigenetic regulation to zymogen activation, the multiple regulatory 
checkpoints of matrix metalloproteinases, ensure that their levels of 
activity are strictly controlled in a physiological context, whereas in 
patients with aggressive primary and metastatic brain tumours, this 
homeostasis is lost, resulting in higher than normal expression of matrix 
metalloproteinases (Friedberg, Glantz et al. 1998). Several authors 
suggest that this may increase the invasive capacity of the tumour cells 
and therefore the potential for recurrence in these patients (Vihinen and 
Kahari 2002). In chapters 3 and 4, by exploring the biological 
characterisation of matrix metalloproteinases -2 and -9 in primary and 
metastatic medulloblastoma cell lines, I demonstrated that their levels of 
functionally active MMP-2 and MMP-9 best correlated with their 
metastatic potential. For this reason, the levels of functionally active 
MMP-2 and MMP-9 in CSF samples from paediatric patients with 
primary, metastatic or recurrent medulloblastoma (defined as relapsed 
disease following previous recurrence) were determined, using gelatin 
zymography.  
Due to the selective nature of the intact blood-CSF-barrier, the proportion 
of the tumour-derived MMP-2 and MMP-9 detectable in the patient serum 
would likely be negligible and therefore undetectable. In addition, the 
wide range of physiological and pathophysiological systemic functions in 
which MMPs are involved, would render difficulty in the determination of  




derived from the circulating medulloblastoma cells or non-specific 
systemic inflammation. For these reasons, cerebrospinal fluid sampling 
was determined to be the most sensitive method for the determination of 
tumour associated levels of functionally active MMP-2 and MMP-9 
(Bonner, Bornhorst et al. 2018). 
 
5.2 Objectives and hypothesis 
  
Considering the newer theories that suggest that the mechanisms of 
metastatic spread from the primary brain tumour to the leptomeninges 
may involve both haematogenous and cerebrospinal fluid dissemination, 
we hypothesised that: 
 
1. Epigenetic changes in medulloblastoma occur and may 
contribute to their increased levels of MMP-2 and MMP-9 gene 
expression in comparison to normal cerebellum  
 
2. Increased levels of functionally active MMP-2 and MMP-9 within 
the tumour secretome i.e. patient CSF, will reflect the metastatic 
capacity of the tumour, either in its capability for upregulation of 
functionally active MMP-2/ MMP-9, or manipulating its 
microenvironment by paracrine mechanisms that stimulate 
microglia, immune and endothelial cells to release active MMP-9 




To facilitate easier adoption and clinical translation of our work, we 
examined samples as they had been routinely obtained and stored in the 
current clinical manner i.e. cerebrospinal fluid biopsy via day 14 post-
operative lumbar puncture, and investigated whether handling and 
storage of CSF may affect our results. Once the levels of MMP-2 and 
MMP-9 have been demonstrated to be detectable using laboratory 
techniques, it was postulated that this would increase the likelihood of 
their successful radiological detection using our imaging biosensor.  
 
5.3 Liquid biopsy, handling and storage of 
cerebrospinal fluid samples from paediatric 
medulloblastoma patients 
 
Cerebrospinal fluid (CSF) is largely produced and secreted from the 
choroid plexus, a network of modified ependymal capillaries, located in 
the lateral, third and fourth ventricles of the brain. It represents a modified 
part of the blood-brain-barrier (sometimes referred to as the blood-CSF 
barrier) through which cerebrospinal fluid is produced at an approximate 
rate of 0.3ml/minute in the adult brain (Greenberg and Arredondo 2001). 
CSF production is thought to be physiologically controlled by sympathetic 
and parasympathetic outflow, the former innervating α and β2 
adrenoceptors, thereby stimulating vasoconstriction or vasodilatation of 




There is emerging evidence of a ‘glymphatic’ system in the brain, a 
network of low resistance perivascular channels through which CSF from 
the subarachnoid space flows alongside arteries and arterioles 
penetrating the pia into the brain parenchyma. Once in the interstitium, 
solute exchange between CSF and interstitial fluid occurs, before the 
CSF permeates the basal lamina of capillaries and proceeds to the 
perivenular spaces from where it is drained via the cervical lymphatics or 
absorbed via venous outpouchings known as arachnoid granulations, 
situated within the subarachnoid space (Jessen, Munk et al. 2015). This 
facilitated CSF absorption into the venous sinuses usually occurs down 
a pressure gradient and can be limited in conditions such as venous 
sinus thrombosis where this gradient may be reversed, or where previous 
subarachnoid haemorrhage or infection (meningitis), results in occlusion 








Figure 5.1 Perivascular flow of CSF through the glymphatic system.  
CSF flow from the subarachnoid space enters the perivascular space following arterioles 
as they penetrate the pia. Aquaporin 4 (AQP-4) facilitated CSF-interstitial fluid exchange 




The embryological development of the choroid plexus neuroepithelium 
begins within the fourth week and functions at expected capacity shortly 
after the closure of the neural tube in week 9 of gestation. The total 
volume of CSF circulating around the brain and spinal cord increases 
with age. In newborns, approximately 2ml/kg of CSF is reported, while in 
adults approximately 125-150 ml of CSF are in contained in the 
subarachnoid space at any one time (Greenberg and Arredondo 2001, 
Damkier, Brown et al. 2013) 
In comparison to plasma pH of 7.35-7.45, CSF pH is centred on pH 7.33 
with the same osmolality as plasma in physiological conditions. CSF is 
constituted of 99% water with electrolytes and solutes in the approximate 
concentrations as indicated below (Table 5.1).  
 






As we are interested in the matrix metalloproteinases circulating within 
the cerebrospinal fluid, the ratio and number of white blood cells present 
in the CSF, which could be the potential source of the MMPs, would 
necessitate some consideration (Table 5.2). As per current clinical 
standards, we adapted the accepted physiological cellular CSF 
constituents of: 0 polymorphonuclear leucocytes (PMN) which are acute 
phase immune cells and 0-5 monocytes. We expected clear, colourless 
CSF to be obtained from paediatric patients following atraumatic lumbar 
punctures, but accepted that the resulting colour could be influenced by 
trauma during lumbar puncture, recent surgery or concurrent intrathecal 
therapy.  
Table 5.2  Expected cellular counts in cerebrospinal fluid (Termini, Neman 
et al. 2014). 
 
Where available, this data was collated (Table 5. 3) to ensure that 
increased MMP-2 or MMP-9 signal was likely to originate from the 
circulating tumour cells or exuded by the tumour itself, as opposed to the 





As discussed in the methodology section of this thesis, cerebrospinal 
fluid sampling was performed via lumbar puncture in all patients 
approximately two weeks post-operatively. Briefly, the patient would be 
positioned in the left lateral foetal position and the posterior superior iliac 
spine palpated to localise the interspace of interest: L3/4 or L4/5. In 
children, the latter would be preferred as the spinal cord ends at the L2 
vertebral level. Once the back is thoroughly cleaned with an antiseptic 
solution and a sterile field applied, the entry point is once again confirmed 
and local anaesthetic infiltrated into the skin and subcutaneous tissues 
in the midline of the L3/4 interspace. A spinal needle is then advanced 
and CSF obtained and collected in sterile universal containers. The 
volumes of CSF samples collected are determined by the patient’s age 
and their ability to tolerate the procedure. The needle is withdrawn and 
pressure applied to reduce the risk of creating a spinal haematoma. The 
sample is then sent to the laboratory for urgent sampling and cell 
cytology, with a short period of refrigeration if a short delay to analysis is 
expected.   
Published literature suggests that increased sampling volumes of 
cerebrospinal fluid, repeated sampling and sampling of CSF closer to the 
regions of interest could result in higher yield of the biomarker (Weston, 
Glantz et al. 2011). To investigate the effect of sampling closer to the 
tumour site, we collected cerebrospinal fluid on dural entry following 
craniotomy for further tumour resections in a subset of the paediatric 
patients included in this study. It is also clinically accepted that, as 




drastically affect the specificity and sensitivity of CSF cytology. This can 
however be slightly reduced with refrigeration of the sample for a short 
period if a delayed transport of the sample is expected (Bonner, 
Bornhorst et al. 2018).  For some of the CSF samples examined, it was 
not possible to determine the duration between the  lumbar puncture and 
the processing of the samples prior to their storage at -80°C, following 
sampling and analysis in the usual clinical fashion. Table 5. 3 shows the 
macroscopic and microscopic assessment of the patient cerebrospinal 
fluid samples used in this study. Informed consent for the study was 
obtained from each patient’s parent or their respective adult with parental 
responsibility and the study protocols ethically approved be the National 






5.4 Results  
5.4.1 Investigating the epigenetic and genetic landscape 
of matrix metalloproteinases and their inhibitors   
 
DNA methylation represents one of the epigenetic modifications of gene 
expression. Other forms of epigenetic regulation include chromatin 
remodelling and histone modifications. In many cancers, the addition of 
a methyl group to promoter regions of the gene, often leads to 
suppression of the gene in question. If this occurs in a tumour suppressor 
gene, this can trigger a cascade of mechanisms that may culminate in 
oncogenesis (Roussel and Stripay 2018). As MMPs are matricellular 
proteins involved in many physiological processes such as cellular 
proliferation and remodelling of the extracellular matrix in response to 
injury, it is perhaps not surprising that MMP-2 for example, is 
constitutively expressed at higher levels in infancy and childhood (Ayoub, 
Cai et al. 2005). It therefore follows that epigenetic regulation of MMP-2 
gene expression could be the level most implicated in tumorigenesis.  
To explore this further, analysis of the DNA methylation and gene 
expression data of MMP-2, MMP-9 and EMMPRIN from fresh frozen and 
formalin-fixed paraffin embedded normal cerebellum controls and 
primary medulloblastoma patient samples within the Hovestadt dataset, 
was performed (Hovestadt, Remke et al. 2013, Hovestadt, Jones et al. 
2014, Cavalli, Remke et al. 2017).  As shown in Figure 5.2, the DNA 
methylation of MMP-2 in WNT, SHH, Group 3 and Group 4 MB are 




hypo-methylation of the MMP-2 gene in all the molecular MB subgroups 
appears to translate into reduced MMP-2 gene expression. 
Notwithstanding the considerable variation within the molecular 
subgroups, the comparison of methylation between the normal 
cerebellum and the MB subgroups is statistically significant (p=0.027). 
While analysis of MMP-9 DNA methylation revealed higher mean levels 
of methylation in Group 3, Group 4 and WNT tumours in comparison to 
normal cerebellum and SHH, the pattern of resulting gene expression 
was more complex than that for MMP-2. Mean levels of DNA methylation 
were observed to be highest in Group 4 tumours with resulting gene 
expression much lower than in Group 3 or WNT tumours, while SHH 
tumours with similar methylation levels to WNT, exhibited lower gene 
expression of MMP-9, suggesting subgroup specific differences in the 
effects of DNA methylation of MMP-9 exist.  
Extracellular matrix metalloproteinase inducer (EMMPRIN) stimulates 
MMP release from tumour cells and the stromal cells in their proximity 
and has been correlated with poorer prognosis in MB (Chu, Chen et al. 
2011). For this reason, its DNA methylation and gene expression were 
examined in the same manner as for MMP-2 and MMP-9.  As shown in 
Figure 5.2, DNA methylation levels in EMMPRIN in all four MB subgroups 
were very similar to that observed in normal cerebellum tissue. 
Correlation of the two within the Cavalli dataset performed on the R2 
Genomics Analysis and Visualisation platform suggested that 




              




































Figure 5.2 Correlation of DNA 
methylation patterns and resulting 
gene expression of MMP-2, MMP-9 and 
EMMPRIN in normal cerebellum (na) 
compared to MB patient samples using 
the R2 Genomic Visualisation 
database. 
A. Analysis DNA methylation data from the 
Hovestadt dataset of 276 MB patients and 
8 normal cerebellar samples showing 
hypomethylation of MMP-2, variation in 
MMP-9 methylation and strictly controlled 
methylation of EMMPRIN in all MB 
subgroups in comparison to cerebellum. 
B.  DNA methylation profiling of the MMP-
2, MMP-9 and EMMPRIN genes and   
C. Resulting gene expression from 
Affimetrix Gene 1.1 ST Array profiling of 
763 primary MB from the Cavalli dataset.  
DNA hypermethylation appeared to 
inversely correlate to levels of gene 
expression of MMP-2 and EMMPRIN but 




The DNA methylation profiles and gene expression of the main MMP-2 
and MMP-9 inhibitors, the tissue inhibitors of metalloproteinases TIMP-1 
and TIMP-2 (Figure 5.3), were also examined. DNA methylation levels of 
TIMP-1 was observed to be lowest in the Wnt subgroup, with a resulting 
higher gene expression in the same. However, in Group 4 MB that 
exhibited the highest mean DNA methylation pattern, its TIMP-1 gene 
expression was the lowest of all the MB subgroups, suggesting that DNA 
methylation of the TIMP-1 gene inversely correlates to its gene 
expression.  
While in the case for the TIMP-2 gene (Figure 5.2), both its DNA 
methylation profile and gene expression followed a similar pattern where 
both were observed to be highest in the Wnt subgroup, followed by 
Group 4 and Group 3, with SHH being the exception to the rule. 
This data suggests that while epigenetic regulators of genes coding for 
MMPs and their inhibitors can inform our understanding of the 
pathogenesis of MB and inform our prognostication in some cases, the 
endpoint of their gene expression, gene transcription, protein translation 
and their secretion as functionally active enzymes, may provide better, 












Figure 5.3 Correlation of DNA methylation patterns of TIMP-1 and TIMP-2 with their 
resulting gene expression in MB patients from the Cavalli dataset, as analysed on 
the R2 Genomics and Visualisation platform.  
While there appears to be a correlation of TIMP-1 hypermethylation to increased TIMP-1 
gene expression, this relationship is less clear for TIMP-2, where the pattern of methylation 
largely resembles that of its gene expression. However, there does appear to be a clear 
difference in the levels of hypermethylation of TIMP-2 in comparison to TIMP-1.  
 
5.4.2 Gelatin zymography of cerebrospinal fluid from 
patients with primary and recurrent medulloblastoma  
Characteristics of the cerebrospinal fluid samples obtained from the 

















































PMN 0 Lymph 4 Mono 0 
No organisms 
Neoplastic cells seen No 
1[2]  
Lumbar 
7 years old Residual 4ml 
Clear, straw 
coloured 

















No neoplasia No 
3[1] 
Lumbar 
5 years old Recurrence 10mL 
Clear pale yellow 
fluid 
No counts available 































No counts available 






Table 5.3 continuation: Characteristics of CSF sampled from paediatric patients with medulloblastoma 
5[1] 
Lumbar 
7 years old Relapse 4mls 
Clear colourless 
fluid 










































































Patient 1 was a 7-year-old previously fit and well boy, who presented 
following a three-week history of progressive, intermittent vomiting 
associated with frontal headaches and unsteadiness on his feet.  Initial 
contrast enhanced magnetic resonance imaging showed a 2.7 X 2.4 X 3 
cm lesion arising from the cerebellar vermis, causing obstructive 
hydrocephalus. (Fig. 1) Neuroaxial imaging also demonstrated multiple 
enhancing nodules throughout his spine down to the cauda equina. He 
underwent an emergency posterior fossa craniotomy for resection of his 
midline cerebellar tumour and placement of an external ventricular drain 
(later revised to a ventriculoperitoneal shunt) for hydrocephalus 
management. Histological examination confirmed an anaplastic 
medulloblastoma. A small enhancing residuum in the inferior 4th ventricle 
and extensive leptomeningeal disease was evident on his post-operative 
imaging (Fig.5.2) As his CSF cytology obtained via lumbar puncture 2 
weeks post-operatively was positive for clusters of neoplastic cells, his 
disease was staged as M3 and an intensive course of craniospinal 
irradiation (39.6Gy in 22 fractions with a total dose of 55.8Gy in 31 
fractions to the ‘boost zone’ or resection cavity and possibly other areas 
of metastatic disease) and chemotherapy according to St. Jude’s 
protocol was commenced(Thompson, Ashley et al. 2020).  
Unfortunately, patient 1’s tumour seemed to be chemo-resistant as 
follow-up MRI imaging performed 6 weeks later, showed increased 




where there were more confluent areas of enhancement. Interestingly, a 
further cerebrospinal fluid biopsy obtained at this point was devoid of 
neoplastic cells and therefore deemed negative. While gelatin 
zymography of his cerebrospinal fluid at initial operation was weakly 
positive, in keeping with the cytology result (see sample 1(1)), the CSF 
sample at recurrence (fig sample 1(R2)), demonstrated a 72.3% increase 
in levels of functionally active MMP-2 and a 100% increase in detectable 
levels of functionally active MMP-9, despite the negative CSF cytology 
result. 
Radiotherapy was then initiated, with good treatment response 
demonstrated on imaging performed 2 months after. He however 
required further surgery to improve his response to RT and underwent a 
subtotal resection of the residual cerebellar mass and nodular enhancing 
lesion in his left cerebellopontine angle.  
Patient 1’s leptomeningeal disease responded well to the intensive 
radiotherapy regime, with no evidence of convincing intracranial or 
intraspinal disease seen at imaging 4 months after. He unfortunately 
developed panhypopituitarism and periventricular cavernomas due to his 










Figure 5.4 Patient 1: T1 weighted (T1W) post-contrast pre-operative (yellow-outlined) 
and post-operative (green-outlined) magnetic resonance imaging.  
Patient 1 pre-operative MRI with contrast imaging demonstrating a midline posterior fossa 
mass avidly enhancing with contrast. Spinal imaging shows nodular enhancement in the 
upper cervical cord. Post-operative imaging showing residual tumour (indicated by white 
arrow) surrounding 4th ventricle in Patient 1 cranial MRI head with contrast axial T1W slice 
and contrast enhanced spinal MRI with contrast (sagittal views) showing reduced 










Patient 2 first presented at 11 years of age with a 3-month history of early 
morning headaches and vomiting, followed by a few days of ataxic gait. 
Computer tomography imaging revealed a posterior fossa space 
occupying lesion causing obstructive hydrocephalus, for which he initially 
underwent debulking surgery via a posterior fossa craniotomy and a third 
ventriculostomy. Residual disease was seen in the foramina of Luschka.  
Histological diagnosis confirmed a classical medulloblastoma and 
metastasis was excluded on the basis of negative post-operative imaging 
and cerebrospinal fluid cytology. Patient 2 therefore commenced 
adjuvant chemoradiotherapy (POG 9031).  
His disease unfortunately relapsed 4 years later at which time he was 
treated with combination chemotherapy of oral and intrathecal 
Etoposide, Irinotecan and Temozolomide. Recurrence of patient 2’s 
disease 3 months following completion of chemotherapy was detected 
on follow-up magnetic resonance imaging, which demonstrated 
enhancing foci with associated restricted diffusion in the right anterior 
temporal lobe and right lateral ventricle. This prompted further surgical 
debulking of his cerebellar disease and adjuvant 
Temozolomide/Cyclophosphamide chemotherapy. Despite these 
measures, patient 2’s intracranial disease progressed further to multiple 
enlarged leptomeningeal deposits, the largest in the right temporal lobe 




alongside a new radiotherapy associated meningioma. He was therefore 
palliated and succumbed to his disease soon after. 
Interestingly, patient 2 never had definitive radiological evidence of 
enhancing disseminated spinal disease, which may explain why all his 
cerebrospinal fluid cytology results were negative in the face of obvious 
intracranial disease progression. Zymography of his cerebrospinal fluid 
detected persistent levels of functionally active MMP-2 and MMP-9 with 
progression of his disease, despite negative cerebrospinal fluid cytology.  
 
T2-weighted MR imaging at recurrence (green-outlined) showing a large temporal tumour 
that grew from 3.6X3cm to 4.25X3.4cm (shown) over a period of 3 months. In addition to 
further leptomeningeal deposits in the spine and right lateral ventricle, discovery of this 
tumour contributed to the patient’s poor prognostication resulting in his palliation.  
 
Figure 5.5 T1-weighted post-contrast magnetic 
resonance imaging of patient 2. The pre-operative 
(yellow-outlined) T-1 weighted cranial and spinal 
imaging shows a poorly enhancing midline posterior 
fossa tumour that is filling up the fourth ventricle, 
causing obstructive hydrocephalus. No 
leptomeningeal deposits were visible on pre-operative 





Patient 3 was a 4-year-old boy who presented with a 4-week history of 
headaches, vomiting and unsteadiness. On admission, he was 
increasingly drowsy but rousable with a left 6th cranial nerve palsy. Pre-
operative imaging revealed a midline posterior fossa tumour with patchy 
contrast enhancement and avid diffusion restriction, causing obstructive 
hydrocephalus for which he had emergent placement of an external 
ventricular drain (later converted to a ventriculoperitoneal shunt). He 
subsequently underwent subtotal resection of the cerebellar tumour, 
which was confirmed to be a Group 4 medulloblastoma. Magnetic 
resonance spectroscopy performed on this occasion demonstrated a 
marked choline peak with no identifiable N-acetyl aspartate peak. Of 
note, the post-operative imaging did not confirm presence or absence of 
residual or metastatic disease due to the poorly enhancing nature of the 
primary tumour following contrast administration. For this reason, Patient 
3’s follow-up imaging was repeated 1 month post-operatively and 
revealed a mildly T2/FLAIR sequence nodular enhancing lesion in the 
midline posterior fossa measuring 2.1X 2.2 cm, which was likely residual 
disease. He was therefore initiated on craniospinal irradiation and 
combination chemotherapy (Vincristine, CCNU and Cyclophosphamide). 
Despite this, his residuum progressively enlarged until its growth 
plateaued. At this point the neuro-oncology multidisciplinary team 
recommended further surgery and patient 3 underwent a further 
craniotomy and debulking of his residual disease which was confirmed 




spinal disease. He continued his adjuvant chemoradiotherapy, but 
unfortunately developed tumour recurrence within 14 months of his 
second surgery culminating in further surgery for this and adjuvant 
chemoradiotherapy.   
Once more, cerebrospinal fluid (CSF) cytology assessed throughout his 
recurrent disease was negative on all except one occasion, when it was 
reported as indeterminate with cells showing striking atypia which could 
not conclusively be ruled out as a minor population of neoplastic cells. At 
the point of his last surgery (Figure 5.10, sample 3[2]), his CSF cytology 
was negative despite the demonstrably increased levels of MMP-2 and 
MMP-9 following gelatin zymography of the same samples.  
Following an intensive course of adjuvant craniospinal irradiation, Patient 
3 has remained clinically well, with no radiological detection of recurrence 
















Figure 5.6 T1-weighted post-contrast magnetic resonance imaging of patient 3. Patient 
3’s pre-operative (yellow-outlined) T1-weighted MRI with contrast cranial imaging showing 
a midline posterior fossa mass with patchy enhancement. Spinal imaging was clear of 
leptomeningeal disease. At patient 3’s 2nd relapse (green-outlined), T1-weighted contrast-
enhanced cranial imaging showed a midline posterior fossa mass with patchy enhancement. 












Patient 4 was a 13-year-old boy who presented with a 2-week history of 
frontal headaches, ataxia and papilloedema on examination. His imaging 
on admission showed a 4X3.8cm midline heterogeneous lesion within 
the 4th ventricle compressing the brainstem with patchy contrast 
enhancement and mild diffusion restriction. Magnetic resonance 
spectroscopy demonstrated a marked choline peak with minimal NAA 
elevation. Patient 4 underwent a posterior fossa craniotomy (and had 
subsequent placement of an external ventricular drain) for complete 
resection of his disease. No metastatic dissemination was detected on 
postoperative imaging. Histological analysis confirmed a Group 4 
medulloblastoma and no evidence of viable tumour cells on post-
operative CSF cytology or follow-up imaging. As such, patient 4 was 
commenced on standard risk MB craniospinal radiotherapy followed by 
chemotherapy. He unfortunately developed posterior fossa syndrome 
with marked limb weakness, swallowing and speech difficulties 
necessitating intensive neurorehabilitation, with no obvious cause 
exhibited on post-operative imaging. 
Patient 4’s initial cerebrospinal fluid samples were obtained at diagnosis 
in theatre (sample 4(1)) and following lumbar puncture 6 weeks after 
(sample 4(2)). While the cytology was negative, we obtained 2.5X higher 
levels of functionally active MMP-2 in the recurrent sample compared to 




Patient 4 remains clinically stable to date with no evidence of recurrence 








Figure 5.7 T1-weighted post-contrast magnetic resonance imaging of patient 4. Patient 
4’s pre-operative (yellow-outlined) MRI with contrast imaging of Patient 4 demonstrating a 4 
cm lesion within the 4th ventricle with solid and cystic components resulting in patchy 
enhancement, with no evidence of spinal disease. Patient 4 required repeated post-
operative MRI (green-outlined) with contrast due to the residual enhancement on the T2 
FLAIR sequence (bottom left image), suspected to be residual disease. The bottom right 
image shows repeated T1W MRI head with contrast performed 4 weeks later, which 









Patient 5 was 5 years old at his initial diagnosis with medulloblastoma, 
having presented with a 3-4 month history of occasional headaches. He 
underwent macroscopic complete resection of his 4th ventricular tumour, 
followed by adjuvant craniospinal irradiation and Cisplatin/Etoposide 
combination chemotherapy that was later changed to Cyclophosphamide 
and Vincristine, due to patient’s intolerance of the previous regime. As a 
consequence of his treatment, he later required growth hormone and 
thyroid hormone replacement but remained disease free for over a year. 
He was unfortunately found to have relapsed disease on surveillance 
gadolinium enhanced magnetic resonance imaging, which demonstrated 
a 3mm focal enhancing nodule with associated diffusion restriction at the 
right lateral aspect of the 4th ventricle, 28 months after his initial 
diagnosis. Patient 5 therefore had a further surgery for resection of the 
enhancing nodule in the right lateral 4th ventricle via an occipital 
craniotomy. Complete resection was confirmed on post-operative 
imaging and his post-operative CSF cytology was also devoid of 
neoplastic cells. Of note, this sample remained strongly positive on 
gelatin zymography as shown in figure 5.10. (Patient 5[1]).   
He therefore went on to have stereotactic radiosurgery and unfortunately 
developed a radiation-associated tumour-a frontal osteosarcoma at age 
9, which required further surgery.   He remains on active surveillance 









Figure 5.8 T1-weighted post-contrast magnetic resonance imaging of patient 5.  
Axial and coronal imaging at Patient 5’s initial presentation (yellow-outlined) demonstrating 
an enhancing large 4th ventricular tumour and no evidence of spinal leptomeningeal disease. 
He had complete macroscopic resection of his primary tumour, 2 years prior to his 
recurrence 28 months later. The recurrence is demarcated by the white arrow shown in the 








Patient 6 presented with a 5-week history of headaches and vomiting at 
12 years old. Initial MR imaging showed a posterior fossa minimally 
enhancing tumour, causing obstructive hydrocephalus. Marked elevated 
choline peaks and absent NAA/lipid peaks were demonstrated on MR 
spectroscopy. Neuroaxial imaging excluded disseminated disease and 
patient 6 therefore underwent macroscopic resection of his tumour and 
adjuvant standard risk chemoradiotherapy. Histology confirmed classical 
medulloblastoma and his post-operative CSF cytology showed no 
diagnostic evidence of neoplasia. Patient 6 remained well until 20 months 
post-operatively; when new multiple non-enhancing lesions were 
detected in the left superomedial cerebellum in addition to bilateral 
periventricular diffusion-restricting lesions. He then underwent 
stereotactic radiosurgery and placement of an Ommaya reservoir for 
intrathecal etoposide therapy. Initial follow-up imaging showed 
progressive enlargement of the periventricular lesions but 5 months after 
initiation of treatment for his relapsed disease, MR imaging demonstrated 
complete resolution in 2 of 3 lesions with ongoing improvement. 
Cerebrospinal fluid samples for this patient were collected at initial 
(Sample 6[1]) and subsequent operation as well as opportunistically via 
the Ommaya reservoir, prior to administration of intrathecal 
chemotherapy. In both samples from his primary operation and at the 
insertion of the Ommaya reservoir, CSF cytology was negative despite 




was sensitive enough to detect changes in his disease response 
following consecutive intrathecal administrations as shown in Fig 1.  
He thereafter had further surgery for resection of the residual lesion, on 
which occasion we collected and analysed a cerebrospinal fluid sample 
on dural entry (sample 6[6]).  Patient 6 has since remained well with no 












Figure 5.9 T1-weighted post-contrast magnetic resonance imaging of patient 6.  
Patient 6’s imaging at first presentation (yellow-outline) demonstrating a minimally 
enhancing posterior fossa lesion (indicated by white arrow) with no detectable lesions on 
spinal imaging. The green-outlined contrast imaging (left) and T2W imaging (Zeltzer, Boyett 
et al.) at relapse 24 months post-operatively showed that while no disease recurrence was 
detectable at the primary site, 3 sites of recurrent subependymal disease were detectable 
in the lateral ventricles. 2 of these are demonstrated by the white arrows. These lesions 






















Figure 5.10 Levels of functionally active MMP-2 and MMP-9 within cerebrospinal fluid from matched primary and recurrent MB paediatric patients.  
A. Gelatin zymography of cerebrospinal fluid samples obtained from patients with matched primary and recurrent medulloblastoma (Patients1-4, 6) and relapsed 
medulloblastoma in patient 5. B. Image J Densitometry demonstrating the content of functionally active MMP-2 and MMP-9 in the primary and metastatic samples, 
relative to the loaded recombinant MMP-2 and MMP-9 controls. As shown, in patients 1, 3 and 4 the levels of functionally active MMP-2 were higher at recurrence, while 























Figure 5.11 Serial cerebrospinal fluid samples from Patient 6 in whom surgical resection of his primary tumour was performed prior to sample 6 [1] and 
recurrence detected at 6 [2]. B. Gelatin zymography of his CSF samples demonstrated stepwise increased signal intensity of functionally active MMP-2 and MMP-9 
from detection of the recurrent tumour from 6[2] to 6[5] and reduction in signal intensity with ongoing treatment from 6[5] to 6[7]. A and C demonstrate MMP-2 and MMP-





























Male 8 years 
N/A 
Midline cerebellar vermis 
tumour with multiple 
leptomeningeal enhancing 
nodules in the posterior 
fossa and spinal surface. 
Subtotal resection LCA Positive  M3 




Male 11 years 
24 months 
Multiple new/enlarged 
leptomeningeal deposits on 
R. inferior temporal lobe 




Relapse 12 months 
Right anterior temporal lobe 
lesion+ foci in tight superior 
cerebellar peduncle 




Male 4 years 
 
Posterior fossa midline 









Relapse 14 months 
Mildly T2/FLAIR 
hyperintense lesion at site 














Male 13 years 
N/A 
4th ventricular lesion with 
solid and cystic 




Classical Negative  
Group 4 
M0 
Recurrence 2 months 












Relapse Male 7 years 28 months 
Enhancing nodule right 
lateral 4th ventricular lesion 
Gross total 
resection 




Male 12 years 
N/A 
Posterior fossa tumour 
obstructing 4th ventricle with 
very minimal enhancement 
Gross total 
resection 
Classical Negative  M0 
Recurrence 24 months 
New diffusion restricting 
ependymal lesions in the 
frontal horn and right lateral 
ventricle and anterior body 
of the left lateral ventricle. 
No evidence recurrence at 
primary site & spine clear. 





From these preliminary results, we can concluded that:- 
 Epigenetic modification of the genes involved in the regulation of 
MMPs such as EMMPRIN, TIMPs and the MMPs themselves, 
occurs in all MB sub-groups in comparison to normal cerebellum. 
While these epigenetic changes influence the resulting MMP gene 
expression, it is more than likely that further modification at other 
levels of MMP regulation result in the increased levels of functional 
activity seen in the metastatic and recurrent MB samples.  
 Cerebrospinal fluid cytology remains a grossly inaccurate method 
for the determination of leptomeningeal metastatic disease 
especially in the case of intracranial disease recurrence as 
demonstrated in the unfortunate outcome of Patient 2, who 
succumbed to his metastatic disease.  
 Gelatin zymography of the paired cerebrospinal fluid samples was 
sensitive enough to detect serial changes in the levels of 
functionally active MMP-2 and MMP-9 between the primary and 
recurrent as well as the recurrent and relapsed patients. The 
preliminary data in patients with residual disease suggests that 
the levels of functionally active MMP-2 and MMP-9 remain 
persistently elevated, proposing its usefulness in determining 
tumour burden and patient response to therapy. 
 Cerebrospinal fluid samples obtained in theatre at dural entry such 




of likely recurrence, in the face of conflicting imaging and cytology 
results. While day 14 post-operative lumbar punctures are 
currently performed to determine the tumour burden of viable 
circulating tumour cells, theatre samples could be easily 
translated into clinical practice, to give more robust information 
regarding the patient’s metastatic status at the time of diagnosis, 
without the complications of iatrogenic dissemination.   
 As demonstrated in the pre-operative magnetic resonance 
contrast enhanced imaging of patients 2, 3, 4 and 6, poorly 
enhancing tumours present substantial difficulty in the diagnosis 
and detection of metastases as these often harbour similar 
imaging characteristics to the primary tumours. As such, the use 
of more sensitive MR compatible imaging biomarkers could give 
better diagnostic accuracy and reduce the need for repeat imaging 


















Towards the radiological characterisation 
of matrix metalloproteinases in biological 












6.1 Chapter outline 
Metastasis remains the leading cause of death in paediatric 
medulloblastoma, with a predilection for spread to the leptomeninges 
(Mata-Mbemba, Zapotocky et al. 2018). As such, its detection carries 
substantial prognostic implications for the patient, whose adjuvant 
therapy selection will be determined by the resulting risk stratification of 
their disease. While it is reported that approximately 1 in 3 paediatric MB 
patients present with disseminated disease at initial diagnosis, the actual 
figures are likely to be higher, given the published sensitivity of CSF 
cytology to be as low as 50% (Bennett, Ashmawy et al. 2017, 
Chamberlain, Junck et al. 2017, Torre, Lee et al. 2020). Thus to enhance 
the detection and monitoring of leptomeningeal spread, the preferential 
mode of metastasis in MB, radiological imaging of the entire neuroaxis is 
performed at diagnosis and disease surveillance.  
While Gadolinium contrast-enhanced magnetic resonance imaging is 
widely advocated as the gold standard for diagnosis and surveillance of 
paediatric brain tumours, its diagnostic accuracy for leptomeningeal 
dissemination remains sub-optimal and observer-biased, with published 
sensitivity and specificity both approximating 76-77% (Torre, Lee et al. 
2020). Though its excellent spatial resolution can identify 
micrometastases <5mm3, this may also result in the misdiagnosis of 
physiologically-enhancing vascular artefacts as suspicious, thus 
necessitating specialist neuroradiology expertise for the accurate 




In addition, while most aggressive solid tumours exhibit enhancement 
following administration of intravascular gadolinium contrast, 
medulloblastoma, particularly those from the molecular Group 4 
subgroup, are often poorly or non-enhancing (Thompson, Hielscher et al. 
2016). In these patients, their ensuing leptomeningeal metastases tend 
to share this radiological characteristic, which inevitably results in poor 
detection of spinal disease which could lead to administration of a 
reduced dose or omission of craniospinal irradiation, culminating in the 
unperturbed growth of their metastatic disease. Thus, more sensitive 
imaging techniques that can be easily translated into clinical practice 
could hold prognostic promise, in the personalised management of 
paediatric patients with medulloblastoma.  
Molecular magnetic resonance imaging is an emerging field in which 
alterations in the tumour microenvironment such as cellular metabolism, 
acid-base changes and proliferation for example, could be detected in 
advance of established visible macrometastases (Haris, Yadav et al. 
2015). This type of imaging could provide earlier prognostic and 
therapeutic information and opportunities to interrupt metastatic 
dissemination, by either rendering the pre-metastatic niches hostile with 
intrathecal chemotherapy for example, or definitively demonstrating 
evidence of leptomeningeal spread, thus indicating the need for 
aggressive therapy. 
One such technique involves magnetic resonance imaging using 




detection of specific biomarkers in the tumour proteome (Carril 2017).  
As previously shown in Chapter 5, the levels of functionally active MMP-
2 and MMP-9 in cerebrospinal fluid, appear to give a better prediction of 
the patients’ disease prognosis, in comparison to their CSF cytology 
given that the cytology was mostly negative. It was therefore investigated 
whether this finding would be translatable using a locally developed MRI-
MMP-2/9 biosensor. Briefly, the biosensor is a 19-Fluorine moiety that is 
covalently linked to a gadolinium-III bound DOTA complex by a protein 
substrate specific to MMP-2/MMP-9. In the presence of functionally 
active or activated MMP-2 or MMP-9, the gelatine substrate is cleaved in 
a manner that is similar to the digestion of gelatine in our zymography 
experiments. Upon cleavage, the previously paramagnetically-shielded 
fluorine moiety emits a stronger 19F MR signal which can be detected 














6.2 Objectives and Hypothesis 
To determine whether our 19-Fluorine-MRI-MMP biosensor could be 
used as a prognostic imaging biomarker in metastatic medulloblastoma, 
we firstly investigated the conditions in which the biosensor is activatable, 
by designing experiments using Fluorescence Resonance Energy 
Transfer (FRET) assays (Lei, Jian et al. 2020). As Figure 6.1 illustrates, 
in FRET assays, which our biosensor is modelled after, a donor and 
acceptor fluorophore are linked in close proximity on a peptide substrate 
such as gelatin. Cleavage of the gelatin linking substrate by MMP-
2/MMP-9 within our samples, increases the distance between the donor 
and acceptor fluorophore, augmenting emissions from the excited donor 







Figure 6.1 Representative diagram demonstrating the shared mechanisms of FRET 
assay (A) and our 19-F MRI MMP-2/MMP-9 biosensor (B).  
As shown, the proximity of the quencher synonymous to the Gadolinium-III DOTA complex 
(Gd-III DOTA complex) is proportional to the fluorescence emitted by the fluorophore or 19 





Working towards the characterisation of the levels of functionally active 
MMP-2 and MMP-9 in biological samples using the biosensor, 
Fluorescence Resonance Energy Transfer (FRET) experiments were 
designed using recombinant proteins firstly, to simulate the specific 
conditions employed in the biosensor optimisation experiments as they 
offer a more economical alternative. These recombinant proteins were 
then substituted for concentrated primary and metastatic 
medulloblastoma cell line supernatants before investigating the 
cerebrospinal fluid from paediatric patients with medulloblastoma, to 
ensure its compatibility and stability with more physiological samples.  
The hypothesis was that FRET would be able to detect differential levels 
of functionally active MMP-2 and MMP-9 in the samples tested ranging 
from recombinant proteins to concentrated cell line supernatants and 
cerebrospinal fluid. We believe that the biological samples with the 
highest levels of functionally active MMP-2/MMP-9 in gelatin zymography 
will also exhibit the highest levels of fluorescence in the FRET assays 
and with our fluorine biosensor.   
As the FRET experiments are limited to ex-vivo analyses, the translation 
of this work using an MRI compatible MMP-2/MMP-9 biosensor, would 
enable real-time detection and quantification of metastases at diagnosis 
and disease surveillance, complimenting the gadolinium contrast 
enhancing capabilities of the tumour. In addition, the biosensor could 
hold promise as an intra-operative contrast agent that could enhance the 





6.3.1 FRET Optimisation experiments  
6.3.1.1 Concentration of medulloblastoma cell line supernatants  
 
To strengthen the signal obtained in the biosensor experiments, the 
conditioned medulloblastoma cell supernatants obtained following 48 
hour 2-D culture of 5X106 primary and metastatic medulloblastoma cell 
lines. These were concentrated using Vivaspin® 20 centrifugal 
concentrating columns. Cell line samples designated for each 
experiment were concentrated at the same time, using the same starting 
volume and conditions. To reduce the rate of protein denaturation, the 
samples were centrifuged at 4˚C, which as per the manufacturer’s 
advice, necessitated an increased centrifugation time. To recover both 
MMP-2 and MMP-9 from the samples, columns with membranes with 
molecular weight cut offs of 50,000 MWCO were used. Table 6. 1 below 
shows the resulting volumes of cell line supernatants following column 
concentration. Samples were normalised by dilution to the same volume 










Table 6. 1 Results from centrifugal column concentration of MB cell line supernatants  






DAOY p18 7500 219 34.2 
ONS-76 p29 7500 222.5 33.7 
ONS-76 dnp53 p16 7500 215.5 34.8 
UW228-3 p21 7500 190 39.5 
CHLA-01-MED d53 7500 198.5 37.8 
CHLA-01R-MED d52 7500 92 81.5 
CHLA-01-MED d49 9000 243 37.0 
CHLA-01R-MED d48 9000 178 50.6 
D425-MED p14 7500 200 37.5 
D458-MED p102 7500 238 31.5 
HD-MB03 p60 7500 222.5 33.7 
HD-MB03 p66 7500 200 32.0 
 
6.3.1.2 The effect of acetonitrile concentration on FRET assays 
using recombinant MMP-2 and MMP-9 
 
Due to the negligible background fluorine signal in the human body, the 
fluorine MRI signal after administration of exogenous fluorinated contrast 
agents is proportional to the concentration of fluorinated contrast 




While 19Fluorine MR imaging is highly specific, its sensitivity compared 
to hydrogen based MRI is poor, necessitating increased concentrations 
of the 19F nuclei by saturation of the probe. However, this results in the 
decreased solubility of the probe in water due to increased 
concentrations of the hydrophobic, inert fluorine moiety. One way to 
circumvent this issue is by dissolving the probe in an organic solvent such 
as acetonitrile (ACN). As the MRI-MMP-2/-9 biosensor probe was found 
to be most stable and soluble in 10% acetonitrile, the effect that different 
concentrations of acetonitrile would have on the detection of known 
concentrations of recombinant MMP-2 protein (0.61ng/µl) was 
investigated. The same concentration of the same recombinant protein 
that had been used in the most recent biosensor optimisation 
experiments was employed here.   
As shown in Figure 6.2, while the fluorescence signal of rMMP-2 0% 
acetonitrile solution gradually inclines, the fluorescence increments 
plateau in the 5% acetonitrile solution while the fluorescence signal in the 
10% acetonitrile solution drastically declines with time.  This suggests 
that in the presence of acetonitrile, the recombinant MMP-2 protein had 
precipitated out of the solution, resulting in reduced digestion of the DQ 










Figure 6. 2 FRET Assay of recombinant MMP-2 (0.61ng/µl) in Acetonitrile solutions. 
The fluorescence signal measures as relative fluorescence units (RFU)only increases in the 
absence of acetonitrile while it plateaus in the 5% acetonitrile and declines in the 10% 
acetonitrile solutions. 
To further investigate this effect and determine whether its impact could 
be negated by increasing the concentration of recombinant MMP-2 in the 
sample, similar experiments were repeated in 0%, 5%, 10% and 15% 















Figure 6.3 FRET assay of different amounts of recombinant MMP-2 protein 
(Peprotech) in different percentage concentrations of acetonitrile.  
Serial fluorescence readings taken over 24 hours are graphically represented using 
GraphPad prism.  The highest fluorescence signal from digestion of the DQ gelatin was 




As shown in Figure 6.3, where ACN was absent, the highest 
fluorescence signal was obtained in the solution with the highest MMP-2 
content of 75ng, as expected. While in the 5% acetonitrile solution, the 
sample containing 75ng of rMMP-2 was the least affected though in all 
samples containing rMMP-2, there was a drastic decline in fluorescence 
from the beginning of the experiment. At the acetonitrile concentration of 
10% at which the biosensor probe was most stable, the relative 
fluorescence units (RFU) drastically declined within 2 hours of the 
experiment.  
While the synthesis of the probe was optimised to maximise the density 
of the fluorine moiety and thereby the fluorine signal obtained at MR 
imaging, this increased its hydrophobicity and necessitated its solution in 
the organic solvent, acetonitrile. Furthermore, to enable further 
characterisation of the probe, the precipitation of unwanted proteins 
would be an advantage prior to analysis in liquid chromatography and 
mass spectrometry. While re-synthesis of our 19F MMP MRI probe in a 
more physiological solvent was desirable, this was not achievable within 
the remaining period of this research. Further optimisation was therefore 
carried out, with this caveat in mind.  
While the initial MRI MMP-2/MMP-9 biosensor optimisation experiments 
performed before the scope of this PhD had demonstrated specificity to 
MMP-2 and MMP-9, the DQ gelatine provided in the Enzchek® 
Gelatinase Assay Kit was also reported to be efficiently digested by both 




was equally digested by both rMMP-2 and rMMP-9 or preferentially 
digested by either protein. As shown in figure 6.4, even at a lower 
concentration, rMMP-9 appears to more efficiently digest the DQ gelatine 
when compared to that of r-MMP-2. We aim to repeat this experiment in 







Figure 6.4  FRET assay of different amounts of recombinant MMP-2 protein 
(Peprotech) in different percentage concentrations of acetonitrile. Serial fluorescence 
readings taken over 24 hours are graphically represented using Graphpad prism.  The 
highest fluorescence signal from digestion of the DQ gelatin was observed in the 0% 
acetonitrile group (A).   
 
6.3.1.3 The effect of acetonitrile concentration on FRET assays of 
column- concentrated medulloblastoma cell line supernatants  
Having determined that the FRET assay could be used to correlate the 
levels of functionally activatable recombinant MMP-2 protein, it was 
investigated whether it would reflect the differential levels of functionally 
active MMP-2/MMP-9 in concentrated medulloblastoma cell line 
supernatants.  
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To confirm that endogenous MMP-2 and MMP-9 would be affected by 
the presence of acetonitrile in a similar manner as with the recombinant 
protein, we performed a FRET assay of the same volume of column 
concentrated ONS-76 medulloblastoma cell line supernatant, in 0% and 
10% ACN. As shown in Figure 6.5, the fluorescence from the supernatant 
without ACN gradually increased over time, while the fluorescence signal 
in the 10% ACN solution remained static, suggesting endogenous MMP-







Figure 6.5 FRET assay of column concentrated supernatant from 48 hour culture of 
ONS-76 medulloblastoma cells. 
As expected, reduced and static fluorescence signal was seen in the 10% ACN containing 
solution. 
 
However, FRET analysis of the same experimental set-up with the 
substitution of HD-MB03 conditioned cell supernatant demonstrated an 
increase in the fluorescence signal even in the solution containing 10% 
ACN. As demonstrated in Figure 6.6, though the fluorescence intensity 
is lower in the ACN containing solution, its fluorescence signal continues 
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to increase with time in a near parallel fashion. It was postulated that this 
could be due to the increased levels of functionally active MMP-9 within 
this cell line, which seemed to be somewhat resistant to the precipitation 







Figure 6.6 . FRET assay of column concentrated supernatant from 48 hour culture of 
HD-MB03 (Group 3 metastatic) medulloblastoma cells.  
As demonstrated, the fluorescence signal of the 10% ACN containing solution increases in 
a parallel fashion to that of the solution without ACN. 
 
6.3.1.4 FRET assays of column-concentrated paired 
medulloblastoma cell line supernatants  
 
To determine whether FRET assays and by extension the biosensor, 
could detect differential levels of functionally active MMP-2 and MMP-9 
in biologically paired samples, experiments using concentrated cell line 
supernatants from primary and metastatic MB cell lines were performed.  
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Figure 6. 7 FRET assay of column concentrated supernatant from 48 hour culture of 
paired Group 3 primary-D425-Med and metastatic D458-Med medulloblastoma cells. 
As shown, the levels of functionally active MMP-2 and MMP-9 are much higher in the 
metastatic cell line D458-Med. 
 
As shown above in Figure 6.7, the levels of fluorescence slowly incline 
with time but begin at much higher fluorescence levels in the 
concentrated cell line supernatants of the metastatic line, D458-Med. As 
the D458-Med cell line was derived from cells that had metastasised to 
the cerebrospinal fluid of the patient, these cells exhibit higher levels of 
functionally active MMP-2 and MMP-9 which may have enabled their 
dissemination and survival in the CSF. 
Repeating the same experiment in the paired Group 4 MB cell lines 
CHLA-01-MED (primary) and CHLA-01R-MED (metastatic), a higher 
level of fluorescence was depicted from the latter in Figure 6. 8, 
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suggesting its higher levels of functionally active gelatinases digested 







Figure 6. 8  FRET assay of column concentrated supernatant from 48 hour culture of 
paired Group 4 primary-CHLA-01-Med and metastatic CHLA-01R-Med 
medulloblastoma cells.  
Though the difference is less striking when compared to the previous Group 3 pair, this 
experiment showed higher levels of fluorescence in the metastatic cell line. 
 
To determine whether the FRET assay could detect differential levels of 
functionally active MMP-2 and MMP-9 between cell lines with differential 
metastatic potential, we examined the concentrated cell supernatants 
from the metastatic SHH cell line ONS-76 (wt p53) and its counterpart 
ONS-76 (dnp53). With a binding site within the promoter of the MMP-2 
gene, p53 has been shown to exert transcriptional regulation of MMP-2. 
(Bian J, 1997) As shown in figure 6.9, the cell line with wild type functional 
p53 ONS-76 (wt p53), also demonstrates higher levels of fluorescence 
with increasing time, likely as a result of higher levels of functionally 
active gelatinases.   
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Thus the increased fluorescence signal in the preserved p53 ONS-76 cell 
line will likely contain higher levels of functionally active MMP-2 








Figure 6. 9 FRET assay of the SHH MB cell line ONS-76 (wt p53) in black and ONS-76 
(dnp53) in red.  
This shows that the levels of functionally active MMP-2/MMP-9 are higher in the cell line in 
which the p53 is functionally intact. 
 
6.3.1.5 The effect of using reaction buffer on FRET assays of 
column-concentrated medulloblastoma cell line supernatants  
 
As the FRET assay was used to model the biosensor experiments, it 
seemed pertinent to investigate whether the reaction buffer provided 
within the Enzchek Gelatinase Assay Kit made a difference in the 
resulting fluorescence signal levels, as this reagent was not used in the 
biosensor experiments. The reaction buffer was supplied as a 10X 
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solution constituted of 50mL of 0.5M Tris-HCl, 1.5M NaCL, 50mM CaCl2 
and 2mM of sodium azide pH 7.6. 
FRET experiments of ONS-76 (wt p53) concentrated supernatant without 
acetonitrile were performed, wherein neutral pH-phosphate buffered 
saline was used to substitute the reaction buffer. As depicted in Figure 6. 
10, the resulting fluorescence signals are higher in the samples without 
reaction buffer at each given time point. This suggests that the depicted 
levels of functionally active MMP-2 and MMP9 would likely be higher in 









Figure 6. 10 FRET assay of column concentrated supernatant following 48-hour 
culture of ONS-76 medulloblastoma cells.  
To determine the effect of the reaction buffer used for FRET assays on the levels of 
fluorescence from DQ gelatin digestion, ONS-76 supernatants were examined with and 
without (+PBS) reaction buffer.   As demonstrated, the addition of reaction buffer appeared 
to reduce the resulting levels of fluorescence with increasing time.  
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6.3.1.6 FRET assays of cerebrospinal fluid from paediatric patients 
with primary and recurrent medulloblastoma  
 
To determine whether the levels of functionally active MMP-2 and MMP-
9 within naive cerebrospinal fluid would result in a detectable 
fluorescence signal, CSF samples from the Patient 1-4 who presented 











Figure 6. 11 FRET assay of naïve CSF samples from Patient 1 at their first presentation 
(primary) and following growth of the residual tumour.   
As demonstrated, the levels of fluorescence are very similar suggesting that higher levels of 
functionally active MMP-2 and MMP-9 remained present within the CSF. This is confirmed 
in the gelatin zymography results of the same samples in Chapter 5. 
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Figure 6. 12  FRET assay of naïve CSF samples from Patient 2 at the first recurrence 
of their MB (recurrence) and following relapsed MB.  
Once more, the levels of fluorescence are incredibly similar suggesting similar levels of 









Figure 6. 13 FRET assay of naïve CSF samples from Patient 3 at recurrence of their 
MB (recurrence) and following relapsed MB.  
Interestingly the levels of fluorescence detected in the CSF sampled at relapse mirrored 
the recurrence very closely in a similar manner as in the patient in Figure 6.12. 
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Figure 6. 14 FRET assay of naïve CSF samples from Patient 4 at his first presentation 
with MB (primary) and recurrence of their disease.  
In a manner similar to that of Patient 1 who also presented with primary and recurrent MB, 
the fluorescence signal in the primary sample appears to be higher but begins to plateau by 
100 minutes while the recurrent CSF fluorescence continues to increase.  
 
Figures 6.11-6.14 demonstrate a striking similarity in the fluorescence 
signal from FRET assay experiments of cerebrospinal fluid samples, 
taken at either the primary and recurrent presentations (Figure 6. 11 and 
Figure 6. 14) of the patients’ MB or at recurrence and relapse (Figure 6. 
12 and Figure 6. 13) as specified in each figure. This suggests that the 
levels of functionally active MMP-2 and MMP-9 are detectable and 
comparable in both stages. Furthermore, the similarity in the levels of 
fluorescence between the primary and recurrent or recurrent and 
relapsed medulloblastoma, suggest that at the time these tumours are 
detectable as visible macrometastases, they are secreting similar levels 
of functionally active MMP-2 and MMP-9. This finding supports the 
hypothesis that the levels of functionally active MMP-2 and MMP-9, could 
be clinically relevant.  
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6.4 19Fluorine MRI MMP-2/MMP-9 biosensor 
experiments 
6.4.1 Biosensor optimisation experiments and proof of 
principle 
To determine whether the biosensor would be responsive to functionally 
active MMP-2 and MMP-9, experiments using known concentrations of 
recombinant proteins were performed. As described in recently published 
work (Faas, Krupa et al. 2019), recombinant MMP-1, MMP-2, MMP-9 
and MMP-12 were purchased from R&D systems (Minneapolis) and 
reconstituted to concentrations of 75µg/ml in a 0.05% Brij 35 developing 
buffer, pH 7.5. To ensure their maximal activity, these recombinant 
proteins were incubated in a 1mM solution of 4-aminophenylmercuric 
acetate (APMA) in DMSO. APMA is a well-established MMP zymogen 
activating agent, used to amplify MMP activity prior to molecular biology, 
organic chemistry and nuclear magnetic resonance imaging 
experiments. Interestingly, the recombinant MMP-2 only required 1 hour 
of incubation while MMP-9 required a 24-hour incubation period at 310K 
(37˚C), following which they were and stored in aliquots at 193 K (-80˚C) 
to preserve maximal activity and thawed immediately prior to use (Faas, 
Krupa et al. 2019) 
The optimisation experiments were carried out in a Bruker Avance III 400 
MHz (9.4 tesla) spectrometer and microimaging system which was tuned 
to 376.5 MHz.  For each experiment, 600µl of 1.2mM of the 19-Fluorine 




determine the probe’s sensitivity to MMP-2 and MMP-9, 5 µl of 75 µg/mL 
activated recombinant MMP-2 or MMP-9 were incubated in a 5mm NMR 
tube and placed within a receptacle in the 19Fluorine coil. Due to the 
complexity of this imaging, these experiments were was undertaken in 
the Sir Peter Mansfield Imaging Centre by Dr Henryk Faas, Professor 
Thomas Meersman and his team. Samples were imaged alongside 
controls without MMP for 12-18 hours and the spectroscopy analysed 
with Igor Pro 7. A representative 1H-NMR spectra of the probe, as it is 
digested by the recombinant MMP-2/9 is shown below.  
 
  
   
   
 
 
Figure 6.15 19-Fluorine MMP2/MMP-9 biosensor optimisation experiments  
A. Proton spectroscopy of the 19-fluorine probe with increasing time of incubation with 
activated recombinant MMP-2/9. At time 0, the lowest peak visible shows a larger curve 
width which is synonymous with a higher concentration of the probe. As cleavage of the 
probe by MMP-2 or MMP-9 occurs, this linewidth continually diminishes with time. B. 
Representative diagram of fluorine signal change following biosensor incubation with 
activated recombinant MMP-2/9. As the probe is cleaved, increased distance between the 
fluorine moiety and the Gd-DOTA complex, results in an increasing fluorine signal with time. 
 
Having demonstrated that the probe was digested by recombinant 
activated MMP-2 and MMP-9, similar experiments were designed and 












ensure specificity of the probe. These experiments showed no similar 
changes in signal in the biosensor or fluorine signal, following when 
incubated with 5 µl of 75 µg/mL of activated MMP-1 and MMP-12 in 
comparison to the controls (Faas, Krupa et al. 2019). 
As the most repeatable results were obtained in these conditions, they 
were taken forward and the biosensor deemed ready for experiments 
using biological samples of conditioned medium from medulloblastoma 
cell lines prior to planned experiments with patient derived cerebrospinal 
fluid samples.  
6.4.2 Biosensor detection of functionally active MMP-2 
and MMP-9 in concentrated cell supernatant 
 
To maximise the signal obtained from the biosensor, concentrated 
supernatant from the most aggressive medulloblastoma cell line, HD-
MB03, a group 3 metastatic cell line was selected. To reduce the dilution 
of the biosensor, 50µl of the supernatant was added to a 5mm diameter 
NMR tube containing 600 µl of the biosensor, pH 7.5, temperature 293 
Kelvin (20˚Celcius). The NMR tube was placed in the centre of a 
microimaging Bruker head alongside a tube containing a similar volume 
of the negative control, i.e. no added supernatant or recombinant protein. 
The samples were then imaged by our team at the SPMIC using a 
fluorine coil with a 19-fluorine frequency of 564.6 megahertz and 
detected on a Bruker Avance III 400 megahertz spectrometer. As shown 




of gadolinium signal (synonymous with an increase in the fluorine signal) 
following digestion of the gelatin substrate linker within the biosensor, by 









Figure 6.16 19-Fluorine MRI MMP-2/MMP-9 imaging of concentrated cell supernatant 
A. Schematic diagram showing experimental set up. B. Spectral imaging performed a t=0 
just after addition of concentrated HD-MB03 cell supernatant showing similar Gadolinium 


















The results presented suggest the following conclusions: 
 Though the biosensor is constituted in 10% acetonitrile, we have 
shown through our FRET experiments that this organic solvent may 
cause the precipitation of our proteins of interest out of the samples, 
resulting in false negative results. For this reason, further work into 
the re-constitution of the biosensor in a more hydrophilic physiological 
solvent is under investigation.  
 
 The FRET assay demonstrates similar levels of fluorescence in 
samples obtained at primary and recurrence of MB and recurrence 
and relapse of MB in paediatric patients. This confirms that the levels 
of functionally active MMP-2 and MMP-9 hold prognostic significance 
and are detectable using imaging modalities, suggesting they would 
be suitable imaging prognostic biomarkers. As the biosensor 
experiment showed a substantial reduction in the gadolinium signal 
following addition of the supernatant, it suggests that the biosensor 
will also be able to detect the levels of functionally active MMP-2 and 
MMP-9 in patient CSF. This will be the next step following synthesis 





























7.1 Background and rationale 
With a reported incidence of 5 cases per million children (Juraschka and 
Taylor 2019), medulloblastoma is a considered a rare but devastating 
disease that constitutes nearly 20% of all paediatric brain tumours 
(Holgado, Guerreiro Stucklin et al. 2017). It is a highly malignant (WHO 
grade IV) embryonal tumour of the cerebellum, which presents with 
radiological or cytological evidence of metastasis at diagnosis in 
approximately one third of patients (Holgado, Guerreiro Stucklin et al. 
2017).   
The clinical presentation of paediatric patients with MB is dependent 
upon the patient age and concomitant hydrocephalus. MB in infants may 
manifest as increased head circumference, vomiting, irritability, failure to 
thrive and developmental delay, while older children and young adults 
may complain of headaches, nausea and vomiting, unsteady gait, 
incoordination and intellectual difficulties at school or university (Millard 
and De Braganca 2016).  
While the multimodal therapeutic approach of maximal safe surgical 
resection, adjuvant chemotherapy, and irradiation of the tumour bed and 
neuroaxis in patients older than 3-5 years of age, have significantly 
improved survival, metastasis remains the predominant cause of 
mortality in paediatric medulloblastoma (Van Ommeren, Garzia et al. 
2020). Building upon the pioneering study of craniospinal irradiation in 
medulloblastoma by Paterson et al. in 1953, the previously deemed 




60% survival (Paterson and Farr 1953). The subsequent introduction of 
adjuvant chemotherapy over the last 40 years culminated in the current 
5 year survival of 70-80% in patients stratified in the average risk 
category, while in the less fortunate high risk patients, 5 year survival is 
given as 60-65% (Millard and De Braganca 2016).   
The prognosis for paediatric patients with recurrent and relapsed 
(following previous recurrence) MB is poorer still and considered a 
predominantly pre-terminal diagnosis (Hill, Richardson et al. 2020). 
Owing to its preference for spread to the leptomeninges, the child with 
suspected MB will have diagnostic MRI brain and staging spinal scans 
for anatomical localisation of the tumour and exclusion of macroscopic 
metastases within the neuroaxis, as well as cerebrospinal fluid cytology 
from lumbar puncture ~ 2 weeks post-operatively (Dufour, Beaugrand et 
al. 2012).  
Following discussion of the patient at a paediatric neuro-oncology MDT, 
the child would be risk stratified to guide their subsequent management. 
Factors traditionally considered for risk stratification of these patients 
include their age (to determine patient suitability for radiotherapy), the 
volume of residual tumour following maximal safe resection (high 
risk: >1.5cm3; average risk: <1.5cm3) and radiological (MRI of neuroaxis) 
or cytological determination of metastasis as defined by Chang’s criteria 
(Dufour, Beaugrand et al. 2012).   
While significant advances attained in the genomics and molecular 




correlation of their MB subgroup and histological subtypes as defined by 
the revised WHO staging of MB (Louis, Perry et al. 2016), our methods 
of diagnosing disease dissemination lag behind.   
Considering the serious prognostic implications associated with 
metastasis and recurrence of MB, current disease surveillance imaging 
at the magnetic field strength of clinical MRI scans (1.5-3 Tesla) may be 
too insensitive to detect pre-metastatic changes that herald 
macrometastases. Many scientists and clinicians postulate that this pre-
macro-metastatic phase would be the ideal opportunity to intervene, as 
once established macrometastases are evident on radiological imaging, 
it may too late. Furthermore, the inadequacy of CSF cytology and the 
vast array of confounding factors associated with its post-operative, 
lumbar puncture sampling in paediatric patients, limit its sensitivity as a 
prognostic marker of disseminated disease (Escudero, Llort et al. 2020).  
Therefore to improve the accuracy of risk stratification of paediatric 
patients with MB and inform our provision of tailored multimodal 
treatment regimes, we sought to:- 
 Discover a biomarker of increased metastatic potential in 
paediatric MB cell lines 
 Determine and optimise a method for the robust detection of the 
biomarker that could be translated into clinical practice 
 Work towards the translation of the prognostic biomarker into an 
imaging biomarker to promote the timely, dynamic diagnosis of 




A model described by Dregely et al. 2018, for the development of imaging 
biomarkers in cancer was employed as a guideline.  
 
Figure 7.1 Schematic diagram of the stepwise development of an imaging biomarker 
The above pathway was used to guide our development of an MRI compatible imaging 
biomarker, which would correlate the metastatic potential and behaviour of paediatric MB 
and delineate laminar and nodular leptomeningeal metastases that would otherwise be 
difficult to detect on conventional MRI imaging of the neuroaxis. Adapted image from 
(Dregely, Prezzi et al. 2018). 
 
Guided by the schematic pathway depicted in Figure 7.1 as well as the 
‘roadmap’ for imaging biomarkers in cancer (O'Connor, Aboagye et al. 
2017), the elucidation of a biomarker expressed by all medulloblastoma 
(MB)  subgroups, that could be used to predict the metastatic potential of 





7.2 The elucidation of a biomarker of increased 
metastatic potential in MB. 
 
To streamline the potentially elusive search of a prognostic biomarker of 
metastasis in MB, the determination of differentially expressed proteins 
in matched pairs of subgrouped medulloblastoma cell lines, with known 
metastatic status was performed. Having been previously demonstrated 
to be enriched in the metastatic counterpart of a matched pair of Group 
4 MB cell lines, genes involved in the extracellular matrix (ECM) were 
chosen as our starting point (Wu, Northcott et al. 2012).  
Furthermore, given the increasing evidence of intra-tumoural biological 
heterogeneity between clones of the same MB tumour, it was postulated 
that differentially expressed proteases and protease inhibitors could help 
explain the diverse tumour microenvironments inhabited by the primary 
cerebellar MB and metastatic leptomeningeal deposits (Zou, Poore et al. 
2020).  
Conditioned supernatant from matched pairs of primary and metastatic 
Group 3 and Group 4 MB cell lines derived from male paediatric patients 
aged five and 8 years of age at initial diagnosis respectively, were 
examined using a protease and protease inhibitor array kit (Figure 3.1). 
The group 3 metastatic cell line D458-Med exhibited substantially higher 
expression of KLK5 (95% increase), MMP-3 (62.9% increase) and MMP-
2 (56.9% increase) proteases in comparison to its primary counterpart 
(Table 3.1). Furthermore, there was a distinct decrease in the levels of 




supernatant as well a limited array of protease inhibitor analytes in 
comparison to the range demonstrated by its primary counterpart (Figure 
3.2). The highly expressed proteases and downregulated protease 
inhibitors in the secretome of the metastatic Group 3 MB cell line could 
result in unchecked matricellular degradation, which would likely be 
advantageous and conducive to the migration of the metastatic cells. 
Review of the analytes detected in conditioned supernatant from the 
matched primary (CHLA-01-MED) and recurrent (CHLA-01R-MED) 
Group 4 cell lines (Figure 3.3), demonstrated the increased expression 
of MMP-2 in the latter’s secretome (97.3% increase) in comparison to the 
former (Table 3.3). This result complemented the increased MMP-2 
expression demonstrated in the proteomic analysis of the recurrent 
CHLA-01R-MED by Gu et al. 2017 (Gu, Chen et al. 2017).  Once again, 
the array of protease inhibitors expressed by the metastatic Group 4 cell 
lines was limited in comparison to those secreted by the primary, echoing 
the pattern observed in the Group 3 MB cell lines (Figure 3.4).   
While other proteases were highly expressed in both metastatic Group 3 
and 4 cell lines, MMP-2 was selected as the foremost biomarker for 
further study, as it was highly differentially expressed in both the 
metastatic MB cell line supernatants and is well-correlated to higher 
grade, aggressiveness and staging in other cancers (Isaacson, Jensen 
et al. 2017). Its fellow gelatinase MMP-9, which has also been shown to 
be overexpressed in metastatic tumours including medulloblastoma, was 




of the interactions of MMP-2 with MMP-9 and its endogenous tissue 
inhibitors of MMPs (TIMPs) which were also differentially expressed in 
the matched primary and metastatic MB cell lines.  
7.3 Biological characterisation of MMP-2 and MMP-
9 in 2-D cultured sub-grouped MB cell lines 
Considering the multi-level regulation of MMPs, it was deemed 
necessary to investigate the expression of MMP-2 and MMP-9 at 
epigenetic, genetic, protein and functional activity levels.  In addition to 
portraying a comprehensive landscape and determining which would be 
the most robust level for translation into clinical practice, it was postulated 
that the activation and inhibition of MMP-2 and MMP-9 would be the 
levels most highly implicated in the metastatic MB cell lines and patients.  
To this end, a panel of 9 sub-grouped medulloblastoma cell lines were 
closely examined and cultured in their optimal cell culture medium in the 
manner described in the methodology section of this thesis. Matched, 
paired cell lines destined for the same experiment were cultured at the 
same time and cell pellets as well as conditioned supernatant obtained 
simultaneously. This was done to reduce the confounding effects from 
potential differences in the handling of samples destined for comparison, 
including factors such as ambient temperature, or slight differences in 
batch preparations of chemicals and serum, for example, that would be 




Overall, at the gene level, MMP-2 was highly expressed in the MB cell 
lines with higher metastatic potential i.e. derived from MB tumours of 
higher ‘M’ grade or cell lines harbouring mutated p53 genes, the latter 
being well known markers of poor prognosis (Ramaswamy, Nör et al. 
2016). As shown in Figure 3.5, MMP-2 gene expression was highest in 
the metastatic Group 4 cell line CHLA-01R-MED, which in comparison to 
its primary counterpart demonstrated statistical significance  (ANOVA; 
p=0.0215) in comparison to expression levels from the remaining cell 
lines. While variation in the protein expression of MMP-2 from the panel 
of 9 MB cell lines prevented a statistically significant result, a trend 
towards higher MMP-2 protein expression was observed in the 
metastatic cell lines, compared to their primary counterparts within each 
subgroup (Figure 3.6)     
While gene expression of MMP-9 was not feasible given technical 
difficulties with primer optimisation, this was thought to be due to the 
incredibly low levels of MMP-9 gene expression in MB. This theory is 
supported by the low levels of MMP-9 expression in MB patient samples 
from the Cavalli dataset (Cavalli, Remke et al. 2017), analysed on the R2 
Genomics and visualisation platform (R2).  
However, at the protein level, MMP-9 expression was highly variable with 
no results of statistical significance following western blotting of the MB 
cell lines. These experiments further reinforced the potential of MMP-2 




Given the fundamental role of MMPs in both physiological and 
pathological circumstances, in the enzymatic remodelling of the 
extracellular matrix, the regulation of their functional activity was believed 
would best correlate the metastatic potential and behaviour of MB. As 
such, gelatin zymography was used to examine the levels of functional 
activity in 48-hour conditioned supernatant derived from the same panel 
of MB cell lines. These experiments demonstrated a statistically 
significant increase (ANOVA; p=0.022) in the levels of functionally active 
MMP-2 secreted by the metastatic group 4 MB cell line CHLA-01R-MED, 
in comparison to its matched primary (Figure 3.10). On the other hand, 
the highest levels of functionally active MMP-9 were detected in the 
supernatant from SHH and Group 3 cell lines with the highest metastatic 
potential (Figure 3.10).  
ELISA experiments to determine the optimal storage of the MB cell line 
derived conditioned supernatant and later MB patient cerebrospinal fluid, 
showed a stepwise decline in the MMP-2 protein content with each week 
of storage at 4˚C. All supernatant samples and cerebrospinal fluid 
samples obtained from theatre, were therefore stored at -80˚C, to 
minimise protein degradation as much as possible.  
Having established that the levels of functional activity best correlated 
with the expected metastatic potential of subgrouped MB cell lines 
cultured in 2-D, we explored whether this finding would be observed in 
subsequent experiments involving 3-D cultured MB, a step towards the 




7.4 Functional characterisation of matrix 
metalloproteinases in 3-D models of 
medulloblastoma 
 
While 3-D models of MB do not mirror the exact nature of the in vivo 
metastatic tumour microenvironment, they present an opportunity to 
better interrogate specific conditions that play a role in the metastatic 
niche. This is invaluable, given the rarity of MB and subsequently, the 
limited access to metastatic patient samples, which further prevent the 
interrogation of the in vivo tumour microenvironment.  
On the other hand, animal models are expensive to maintain, require 
expert licensing for their use and may perish prior to the establishment 
of disseminated disease. For these reasons, customisable 3-D models 
are preferable as they enable the recapitulation and interrogation of the 
in vivo tumour microenvironment, with improved biological relevance 
(Van Ommeren, Garzia et al. 2020).  
Given our findings that 2-D cultured MB secrete functionally active MMP-
2 and MMP-9 in levels that correlate with their metastatic potential, we 
sought to determine whether altering their tumour microenvironment 
would alter their levels of secreted MMPs. It was postulated that a 3-D 
microenvironment would better simulate the in vivo setting and thus 
better portray the influence of the primary (cerebellum) and metastatic 
(leptomeningeal for example) milieu upon the secretion of MMP-2 and 




To best explore this, two forms of 3-D cell culture were used. A migration 
spheroid model that was previously optimised by a colleague Dr Sophie 
Roper (Roper S, 2019) for SHH MB and a 3-D invasion transwell assay, 
also optimised by another colleague Dr Macha Aldighieri (Aldighieri 







Figure 7.2 Schematic diagram of the 3-D models used.  
A. Boyden chamber also known as the transwell assay in which a gradient across a semi-
permeable membrane with an ECM component coating, enables the determination of a cell 
line’s capacity to invade and metastasize. B. A multicellular spheroid model consisting of the 
same or a combination of different cell types can be used to study the migration patterns of 
3-D MB spheroids across an ECM-like matrix. Image adapted from (Kramer, Walzl et al. 
2013). 
 
While initial spheroid model experiments included the Group 3 MB cell 
line HD-MB03, their lack of formation of tight spheroids introduced 
unacceptable variation when transferred between media or matrix 
coatings. While their looser cell aggregates may be a result of their highly 
metastatic nature, early apparent dissemination captured in 
photomicrographs at 24 hours, could have resulted from mechanical 






To explore whether key components present within the primary MB 
microenvironment such as hyaluronan (recapitulating the cerebellar 
parenchyma) or collagen IV (enriched in the leptomeningeal metastatic 
milieu), spheroid migration assays over different matricellular protein 
combinations were performed. DAOY mut p53 (M0), ONS-76 wt p53 
(M2) and UW228-3 wt p53 (M0) were seeded onto either a pure or factor-
supplemented collagen IV matrix or a pure or supplemented hyaluronan 
matrix and allowed to migrate over 72 hours (Figure 4.5, Figure 4.6).  
As the  spheroids were generated from considerably lower cell numbers 
(range: 250-1500 cells) in comparison to those examined at 2D-culture 
(5X106 cells), the resulting low levels of secreted functionally active 
MMP-2 and MMP-9 proved difficult to detect at 24 and 48 hours. This 
necessitated further optimisation of the zymography protocol to maximise 
detection of the MMP-2 and MMP-9 signal. Even so, a trend towards 
increased levels of detectable functionally active MMP-2 and MMP-9 was 
observed at 48 hours in all SHH cell lines (Figure 4.3).   
The spheroid migration experiments began with Day 4 SHH spheroids 
generated as previously described and seeded on top of a combination 
of modifiable hyaluronan- based matrices (Hystem©). This was found to 
result in highly statistically significant differences in the levels of 
functionally active MMP-2 (ANOVA; p=0.0004) and MMP-9 (ANOVA; 
p=0.0333) secreted by DAOY spheroids, seeded on top of pure 
hyaluronan or hyaluronan supplemented with collagen I, Laminin I, 




4.5). Photomicrographs of these experiments (Roper 2019) reportedly 
portrayed similar extents of migration of the DAOY spheroids across all 
matrix combinations.  
Likewise, ONS-76 spheroids migrated equally well across all HA- based 
matrices as across the Collagen IV matrix. However, 72-hour migration 
across collagen IV appeared to result in lower secreted levels of 
functionally active MMP-2 and MMP-9 in comparison to migration across 
HA matrices. Interestingly, the levels of MMP-9 were most accentuated 
in ONS-76 spheroids cultured on top of HA/Laminin I and HA/vitronectin 
combinations (Figure 4.6).  
Though not statistically significant, this data suggests that the notion of 
CD44-mediated, hyaluronan-dependent MMP-9 activation (Novak and 
Kaye 2000) may explain the pattern of MMP-9 secretion from ONS-76 
spheroids cultured on hyaluronan-based matrices (Figure 4.6). 
Confirmation of their differential hyaluronan receptor expression 
revealed that while both DAOY and ONS-76 spheroids have been shown 
to express CD44 receptors at high levels by immunohistochemistry, their 
expression of the other, receptor for hyaluronan-mediated motility 
(RHAMM) was not determined (Roper 2019). As the UW228-3 SHH 
spheroids did not demonstrate any convincing migratory behaviour on 
any ECM coating, these spheroids were cultured alongside the other two 
as a somewhat negative control.  
While it was postulated that encapsulation within the established 3-D 




and ONS-76 spheroids, this was not proven as when initially embedded 
within hyaluronan based hydrogels, no invasive behaviour was 
observed.  
However, embedding of single MB cells within a pure hyaluronan gel as 
performed by my post-doctorate fellow Dr F. Linke resulted in marked 
increases in the signals of MMP-2 and MMP-9 detectable by gelatin 
zymography (Fig. 4.8). As this screening experiment demonstrated that, 
the biophysical characteristics of the tumour microenvironment could 
alter the levels of functionally active MMP-2 and MMP-9, further 
optimisation of the embedding of older spheroids into hyaluronan-based 
hydrogels, is ongoing.  
While modulating components of the interstitial matrix such as 
hyaluronan or collagen IV had quantifiable effects on the levels of MMP-
2 and MMP-9 secreted by MB spheroids and cells, we wondered whether 
the presence of immune cells within the tumour microenvironment would 
result in higher levels of secreted MMP-2 and MMP-9. 
 To this end, DAOY and ONS-76 spheroids were co-cultured with varying 
numbers of macrophages and seeded on top of a collagen IV coating on 
Day 4. Following 72 hours of migration, conditioned supernatant from 
these spheroids demonstrated increasing levels of functionally active 
MMP-9 signal with concurrent increasing numbers of macrophages 
present. While preliminary, this data suggested that majority of the 
detectable MMP-9 likely emanates from the MB tumour’s cellular 




supernatant from 2-D cultured SHH also demonstrated their secretion of 
high levels of MMP-9, it may be that their serum-complemented media 
contained immune mediators such as complement proteins, that 
recapitulated the effects seen in SHH tumours in vivo. 
Immunohistochemical studies of SHH-MB have demonstrated high 
levels of MMP-9 at the tumour edges, as well as a predilection for 
immune cell infiltration (Margol AS 2015).  
Further work in the co-culture of SHH spheroids with other cellular 
components such as astrocytes and microglia would be useful in the 
accurate characterisation of the interactions between MB and their 
specialised brain tumour microenvironments.  
7.5 The effect of pharmacological inhibition of 
MMP-2 and MMP-9 on the patterns of migration 
and invasion of 3-D cultured MB 
 
Having observed the unimpeded migration of DAOY (M0) and ONS-76 
(M2) SHH spheroids across a combination of different ECM component 
coatings, we sought to determine whether pharmacological inhibition of 
their secreted MMP-2 and MMP-9, would alter the migration patterns or 
behaviour.  
To more closely recapitulate the in vivo matricellular landscape, tissue 
inhibitors of MMPs (TIMPs) were used. To determine which inhibitors 
from the family of four would be optimal, DNA methylation and gene 




were analysed using the R2 Genomics and visualisation platform. We 
found that TIMP-1 DNA was hypomethylated relative to normal 
cerebellum, with statistically significant differences (ANOVA; p=0.015),   
in the methylation levels of the subgroups and cerebellum.  Furthermore, 
Kaplan-Meier survival analysis of high versus low gene expression of 
TIMP-1 and TIMP-2 revealed a stark difference in the more favourable 
prognosis of MB patients with high levels of TIMP-1 gene expression 
compared to those with high levels of TIMP-2, while those for TIMP-3 
and TIMP-4 did not demonstrate any significant survival advantage 
(Figure 4.14).  
In addition, TIMP-1 gene and protein overexpression has been positively 
correlated with poorer outcomes in brain tumours as well as other 
cancers (Jackson, Defamie et al. 2017). Taken together, these findings 
suggest that TIMP-1 upregulation is an inducible regulatory step that is 
triggered in highly aggressive and metastatic tumour microenvironments. 
While TIMP-1 may function as a good biomarker of increased metastatic 
potential in other cancers, this may not be the case in MB, as 
demonstrated in our protease and protease inhibitor experiments of 
conditioned supernatant from matched primary and metastatic Group 3 
MB, in whom levels of TIMP-1 and TIMP-2 were both decreased in the 
metastatic cell lines (Figure 3.4).  
Conversely, TIMP-2 expression is reported to be ‘equivocal’ in most 
cancers (Jackson, Defamie et al. 2017). However, its seemingly 




TIMP-2 a less optimal candidate inhibitor given the confounding effects 
it may cause (Jackson, Defamie et al. 2017).  
Following treatment with recombinant forms of either TIMP-1 or TIMP-2 
at 25 and 50nM concentrations, DAOY (M0), ONS-76 (M2) and UW228-
3 (M0) SHH spheroids remained viable. Surprisingly, despite clear 
demonstration of inhibition of their 72 hour conditioned supernatant 
(Figure 4.16), there was little convincing evidence of restricted migration 
in all three cell lines (Figure 4.15). This suggests that MMP-2 and MMP-
9 may not be essential for the migration of SHH-MB spheroids across an 
extracellular matrix. While examination of the photomicrographs of these 
experiments, suggested a possible alteration in the mode of migration,  
from collective to single cell migration (Figure 4.18, Figure 4.19), more 
experiments are needed to demonstrate this observation conclusively.  
Therefore, to explore whether the invasive potential of MB would 
correlate to their secreted levels of functionally active MMP-2 and MMP-
9, it was thought that transwell assays would be the best model. Having 
demonstrated statistically significant differences in the gene expression 
and functional activity of MMP-2 and MMP-9 between the matched 
primary and metastatic Group 4 MB cell lines, these and their Group3 
matched pair counterparts were examined, after optimisation 
experiments using the highly aggressive Group 3 cell line, HD-MB03.  
Their semi-adherent phenotype when cultured in 2-D made the transwell 
invasion assay a more suitable model for  Group 3 and 4 MB cell lines in 




This suggests that the 2-D phenotypes may correlate with the strength of 
the cell-cell interactions between the MB subgrouped samples, which 
may contribute to their respective predilection for dissemination to 
anatomically distant sites from the primary tumour (Kramer, Walzl et al. 
2013).  
Given that Group 3 and 4 MB predominantly metastasise to the 
leptomeninges, an optimised transwell model recapitulating invasion 
through the BBB was used (Aldighieri 2020). Using HD-MB03 cells for 
further optimisation, it was determined that a Collagen IV/laminin I barrier 
would best model the proteins most prevalent in the BBB (Figure 4.21). 
Following confirmation that recombinant TIMP-1 and TIMP-2 proteins at 
10nM, 25nM, 50nM and 100nM would not be cytotoxic (Figure 4.22), we 
proceeded to treat 100,000 HD-MB03 cells with rTIMP-1 at 100nM for 48 
hours prior to permitting their invasion for a further 24 hours.  
Remarkably, this rTIMP-1 treatment did not have any effect on the 
invasive capacity of the cells as shown in Figure 4.23. This finding would 
support our previous suspicions that the TIMP proteins may promote 
modified migratory/invasive behaviour, promoting single rather than 
collective cell movement, which in the transwell invasion model, would 
be advantageous.  
We therefore explored whether the differentially expressed MMP-2 and 
MMP-9 levels from the matched Group 3 and Group 4MB cell lines would 
correlate with their expected differential invasive capacity. Replicated 




surprisingly well with their levels of secreted functionally active MMP-2 
and MMP-9 as depicted in Figure 3.10. Once again this finding was 
highly statistically significant for the Group 4 MB pair (t-test; p<0.05), 
suggesting that the levels of functionally active MMP-2 would be a 
suitable biomarker for prognosis, especially in Group 4 MB.  
This is especially significant, given that Group 4 MB are the least likely 
to demonstrate contrast enhancement in neuroaxial contrast-enhanced 
MR imaging, resulting in poorly detectable leptomeningeal deposits. We 
therefore progressed to examine a small cohort of available 
cerebrospinal fluid samples from paediatric patients, who received 
management at our centre.  
 
7.6 Validation of MMPs as prognostic biomarkers in 
paediatric MB patient samples  
 
To gain a balanced impression of the MMP landscape in paediatric 
patients with MB, DNA methylation and gene expression data of MB 
patient samples from the Hovestadt and Cavalli dataset were analysed 
on the R2 Genomics and Visualisation platform (Cavalli, Remke et al. 
2017) . While it is widely postulated that epigenetic regulation and its 
resulting gene expression would serve as optimal levels for biomarker 




In the Hovestadt dataset, whereas MMP-2 hypomethylation was 
observed in DNA from MB patient samples compared to normal 
cerebellum, the methylation pattern for MMP-9 varied around the mean 
levels detected in normal cerebellum, while it appeared to be stringently 
regulated in EMMPRIN at levels observed in normal cerebellar tissue 
(Figure 5.2). Conversely, the same analysis applied to the DNA 
methylation and subsequent gene expression of TIMP-1 revealed an 
inverse correlation between the levels of DNA methylation and its 
resulting gene expression in all subgroups, while a similar trend was 
observed for TIMP-2 in all MB subgroups except SHH (Figure 5.3). While 
reasons for these observations are difficult to decipher, review of the 
epigenetic modulation of MMP related genes demonstrated the 
difficulties associated with predictions given the likelihood of subgroup 
specific epigenetic regulations and their effects on subsequent gene 
expression.  
Thus, the examination of cerebrospinal fluid from paediatric patients with 
MB was postulated to be the optimal medium from which to detect 
biomarkers of increased metastatic potential.  
While the evidence of a glymphatic pathway of cerebrospinal fluid 
circulation along perivascular spaces of brain vasculature has led to its 
designation as the lymphatic pathway in the brain, it may also explain 
why it has been reported that sampling of cerebrospinal fluid close to a 
tumour improves the sensitivity of the cytology. This observation made 




from cerebrospinal fluid obtained through lumbar punctures 14-days 
following surgical resection of the primary MB. Considering the likelihood 
of circulating tumour cells within the lumbar subarachnoid space would 
likely deposit in the thecal sac under gravity, CSF sampling above this 
level would more than likely return negative results.  
Furthermore, factors associated with the sampling, delivery and storage 
of the CSF could result in erroneously negative results, even in the 
presence of radiologically proven leptomeningeal disease. These include 
a CSF sampling volume of less than 10 ml, delays of sample delivery to 
the lab for processing and cooling as well as inappropriate storage and 
handling of the samples. Given the less than ideal manner in which 
clinical samples may be handled in our current resource scarce NHS, 
these factors may result in the erroneous risk stratification of patients with 
high-risk metastatic disease, being labelled as average-risk, and 
prescribed sub-optimal therapy regimens. While this has obvious 
implications for the prognosis in the affected children, it also worryingly 
culminates in significant neurocognitive, health and psychosocial 
morbidity from therapies necessitated at disease recurrence or relapse. 
 Out of 10 CSF samples from lumbar puncture performed in six paediatric 
patients with MB who were treated at our centre, only one sample gave 
a positive result, in Patient 1 who presented with metastatic 
dissemination at diagnosis. This result is even more concerning given 




approximately 50% (Bennett, Ashmawy et al. 2017, Chamberlain, Junck 
et al. 2017).  
 Furthermore, in Patient 4 who returned with an intraventricular 
recurrence of his Group 4 MB, his CSF cytology remained negative while 
zymography of the same CSF samples demonstrated strong signals 
denoting the increased levels of functionally active MMP-2 and MMP-9 
within the samples (Figure 5.10). Interestingly, surveillance CSF 
sampling from patient 6 obtained via an Ommaya reservoir, an indwelling 
catheter that sits within the lateral ventricles, demonstrated continually 
increasing levels of MMP-2 and MMP-9 on zymography, preceding the 
radiological detection of his macrometastases.  
While the levels of functionally active MMP-2 and MMP-9 could be 
attributed to tumour or implant-associated inflammation, the cellular 
characteristics of the cerebrospinal fluid samples in Table 5.3 suggest 
otherwise. This finding further supports the validity of the detection of 
levels of functionally active MMP-2 within patient CSF as a robust 
biomarker of dissemination that could be used to improve prognostication 
of patients as well as enable earlier detection of recurrent disease and 
treatment response on surveillance. Furthermore, the sensitivity of 
gelatin zymography appears to be better than that CSF cytology as 
demonstrated by the CSF samples obtained in theatre for Patient 4[1] 
that was strongly positive in comparison to the sample from lumbar 
puncture 2 weeks later (sample 4[2]). While the sample size of this proof 




of cerebrospinal fluid samples obtained at the point of dural entry in 
theatre, and subsequent expedited delivery to a lab for processing and 
storage at -20˚C at least, would improve the diagnosis of disease 
dissemination in paediatric patients with MB.  Furthermore, these 
pragmatic and attainable improvements are likely to be easily translated 
into clinical practice, with little specialised equipment required.  While 
ELISA or protease and protease inhibitor assays could also be argued to 
give similarly quantifiable results, these methods incur substantial 
financial costs of the kit and equipment required.  
However, to further improve the accuracy or radiological detection of 
metastatic dissemination, the use of an MRI compatible MMP-2/-9 
biosensor administered as intrathecal or intravenous contrast could 
prove a promising tool in our quest to improve the risk stratification of 
paediatric patients with MB.  
 
7.7 Improving the risk stratification of paediatric 
patients with MB using our 19Fluorine-MMP-MRI 
biosensor 
 
Metastatic dissemination is arguably the most powerful determinant of a 
medulloblastoma patient’s prognosis. However, our current clinical 
methods used to detect it have a reported sensitivity of 50-76% (Bennett, 
Ashmawy et al. 2017), resulting in suboptimal management and  




While MRI is the designated gold standard tool for the identification of 
neuroaxial disease in the paediatric patient with MB, the subtle 
appearances of leptomeningeal disease can prove incredibly difficult to 
diagnose, especially without specialist neuro-radiology expertise or in the 
case of non-enhancing MBs as is often observed in Group 4 MB (Figure 
7.3). As the most commonly occurring and the second most likely 
subgroup to metastasise to its preferred leptomeningeal and sanctuary 
sites, the poor contrast uptake of Group 4-MB renders the diagnosis of 
their metastatic deposits incredibly difficult (Holgado, Guerreiro Stucklin 
et al. 2017).  
 
 
Figure 7.3 Typical MRI appearances of the four MB subgroups 
A. WNT-MB commonly arise in the cerebellopontine angle and demonstrate avid 
enhancement with gadolinium contrast. B. SHH-MB, which typically arise in the lateral 
cerebellar hemispheres. C. An avidly enhancing midline cerebellar tumour is most likely to 
be a Group-3 MB. D. The characteristic appearance of the poorly enhancing Group 4 midline 
MB. Image reproduced from Holgado et al. 2017.  
 
Therefore to determine whether our locally synthesised 19 Fluorine-
MMP/MRI biosensor could be used to translate the levels of functionally 
active MMP-2 and MMP-9 into prognostic imaging biomarkers, FRET 
assays were used to examine the conditioned MB cell line supernatant, 




Having demonstrated the strongest correlation of increased levels of 
functional gelatinases with the differential metastatic potentials of the 
matched primary and recurrent Group 4 cell lines, 48 hour conditioned 
supernatant was centrifuged, column-concentrated and stored at -80˚C. 
These measures ensured the maximal retention of their enzymatic 
activity, which would be crucial for the working of the biosensor. While 
the FRET assays nicely demonstrated stark differences in the levels of 
fluorescence emitted by the quenched digested gelatin, the experiments 
also suggested that the 10% acetonitrile (ACN) solvent used in the 
biosensor synthesis, precipitated proteins out of the solution, resulting in 
decreasing levels of fluorescence in the presence of ACN. This 
highlighted the importance of using physiologically compatible solvents, 
to develop radiological contrast agents. While our biosensor contains a 
Gadolinium moiety, its administration would incur a less overall volume 
of contrast, which is preferential especially in allergic patients.  
While the biosensor experiments proved its immense value for potential 
application as an imaging biomarker, further optimisation is required to 
improve its sensitivity and hence, enable the dynamic, detection of 
endogenous MMP-2 and MMP-9 as successfully as has been 
accomplished with their recombinant protein forms. Once established, 
this imaging modality could improve the detection of metastasis at 
diagnosis, during intra-operative MB resection with use of the intra-
operative MRI to maximise safe resection, as well as during surveillance, 




7.8 Proposals for future work 
Given our current findings, focussed efforts in the following domains 
would advance our mission to improve our risk stratification of MB 
patients and improve our provision of personalised, patient-centred care.  
 The development of more complex 3-D culture models that would 
better recapitulate the in vivo tumour microenvironment including 
both cellular and ECM components of the specialised brain 
tumour milieu, as well as incorporation of immune cells. 
 
 Streamline and standardise the clinical methods employed in the 
diagnosis and detection of MB dissemination. This may involve 
enforcing the RANO criteria for the radiological assessment of the 
neuroaxis; improving the methods of CSF biopsy by undertaking 
clinical trials to:       
 1. Establish whether the sensitivity of CSF cytology is 
  improved when CSF is sourced at dural entry in 
  theatre, in comparison to lumbar puncture 2 week’s 
  post-operatively;  
 2.  Determine whether analysis of patient CSF levels of 
  functionally active MMP-2 and MMP-9 using gelatin 
  zymography, ELISA or FRET techniques, would 
  result in more accurate diagnosis of MB  metastasis 
  culminating in robust risk stratification of patients   




 Continue optimisation of the MRI compatible MMP-2/9 biosensor 
to increase the sensitivity of its detection of endogenous MMP-2 
and MMP-9. Ensuring that the biosensor is stable and soluble in 
a physiological solvent, will facilitate its safe translation into animal 
models and patients alike.  
7.9 Concluding statement 
Having demonstrated the biological validity of MMP-2 as a biomarker of 
poorer prognosis in MB, we aim to translate it into an MRI compatible 
imaging biomarker. This would enable accurate determination of a 
patient’s risk of metastasis at first presentation with MB as well as on 
disease surveillance. With further optimisation, the biosensor could also 
be used as an adjunct, to improve the extent of maximal safe resection 
when given pre-operatively and imaged using the intraoperative MRI. 
While further work to improve the biosensor imaging is required, we have 
shown that liquid biopsy of patient cerebrospinal fluid at operation would 
likely improve the sensitivity of CSF cytology, without the confounding 
factor of iatrogenic dissemination associated with post-operative CSF 
sampling. Furthermore, streamlining the storage and handling of CSF 
samples, would be paramount to enhancing sensitivity and specificity of 
any CSF-based detection of circulating tumour cell DNA, protein or 
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Appendix Figure 1   Cavalli dataset differential gene expression in MB subgroups and 


























Spheroid macro written by Dr Ivanov and modified by Dr Roper:  
//This macro aims to automate spheroid size measurement in three-dimensional cell culture. 
It requires input and output folders with images only, processes the images, records a file 
with spheroid measurements (Area, Ferret max, Ferret min, etc.) and writes an image with 
the outline/s of the determined spheroid/s.  
//The spheroid detection and size determination function to be repeated for every image is 
defined below 
function action(inputFolder,outputFolder,filename) { 
open(inputFolder + filename); 
//sets scale to predetermined values from calibration slide 
run("Set Scale...", "distance=1360 known=1000 pixel=1 unit=µm global"); 
run("16-bit"); 
//run("Brightness/Contrast..."); 
run("Enhance Contrast", "saturated=0.35"); 
//Uses Yen thresholding algorythm  
setAutoThreshold("Yen"); 
setOption("BlackBackground", false); 
run("Convert to Mask"); 
//Gets the ratio between black (spheroid) and white (background) pixels. If we assume a 
single spheroid, the ratio between black and white pixels would allow us to estimate the size 
of the spheroid. 
getHistogram(0,hist,256); 
ratio = hist[255]/hist[0]; 
//If there are more pixels detected as spheroid(black) than background(white) then the 
spheroid has not been detected due to variations in background 
if (ratio>1) { 
 // closes the image, reopens it, subtracts the background and proceeds as normal 
 close(); 
 open(inputFolder + filename); 
 run("16-bit"); 
 // Subtract Background is not used in the default function because it can lead to 
merging of spheroids and debris or it can remove the core of the spheroid leaving a very 
thin interrupted edge. In certain cases where the edges of a spheroid are very bright 
removing the background can give better results. 
 run("Subtract Background...", "rolling=50 light"); 
 setAutoThreshold("Yen"); 
 setOption("BlackBackground", false); 
 run("Convert to Mask"); 
 run("Remove Outliers...", "radius=15 threshold=0 which=Dark"); 
 getHistogram(0,hist,256); 




 //The strategy here is to act differently according to spheroid size. The general 
pattern is to expand and then shrink back the spheroids in order to include all cells on the 
edges. Then a series of functions are used to remove noise and the Watershed function 
separates fused or superimposed particles. The Analyze particles function is targeted to the 
specific spheroid size according to the black/white pixel ratio. 
if (ratio<0.001) {  
 run("Maximum...", "radius=8"); 
 run("Fill Holes"); 
 run("Minimum...", "radius=8"); 
 //small spheroids require a more "gentle" function to clean up noise 
 run("Median...", "radius=2"); 
 run("Maximum...", "radius=25"); 
 run("Minimum...", "radius=25"); 
 run("Fill Holes"); 
 run("Watershed"); 
 run("Analyze Particles...", "size=4000-Infinity circularity=0.20-1.00 show=[Overlay 
Outlines] display exclude include summarize");}; 
if (ratio >=0.001 && ratio<0.01) { 
 run("Maximum...", "radius=8"); 
 run("Fill Holes"); 
 run("Minimum...", "radius=8"); 
 //slightly bigger spheroids and a more rigorous function to remove noise 
 run("Remove Outliers...", "radius=10 threshold=0 which=Dark"); 
 run("Watershed"); 
 run("Analyze Particles...", "size=10000-Infinity circularity=0.20-1.00 show=[Overlay 
Outlines] display exclude include summarize");}; 
if (ratio>=0.01 && ratio<0.2) { 
 run("Maximum...", "radius=8"); 
 run("Fill Holes"); 
 run("Minimum...", "radius=8"); 
 run("Remove Outliers...", "radius=15 threshold=0 which=Dark"); 
 run("Median...", "radius=4"); 
 run("Watershed"); 
 run("Analyze Particles...", "size=20000-Infinity circularity=0.20-1.00 show=[Overlay 
Outlines] display exclude include summarize");}; 
if (ratio>=0.2 && ratio<1) { 
 //Very big spheroids generally do not need to be expanded much to fill up the edges.  
 run("Maximum...", "radius=3"); 
 run("Fill Holes"); 




 //Outliers and noise are removed rigorously 
 run("Remove Outliers...", "radius=50 threshold=0 which=Dark"); 
 run("Minimum...", "radius=30"); 
 run("Maximum...", "radius=30"); 
 run("Watershed"); 
 run("Analyze Particles...", "size=50000-Infinity circularity=0.20-1.00 show=[Overlay 
Outlines] display exclude include summarize");}; 
 if (Overlay.size > 0) { 
//Sends particles detected to the ROI manager 
run("To ROI Manager"); 
close(); 
//Reopens the original image and pastes the outlines of the determined particles onto it 
open(inputFolder + filename); 
run("From ROI Manager"); 
outputPath = outputFolder + filename; 
save(outputPath); 








inputFolder = getDirectory("Choose the input folder!"); 
outputFolder = getDirectory("Choose the output folder!"); 
//Delete the next line if you want to see how the macro works on the images. However that 
will reduce processing speed. 
setBatchMode(true); 
images = getFileList(inputFolder); 
//Sets the measurements that are recorded for each spheroid 
run("Set Measurements...", "area centroid shape feret's display add redirect=None 
decimal=1"); 
//That is the cycle that runs through all images 
for (i=0; i<images.length; i++) {  
 action(inputFolder,outputFolder,images[i]); 





//Writes in the Results and Summary windows and saves the data. 
selectWindow("Results"); 
saveAs("Measurements", "" + outputFolder + "Results.txt"); 
selectWindow("Summary");  
saveAs("Text", "" + outputFolder +"Summary.txt"); 
setBatchMode(false); 
 
Macro for Image J analysis of protease and protease inhibitor 
microarrays 
A publically available Image J macro for the analysis of protease and 
protease inhibitor microarray was used to perform densitometry on the 
digital images (.TIFF) following chemiluminescence of the microarrays 
(https://imagej.nih.gov/ij/macros/toolsets/Protein%20Array%20Analyzer.
txt). The image below demonstrates the manner in which the microarrays 
were analysed. The macro coded for the subtraction of the background 
from each analyte. The resulting densitometries were then normalised to 






Image J densitometry of western blot membranes and zymograms 
Following chemiluminescence of each membrane using our machine 
(LAS 4000 mini Biomolecular imager, GE Healthcare), the images saved 
as TIFFs were imported into Image J software. Photographs of each 
zymogram was taken with a 14MP phone camera and saved as digital 
files as well (.tiff). Densitometric analysis was performed as shown 
below.  
1. Open Image J software after downloading from NIH website. 
https://imagej.nih.gov/ij/download.html 
2. Highlight the rectangular left sided button and select Analyse and 




3. This will highlight the first lane as shown. This is your region of interest 
(ROI). You can drag this box horizontally without changing its dimensions 
to each lane to improve validity between your measurements.  
 
4. Once an ROI is selected, press ‘ctrl+M’ or select ‘Measure’ under the 
Analyse section.  
5. Ensure to measure an ROI area of background which can be 
subtracted from the densitometry of each sample.  
6. Once all the measurements are complete, export these to Excel and 
normalise them to the volumes of protein lysate loaded for each sample. 
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